



SEMINAR SERIES

**NUTRITIONAL DERMATOLOGY:
ADVANCES FOR ACNE, ACNE
INVERSA, ECZEMA, AND PSORIASIS**



Nutritional Dermatology: Advances for Acne, Atopic Dermatitis, and Psoriasis



1

Speaker Disclosure

Benjamin I. Brown, ND

Director, the Nutritional Medicine Institute

Editor, the Nutritional Medicine Journal

Director of Clinical Education, Pure Encapsulations, UK and Ireland

Host, Positive Health Podcast

W: scientificwellness.com

#BenBrownND

I am a consultant for Pure Encapsulations. I have no other relevant conflicts of interest to disclose.



2

Learning Objectives

Related to the clinical management of skin disorders with nutritional therapy:

- Review existing clinical evidence for dietary and nutrient-based supplements
- Explore recent research on new interventions
- Identify nutritional interventions that target disease subgroups
- Consider pros and cons of biomarkers and tests that may guide nutritional interventions
- Summarise pragmatic, evidence-based, personalised management

Note: supplementary notes cover topics in considerable detail. Some interventions, such as natural topical therapies, those exclusively used to prevent drug side-effects, or with limited clinical data, may not be covered due to time constraints but are in the notes for your reference.



3

Introduction



4

Unmet need

“The role of diet and nutrition in the management of chronic inflammatory skin conditions such as eczema, psoriasis and acne is one of the commonest questions asked by patients. Despite this, there is little guidance or training to help healthcare professionals provide disease-specific evidence-based recommendations to patients..”

British Journal of Dermatology, Volume 188, Issue Supplement_4, June 2023



5

Education and collaboration

“We received 95 responses from dermatology nurses and 64 from doctors. Over 60% of respondents held senior positions with over 10 years of experience. Almost 100% of respondents reported being asked about diet by patients and 73.1% did not feel confident when answering these questions.”

“Over 90% of respondents felt that additional nutrition training and access to specialist dietician support would be of benefit to dermatology practice.”

British Journal of Dermatology, Volume 188, Issue Supplement_4, June 2023



6

Acne vulgaris



7

Acne vulgaris

“Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from androgen-induced increased sebum production, altered keratinization, inflammation, and bacterial colonization of hair follicles on the face, neck, chest, and back by *Propionibacterium acnes*.”

Lancet. 2012 Jan 28;379(9813):361-72.



8

Acne vulgaris
Foyed Williams, Robert Fitzpatrick, Scott Gerner

Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from androgen-induced increased sebum production, altered keratinization, inflammation, and bacterial colonization of hair follicles on the face, neck, chest, and back by *Propionibacterium acnes*. Although such colonization with *P. acnes* and follicle hyperplasia might have important roles in the disease, exactly what triggers acne and how treatment affects the course of the disease remain unclear. Other factors such as diet have been implicated, but are proven. Facial spacing due to acne affects up to 20% of teenagers. Acne can persist into adulthood with detrimental effects on self-esteem. There is no ideal treatment for acne, although a variety of options for reducing lesions can be found for most patients. Good quality evidence on comparative effectiveness of various topical and systemic acne therapies is scarce. Topical therapies including benzoyl peroxide, retinoids, and antibiotics when used in combination usually improve control of mild to moderate acne. Treatment with combined oral contraceptives can help women with acne. Patients with more severe inflammatory acne usually need oral antibiotics combined with topical benzoyl peroxide to decrease antibiotic resistance. Oral isotretinoin is the most effective therapy and is used only in severe disease. Although its use is limited by teratogenicity and other side-effects, dermatitis, mucositis, and dry lips, the use of photodynamic therapy, new research is needed into the therapeutic comparative effectiveness and safety of the more products available, and to better understand the natural history, etiology, and triggers of acne.

Introduction
Acne is a disease of the pilosebaceous unit—hair follicles, to the sites that are associated with an enlarged pore (the dilated infundibulum) and sebaceous gland (the sebaceous gland). The clinical features of acne include comedones (open and closed comedones), inflammatory lesions (papules and pustules), and various degrees of scarring. The distribution of acne corresponds to the highest density of pilosebaceous units: face, neck, upper chest, shoulders, and back. It is most common in teenagers and young adults. Acne is characterized by inflammation of the pilosebaceous unit, which is associated with hyperkeratinization, increased sebum production, and bacterial colonization of the pilosebaceous unit. Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from androgen-induced increased sebum production, altered keratinization, inflammation, and bacterial colonization of hair follicles on the face, neck, chest, and back by *Propionibacterium acnes*.

Prevalence and natural history
Acne affects almost all people aged 15 to 25 years, and prevalence increases to about 15–20% in older people. Prevalence estimates are difficult to compare because definitions of acne and acne severity have differed so much between studies, and because estimates are confounded by the availability and use of acne treatments. Surveys of self-reported acne have proven unreliable. Although prevalence of a moderate disease was often positive and self-reported, one population study in Germany found that 60% of those aged 20 to 29 years and 40% of those aged 30 to 39 years had moderate acne. Another study of more than 2000 adolescents found that 1% of men and 5% of women still had moderate acne at the age of 40 to 49 years.¹

Acne typically starts in early puberty with increased facial sebum production, and mild facial comedones followed by inflammatory lesions. Inflammation starts before the age of 12 years in usually more comedonal than inflammatory, possibly because such individuals have early or begun to produce enough sebum to support large numbers of *Propionibacterium acnes*.² One prospective study of 111 children aged 5 to 12 years, followed up for an average of 2.5 years, found an increasing number of glands switching on sebaceous production over time.³ Subsequent expansion of the pilosebaceous unit has been found in the same and then facial acne occurred earlier in children who developed acne than in children of the same age and gender whose who did not, suggesting that progression of sebaceous production or expansion of pilosebaceous unit has to do with puberty and precedes acne or moderate disease severity. Evidence of acne severity includes early onset of comedonal acne⁴ and increasing number of facial comedones with acne lesions,⁵ factors that can cause acne to flare include the menstrual cycle, pregnancy, and treatment acne.^{6–8} Indeed, about 50% of women affected by acne vary according to ethnic group.⁹ Acne severity is a chronic disease that often persists for many years.¹⁰ There is little research about what factors might predict whether one will be acne-prone.¹¹ We could not find any good quality cohort studies examining the natural history of acne, longitudinal prevalence surveys of different populations showing a gradual decrease in

Search strategy and selection criteria
Our main search of evidence included all systematic reviews on acne published between 1990 and 2012 which have been registered in MEDLINE—database of abstracts and reviews of articles—supported by specific search strategies for articles published between 2003 and 2012, complete search terms were “acne”, “acneiform”, “pimples”, and “acne”, “acne”, “acneiform”, “pimples”, “pimples”, “acneiform”, and “pimples”. We also searched other databases for evidence.

www.thelancet.com Vol 379 June 16, 2012

Downloaded from The Lancet on 04/16/2015. See the full article on www.thelancet.com. Copyright © 2012 Elsevier Inc. All rights reserved.

Gut-brain-skin axis




Figure 1 Potential Pathways of the Gut-Brain-Skin Axis in Acne Vulgaris [1] Psychological distress alone or in combination with [2] high fat diet, processed comfort foods devoid of fiber, cause alterations to [3] gut motility and microbiota profile [4]. Loss of normal microbial biomass (Dysbiosis) in particular causes intestinal permeability and endotoxin gain systemic access [5]. Burden of inflammation and oxidative stress is increased, substance P is elevated, insulin sensitivity is decreased due to endotoxemia [6]. In those genetically susceptible to acne vulgaris, this cascade increases the likelihood of excess sebum production, exacerbations in acne and additional psychological distress. Both probiotics and antimicrobials may play a role in cutting off this cycle at the gut level.

Bowe W, et al. *Benef Microbes*. 2014 Jun 1;5(2):185-99.



9

Isotretinoin

“Individuals differ in terms of the prevalence and risk factors for isotretinoin side effects. Age, gender, dose, duration of treatment, drug interactions, comorbidities, and genetic susceptibility are a few examples of variables that may affect the frequency and intensity of adverse reactions.”

Cureus. 2024 Mar 11;16(3):e55946.

Cureus Open Access Article
DOI: 10.7755/cureus.13866

Side Effects of Treating Acne Vulgaris With Isotretinoin: A Systematic Review

Wahid Rajput¹, Nathan D. Brinkler²

Abstract

The purpose of this review is to provide a comprehensive overview of the side effects of isotretinoin treatment for acne vulgaris. This review includes a systematic search of the literature for side effects related to isotretinoin treatment. Through a comprehensive search and analysis of the literature, we discuss the various side effects, their incidence, management strategies, and the relevance of these side effects to clinical practice.

Introduction And Background

Isotretinoin is a retinoid used for the treatment of severe acne vulgaris. It is a derivative of vitamin A and is known for its effectiveness in treating acne. However, it is also associated with a range of side effects, including dryness, skin irritation, and changes in skin color. This review aims to provide a comprehensive overview of the side effects of isotretinoin treatment, including their incidence, management strategies, and the relevance of these side effects to clinical practice.


Review

Isotretinoin is a drug that is widely used for the treatment of acne vulgaris. It is a derivative of vitamin A and is known for its effectiveness in treating acne. However, it is also associated with a range of side effects, including dryness, skin irritation, and changes in skin color. This review aims to provide a comprehensive overview of the side effects of isotretinoin treatment, including their incidence, management strategies, and the relevance of these side effects to clinical practice.




10

Acne vulgaris: dietary management options




11

Acne vulgaris: nutrient management options



12

Acne vulgaris: dietary management options



13

A disease of our time

In westernized societies, acne vulgaris is a nearly universal skin disease afflicting 79% to 95% of the adolescent population. Of 1200 Kitavan subjects examined (including 300 aged 15-25 years), no case of acne (grade 1 with multiple comedones or grades 2-4) was observed. Of 115 Aché subjects examined (including 15 aged 15-25 years) over 843 days, no case of active acne (grades 1-4) was observed.

Arch Dermatol. 2002 Dec;138(12):1584-90.



14

OBSERVATION

Acne Vulgaris

A Disease of Western Civilization

Loren Cordile, PhD; Stefan Lindberg, MD, PhD; Magdalena Harrold, PhD; Kim Hill, PhD; S. Boyd Eaton, MD, Jeanne Bond-Miller, PhD

Background: In westernized societies, acne vulgaris is a nearly universal skin disease afflicting 79% to 95% of the adolescent population. In contrast, in nonwesternized societies, the prevalence of acne is low. We report the prevalence of acne in 2 nonwesternized populations: the Kitavians of Papua New Guinea and the Aché hunter-gatherers of Paraguay. Additionally, we analyze how elements in nonwesternized environments may influence the development of acne.

Observation: Of 1200 Kitavan subjects examined (including 300 aged 15-25 years), no case of acne (grade 1

with multiple comedones or grades 2-4) was observed. Of 115 Aché subjects examined (including 15 aged 15-25 years) over 843 days, no case of active acne (grades 1-4) was observed.

Conclusions: The astounding difference in acne incidence rates between nonwesternized and fully westernized societies cannot be solely attributed to genetic differences among populations but likely results from different environmental factors. Identification of these factors may be useful in the treatment of acne in Western populations.

Arch Dermatol. 2002;138:1584-1590

A ONE AFFECTS between 40 million and 50 million individuals in the United States.¹ Although acne mainly affects adolescents, it is also present in children and adults. One study found some degree of facial acne in 3% of women and 40% of men older than 25 years.² In this same young, clinical facial acne affected 12% of the women and 3% of the men and persisted into middle age. Corfield and Goddard³ the incidence of acne is lower than in westernized populations. Schacter,⁴ a general practitioner who spent almost 30 years among the Inuit (Eskimo) people as they made the transition to modern life, reported that acne was absent in the Inuit population when they were brought and living in their traditional manner, but upon acculturation, acne prevalence became similar to that in Western societies.

For editorial comment

Sugar and acne

Patients with acne restricted sugar intake by eliminating soft drinks, candy, and cake, and limiting sugar in coffee or tea to 2 teaspoons per day. After a follow-up period of at least 1 month, substantial improvement or complete clearing of lesions was seen in 84% of those consuming the low-sugar diet.

Arch Dermatol 1961;83:968-969.

Should We Limit Sugar in Acne?

THEODORE CONNORREY, M.D., Ph.D., AND JENNA GRILL, M.D., CHICAGO

The pathogenesis of acne is not clear, although we now have more information about it. Much has been written and said about the role of the endocrines, although the exact influence of their products and activity and relationships to one another remain to be spelled out. The anatomical and histologic factors in acne have lately received much attention. By these approaches certain changes are commonly seen and are suspect. One of these is the keratinous ring at the follicular ostium. It seems, however, the latter is by no means an obligatory preliminary to the appearance of the overt acne lesion. Diet has received its full share of consideration and speculation. Most dermatologists agree that such foods as chocolate and nuts, and the 2 halogen radicals, iodides and bromides, exacerbate acne. There is disagreement about the effect of fats and lipids; however, many physicians have limited sugar in the acne diet. We were not sure about the adequacy of the latter measure, and so we put it to the test in the laboratory and clinic.

Method

Fifteen patients with acne and a similar number of subjects free of it were given sugar-tolerance tests. The 2 groups were similar as to age and were about equally divided between the 2 sexes. Sugar-loading was accomplished by giving 1 gm. of sugar per kilogram of body weight in 200 cc. of orange juice. Blood samples were withdrawn just before and afterward and also one-half hour and one hour later. Glucose levels were determined by the enzymatic relation method and read with the Technicon Analyzer.

Fifty-two patients with acne were divided into 2 groups. One was restricted as to sugar in the diet: all soft drinks containing sugar, candy, and cake were eliminated. Only 2 teaspoons of sugar a day for coffee or tea were permitted. The 2 groups were similar as to age and severity of acne, and there was about the same division between sexes. Each patient was observed a minimum of one month. Active treatment of the 2 groups was similar, consisting of administration of antibiotics.

Results

As can be seen from the tables, there was little difference in the sugar tolerance


TABLE 1—Glucose Tolerance Test Values—Acne

Patient	1/2 Hour	1 Hour	1 1/2 Hour
1.	96	122	129
2.	114	124	129
3.	78	96	102
4.	96	102	102
5.	78	96	102
6.	84	96	102
7.	84	96	102
8.	72	90	96
9.	78	96	102
10.	78	96	102
11.	84	96	102
12.	78	96	102
13.	78	96	102
14.	78	96	102
15.	78	96	102
16.	78	96	102
17.	78	96	102
18.	78	96	102
19.	78	96	102
20.	78	96	102
21.	78	96	102
22.	78	96	102
23.	78	96	102
24.	78	96	102
25.	78	96	102
26.	78	96	102
27.	78	96	102
28.	78	96	102
29.	78	96	102
30.	78	96	102
31.	78	96	102
32.	78	96	102
33.	78	96	102
34.	78	96	102
35.	78	96	102
36.	78	96	102
37.	78	96	102
38.	78	96	102
39.	78	96	102
40.	78	96	102
41.	78	96	102
42.	78	96	102
43.	78	96	102
44.	78	96	102
45.	78	96	102
46.	78	96	102
47.	78	96	102
48.	78	96	102
49.	78	96	102
50.	78	96	102
51.	78	96	102
52.	78	96	102
53.	78	96	102
54.	78	96	102
55.	78	96	102
56.	78	96	102
57.	78	96	102
58.	78	96	102
59.	78	96	102
60.	78	96	102
61.	78	96	102
62.	78	96	102
63.	78	96	102
64.	78	96	102
65.	78	96	102
66.	78	96	102
67.	78	96	102
68.	78	96	102
69.	78	96	102
70.	78	96	102
71.	78	96	102
72.	78	96	102
73.	78	96	102
74.	78	96	102
75.	78	96	102
76.	78	96	102
77.	78	96	102
78.	78	96	102
79.	78	96	102
80.	78	96	102
81.	78	96	102
82.	78	96	102
83.	78	96	102
84.	78	96	102
85.	78	96	102
86.	78	96	102
87.	78	96	102
88.	78	96	102
89.	78	96	102
90.	78	96	102
91.	78	96	102
92.	78	96	102
93.	78	96	102
94.	78	96	102
95.	78	96	102
96.	78	96	102
97.	78	96	102
98.	78	96	102
99.	78	96	102
100.	78	96	102
101.	78	96	102
102.	78	96	102
103.	78	96	102
104.	78	96	102
105.	78	96	102
106.	78	96	102
107.	78	96	102
108.	78	96	102
109.	78	96	102
110.	78	96	102
111.	78	96	102
112.	78	96	102
113.	78	96	102
114.	78	96	102
115.	78	96	102
116.	78	96	102
117.	78	96	102
118.	78	96	102
119.	78	96	102
120.	78	96	102
121.	78	96	102
122.	78	96	102

TABLE 2—Glucose Tolerance Test Values—Control Group

Patient	1/2 Hour	1 Hour	1 1/2 Hour
1.	96	120	120
2.	114	124	129
3.	78	96	102
4.	96	102	102
5.	78	96	102
6.	84	96	102
7.	84	96	102
8.	72	90	96
9.	78	96	102
10.	78	96	102
11.	84	96	102
12.	78	96	102
13.	78	96	102
14.	78	96	102
15.	78	96	102
16.	78	96	102
17.	78	96	102
18.	78	96	102
19.	78	96	102
20.	78	96	102
21.	78	96	102
22.	78	96	102
23.	78	96	102
24.	78	96	102
25.	78	96	102
26.	78	96	102
27.	78	96	102
28.	78	96	102
29.	78	96	102
30.	78	96	102
31.	78	96	102
32.	78	96	102
33.	78	96	102
34.	78	96	102
35.	78	96	102
36.	78	96	102
37.	78	96	102
38.	78	96	102
39.	78	96	102
40.	78	96	102
41.	78	96	102
42.	78	96	102
43.	78	96	102
44.	78	96	102
45.	78	96	102
46.	78	96	102
47.	78	96	102
48.	78	96	102
49.	78	96	102
50.	78	96	102
51.	78	96	102
52.	78	96	102
53.	78	96	102
54.	78	96	102
55.	78	96	102
56.	78	96	102
57.	78	96	102
58.	78	96	102
59.	78	96	102
60.	78	96	102
61.	78	96	102
62.	78	96	102
63.	78	96	102
64.	78	96	102
65.	78	96	102
66.	78	96	102
67.	78	96	102
68.	78	96	102
69.	78	96	102
70.	78	96	102
71.	78	96	102
72.	78	96	102
73.	78	96	102
74.	78	96	102
75.	78	96	102
76.	78	96	102
77.	78	96	102
78.	78	96	102
79.	78	96	102
80.	78	96	102
81.	78	96	102
82.	78	96	102
83.	78	96	102
84.	78	96	102
85.	78	96	102
86.	78	96	102
87.	78	96	102
88.	78	96	102
89.	78	96	102
90.	78	96	102
91.	78	96	102
92.	78	96	102
93.	78	96	102
94.	78	96	102
95.	78	96	102
96.	78	96	102
97.	78	96	102
98.	78	96	102
99.	78	96	102
100.	78	96	102
101.	78	96	102
102.	78	96	102
103.	78	96	102
104.	78	96	102
105.	78	96	102
106.	78	96	102
107.	78	96	102
108.	78	96	102
109.	78	96	102
110.	78	96	102
111.	78	96	102
112.	78	96	102
113.	78	96	102
114.	78	96	102
115.	78	96	102
116.	78	96	102
117.	78	96	102
118.	78	96	102
119.	78	96	102
120.	78	96	102
121.	78	96	102
122.	78	96	102

Increased IGF-1/insulin signalling due to a Western diet (hyperglycaemic carbohydrates; milk and dairy products).



Cells. 2023 Nov 10;12(22):2600.



Dietary intervention

A 12-week intervention with a low glycemic-load (GL) diet in males aged 15 to 25 years, with mild moderate acne found that the diet reduced acne lesions, as well as weight, free androgen index, and increased IGF-1 binding protein and the ratio of saturated to monounsaturated fatty acids of skin surface triglycerides.

Am J Clin Nutr. 2007 Jul;86(1):107-15.

A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial¹⁻³

Abdya S, Smith NJ, Moore, Anna-Rose, Haines, Mikolajczyk, and George A. Veligez

ABSTRACT
Background: Although the pathogenesis of acne is poorly understood, recent epidemiologic studies of non-Hispanic populations suggest that dietary factors, including the glycemic load, may be involved.
Objective: The objective was to determine whether a low-glycemic-load diet improves acne lesion counts in young adults.
Design: From 2004 to 2005, 25 male patients aged 15-25 years were recruited for a 12-wk, parallel design, dietary intervention investigating low-glycemic-load intervention outcomes. The experimental treatment was a low-glycemic-load diet composed of 27% energy from protein and 67% from glucose versus carbohydrate, in terms of the ratio of saturated to monounsaturated fatty acids within reference to the glycemic index. Acne lesion counts and severity were assessed during monthly visits, and insulin resistance (simple fasting insulin/glucose) was measured at baseline and 12 wk.
Results: In 12 wk, mean ± SEM total lesion counts had decreased from 46 ± 6.0 (low-glycemic-load group) to 25 ± 3.3 (high-glycemic-load group) (P = 0.001). The experimental diet also modulated adiposity reduction in weight (-1.8 ± 0.6 kg) and waist circumference (-1.8 ± 0.3 kg) (P = 0.001) and body mass index (BMI) (-1.07 ± 0.28 kg/m²) (P = 0.001) and insulin resistance improvement in insulin sensitivity (-0.22 ± 0.12 compared with 0.47 ± 0.21) (P = 0.002) than did the control diet.
Conclusions: The improvement in acne and insulin sensitivity after 12-week dietary intervention suggests the potential role of dietary factors in acne pathogenesis. However, further studies are needed to isolate the independent effects of weight loss and dietary intervention and to further elucidate the underlying pathophysiologic mechanisms. *Am J Clin Nutr* 2007;86:107-15.

KEY WORDS: Acne, glycemic index, glycemic load, insulin resistance, hyperinsulinemia

INTRODUCTION
Acne is a common and annoying skin disorder that affects the individual of all ages. In Western populations, acne is estimated to affect 70-85% of the adolescent population, 80-90% of adolescents older than 25, and 12% of women aged 70 or more by midlife (1). In contrast, acne is rare in most non-Western societies, such as the Hadza (2), Mursi and Suri (3), Ache (4), Inuit (5), and Hutterite (6) peoples (7). Although IGF-1 and other factors are up-regulated in acne patients, this observation is complicated by the finding that insulin resistance of acute



Effects of a low GI/ GL diet + medication



Int J Dermatol. 2023 Jan;62(1):e39-e42.




Low glycemic load diet

Intervention	Discussion	Guidance
Low glycemic load diet	High-GL diets and resultant insulin resistance and hyperinsulinemia contribute to acne development, while low-GL diets may reduce acne severity.	Limit intake of high-GL foods including refined grains and sugars as well as total available sugars from carbohydrate-rich foods.



19

Acne vulgaris: dietary management options



20

Cocoa

A single-dose of pure cocoa resulted in a significant dose-response related increase in acne lesions in patients with pre-existing acne within 4-days.

J Clin Aesthet Dermatol. 2014 May;7(5):19-23.



ORIGINAL RESEARCH

Double-blind, Placebo-controlled Study Assessing the Effect of Chocolate Consumption in Subjects with a History of Acne Vulgaris

CAROLINE CAPERTON, MD, MSPH; SAMANTHA BLOCK, BS; MARTHA WEA, MD; JONETTE BEHN, MD, PhD; BRIAN BERMAN, MD, PhD
University of Miami School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, Florida; Skin & Cancer Associates, LLP, Co-Director Center for Clinical and Cosmetic Research, Austin, Texas

ABSTRACT
Objective: To assess the effect of chocolate on acne exacerbation in adults between the ages of 18 and 25 with a history of acne vulgaris. **Design:** Double-blind, placebo-controlled, randomized, controlled trial. **Setting:** Single-site, outpatient, research clinical facility at an academic medical institution. **Participants:** Eighteen men between the ages of 18 and 25 were assigned to receive capsules filled with either unprocessed 100 percent cocoa, hydrolyzed potato powder, or a combination of the two, as placebo. **Measurements and Main Results:** Lesions were assessed and photographs were taken of forehead, chin, and face. **Results:** Of the 18 subjects, 15 completed the 4-week trial. There was a statistically significant increase in the number of total acne lesions (comedones, papules, pustules, nodules) was observed on both Day 4 (p=0.0003) and Day 7 (p=0.0003) compared to baseline. A statistically significant Pearson correlation coefficient existed between the amount of chocolate that subject consumed and the number of lesions each subject developed between baseline and Day 4 (r=0.270), while a statistically significant positive correlation existed between baseline and Day 7 (r=0.214). No adverse adverse events occurred. **Conclusions:** It appears that in acne-prone, male individuals, the consumption of chocolate correlates to an increase in the exacerbation of acne.
J Clin Aesthet Dermatol. 2014;7(5):19-23.

The effect that chocolate has on acne has been debated as the benefits, although it has been hypothesized that several factors, including high sugar intake (100), increased levels of insulin, levels of androgens, and abnormal sebum, may have an effect on acne, the role of the diet in the generation and severity of acne remains controversial. In 1982, Comel et al. demonstrated that Westerners have a higher percentage of the population suffering from acne compared to non-Westernized populations, including African, Indian, and Chinese populations. However, Makris and Makris¹ conducted the study for the first time in the placebo but they investigated the effects of chocolate on acne.


The study was conducted in 1989 by Falton et al.² Sixty-five subjects were assigned to consume either a chocolate bar that contained 50 times the amount of saturated fat, or a normal 50g chocolate bar or a chocolate low glycemic bar that contained 25 percent less sugar, corresponding with the 50 percent reduction of saturated fat. Both bars had equal amounts of calories. The results showed that the group that consumed the low glycemic bar had significantly fewer acne lesions than the group that consumed the high glycemic bar. However, Makris and Makris¹ conducted the study for the first time in the placebo but they investigated the effects of chocolate on acne.

DISCLOSURE: The authors report no relevant conflicts of interest.
ADDRESS CORRESPONDENCE TO: Dr. Berne, MD, PhD, Skin & Cancer Associates, LLP, Co-Director Center for Clinical and Cosmetic Research, 2000 Avenida Biscayne, Suite 200, Aptos, FL 32008, Phone: 386-684-0714, Fax: 386-684-0718, E-mail: berne@scapart.com

© May 2014 • Volume 7 • Number 5 • Clinical Aesthetics

21

Pasteurized non-fermented cow's milk, but not fermented milk, is a promoter of mTORC1.




Ageing Res Rev. 2021 May;67:101270.



22

Protein supplements and acne lesions

Total number of acne lesions per person by sex in the months after beginning protein supplement use in a young adult population.



Pontes Tde C, et al. An Bras Dermatol. 2013 Nov-Dec;88(6):907-12.



23


Acne promoting foods

Intervention	Discussion	Guidance
Acne promoting foods	Cow's milk, whey protein, and cocoa have been linked to the development and/or exacerbation of acne. So have dietary supplements vitamin B12 and Kelp.	Consider limiting or eliminating exposure dietary cow's milk, whey protein and cocoa if suspected to be contributing to symptoms. High dose vitamin B12 and Kelp supplements may also contribute to acne-like symptoms.



24

Acne vulgaris: nutrient management options



25


Vitamin A

A review of clinical trials of vitamin A for the treatment of acne identified eight prospective studies published between 1943 and 1981. Of these all the studies reported improvement apart from one study that may have been impacted by an insufficient treatment duration. The treatment response was 82%, which is similar to the clearance rate of 85% observed with isotretinoin.

J Drugs Dermatol. 2022 Jun 1;21(6):683-686.



26




Vitamin A

Intervention	Discussion	Guidance
Vitamin A	Vitamin A may be a suitable alternative to isotretinoin (a vitamin A analogue).	Consider a course of >100,000 IU/daily for 4-months. Although relatively safe, monitor for hypervitaminosis A and avoid in pregnancy.



27

Acne vulgaris: nutrient management options



28

Biotin

In a clinical trial (n=60), biotin supplementation (10 mg/ day) was added to isotretinoin therapy over 4-months. Compared to isotretinoin alone, biotin decreased sign of hair thinning and loss (telogen and increased anagen hair rates) and maintained skin hydration.

Int J Dermatol. 2021 Aug;60(8):980-985.



Journal of
Dermatology

Report

Evaluation of biophysical skin parameters and hair changes in patients with acne vulgaris treated with isotretinoin, and the effect of biotin use on these parameters

Sema E. Aksac¹, MD, Serap G. Bilgili², MD, Goknur O. Yavuz², MD, Ibrahim H. Yavuz², MD, Murat Aksac¹, MD and Ayse S. Karadağ¹, MD

¹Department of Dermatology, Marmara University, Faculty of Medicine, Söğütözü Yolu, Söğütözü, Bursa, Turkey; ²Department of Plastic and Reconstructive Surgery, Faculty of Medicine, Marmara University, Söğütözü Yolu, Söğütözü, Bursa, Turkey

Correspondence: Sema E. Aksac, MD, Department of Dermatology, Marmara University, Söğütözü Yolu, Söğütözü, Bursa, Turkey. E-mail: semaksac@med.marmara.edu.tr

Conflict of interest: None

Funding source: None

doi:10.1111/ijd.15188

Abstract
Aim: Isotretinoin (IT) is a retinoid used in the treatment of acne vulgaris. However, IT has several side effects, including skin dryness and hair loss. Biotin supplementation may help to reduce these side effects. This study aimed to evaluate the effect of biotin supplementation on skin hydration and hair changes in patients with acne vulgaris treated with IT. **Methods:** A randomized, controlled trial was conducted. Sixty patients with acne vulgaris were divided into two groups: Group A (IT 1 mg/kg/day) and Group B (IT 1 mg/kg/day + biotin 10 mg/day). Skin hydration was measured using a digital dermograph, and hair changes were assessed using a digital hair pull test (DHT). **Results:** In group B, the mean hair loss rate decreased significantly (P < 0.05) compared to group A. Skin hydration was maintained in group B, while it decreased significantly in group A (P < 0.05). **Conclusion:** Biotin (10 mg/day) given in addition to isotretinoin treatment decreased hair loss and increased anagen hair rates and helped to maintain skin hydration. The use of 10 mg/day biotin can prevent the mucocutaneous adverse effects of isotretinoin treatment.

Introduction
Acne vulgaris is a disease of the pilosebaceous unit, characterized by increased sebum production, follicular hyperkeratinization, and inflammation. It is a common skin condition that affects a large number of people worldwide. Isotretinoin is the only drug effective in the long-term management of acne vulgaris. Data show that there are many adverse effects during treatment with isotretinoin and that they are dose-dependent. In 80% of patients, adverse effects related to skin and mucous are observed. The most common of these are chapped, dry nose, dry mouth, dry eye, hair loss and conjunctivitis, xeroderma, conjunctivitis, paronychia, dryness, and redness of the skin.¹ Biotin is an essential water-soluble vitamin, and its daily dose is about 30 µg/day.² The reason for the hair loss observed in a patient is the inhibition of the hair cycle by the decrease in the number of hair cells in the anagen phase.³ The frequent toxic effects in the hair with the use of isotretinoin and therefore the disruption of hair metabolism suggest that some mucocutaneous adverse effects observed in patients using isotretinoin are due to reduced enzyme activity.⁴ Biotin is an established vitamin used for measuring hair growth parameters that can be used in the examination room, including digital image analysis with reflectance spectroscopy.⁵ With skin biophysical parameters, sebum, pH, hydration, transdermal water loss (TEWL), erythema, and redness levels of the skin can be measured using noninvasive, painless, and safe methods. With these measurements, the effectiveness of drugs, ambient humidity, and the treatments applied in the skin can be evaluated.⁶

29


Biotin

Intervention	Discussion	Guidance
Biotin	Biotin deficiency may be associated with acne, but more evidence is needed.	Consider >30 µg daily if risk factors for deficiency are present. Reduces mucocutaneous side-effects isotretinoin of at 10 mg daily.



30

Acne vulgaris: nutrient management options



31

Vitamin B3

"A pellagra diagnosis should focus on the presence of the "3 D's" (diarrhoea, dermatitis and dementia). The clinical features of acne include "3 D's": dermatitis (acne, seborrheic dermatitis), dyspepsia, and depression."

American Journal of Clinical and Experimental Medicine. Vol. 9, No. 6, 2021, pp. 204-208.



32

American Journal of Clinical and Experimental Medicine
 2021, Vol. 9, No. 6, 2021
 ISSN: 2154-8213 (Print); ISSN: 2154-8221 (Online)

Acne Vulgaris Is a Special Clinical Type of Pellagra
 Jiang Hai^{1*}, Li Changyi²

¹Research Department, The First Hospital of Guangxi University of Chinese Medicine, Nanning City, China
²Dermatological Department, The First Hospital of Guangxi University of Chinese Medicine, Nanning City, China

Email address:
 *jiaanghai@163.com; lichangyi@163.com

To cite this article:
 Jiang Hai, Li Changyi. Acne Vulgaris Is a Special Clinical Type of Pellagra. American Journal of Clinical and Experimental Medicine. Vol. 9, No. 6, 2021, pp. 204-208. doi:10.11480/ajcem.v9n6.20210904.11

Received: November 3, 2021; Accepted: November 23, 2021; Published: November 24, 2021

Abstract: Background: Acne, the most common skin disease characterized by comedones, papules, pustules, nodules, and/or cysts, has a prevalence of 96% during adolescence. The pathogenesis of acne vulgaris requires further study based on the pathological and pathophysiological changes in acne. Recent findings and evidence: Adolescence is the period when teenagers have very high nutritional demands. The occurrence of acne during adolescence suggests that the patient is nutritionally deficient or has increased nutritional requirements. Malnutrition of vitamins (focus) is the most important cause of abnormal metabolism and endocrine. A pellagra diagnosis should focus on the presence of the "3 D's" (diarrhea, dermatitis and dementia). The clinical features of acne include "3 D's": dermatitis (acne, seborrheic dermatitis), dyspepsia, and depression. Patients with acne are frequently associated with abnormal serum lipid profiles and elevated serum uric acid. Fatty acids are an important pathological change in acne lesions. Nicotinamide is the only vitamin that promotes the effect of cholesterol and other lipids from cells and prevents them from cell formation. Fatty acids in some lesions suggest that patients with acne are deficient in niacin. Recently, several studies have reported the efficacy and safety of nicotinamide and niacin for acne treatment. Summary: Based on an analysis of the clinical features of acne vulgaris, pathological changes in acne lesions and the therapeutic effects of niacin on acne, we propose that acne can be diagnosed as a specific clinical type of pellagra, and niacin is the first choice for the treatment of acne vulgaris.

Keywords: Acne, Niacin, Nicotinamide, Pellagra, Vitamin B3

1. Introduction


Pellagra is a systemic disease resulting from a marked chronic deficiency of Vitamin B3 (niacin and/or nicotinamide [1-3]). Niacin and nicotinamide are precursors of coenzyme I (the reduced form of nicotinamide adenine dinucleotide (NAD)) and coenzyme II (the reduced form of nicotinamide adenine dinucleotide phosphate (NADP)), which either donate or accept hydrogen ions in vital redox-reduction reactions [1, 2]. A pellagra diagnosis should focus on the presence of the "3 D's" (diarrhea, dermatitis and dementia). Nicotinamide and niacin are essential nutrients. However, the later clinical symptoms do not always appear on a patient at the same time; they can appear along a continuum in many patients. Moreover, there are no chemical tests available to definitively diagnose pellagra [1]. If a pellagra patient had symptoms of dementia, it is difficult to evaluate this condition, because the nervous tissues in brain may have been damaged. The current diagnostic approach to pellagra does not provide a basis for early warning, definitive diagnosis, timely treatment, and preventing pellagra from deteriorating and aggravating. Medical doctors cannot diagnose a patient in a timely and accurate pellagra clearly.

Why does niacin deficiency cause pellagra? The pathogenesis of pellagra has not yet been fully elucidated. If pellagra patient had symptoms of dementia, it would be difficult to evaluate the condition because the nervous tissues in the brain may have been damaged. The current diagnostic approach to pellagra does not provide a basis for early warning, definitive diagnosis, timely treatment, and preventing pellagra from deteriorating and aggravating. Medical doctors cannot clearly diagnose patients with mild or

Nicotinamide

An 8-week clinical trial of nicotinamide (750 mg daily), zinc (25 mg), copper (1.5 mg), and folic acid (500 mcg) reported a significant improvement in acne severity with treatment.

Cutis. 2006 Jan;77(1 Suppl):17-28.



Nicotinamide and Zinc in the Treatment of Acne and Rosacea

Supported by an educational grant from Sirius Laboratories, Inc.

Introduction Nicotinamide and Zinc in the Treatment of Acne and Rosacea Helen M. Torck, MD	page 3
The Mechanisms of Action of Nicotinamide and Zinc in Inflammatory Skin Disease David P. Fiverson, MD	page 5
Pharmacologic Doses of Nicotinamide in the Treatment of Inflammatory Skin Conditions: A Review Neil M. Niren, MD	page 11
The Nicamide [®] Improvement in Clinical Outcome Study (NICOS): Results of an 8-Week Trial Neil M. Niren, MD Helen M. Torck, MD	page 17



Vitamin B3


Intervention	Discussion	Guidance
Vitamin B3	Subclinical vitamin B3 deficiency may be associated with acne. Nicotinamide has pharmacological anti-inflammatory effects.	Nicotinic acid at a dose of 500 mg three times daily could be trialed, however patients should be counseled about flushing. A minimum 8-week course of 600 mg to 750 mg of nicotinamide may help reduce acne severity.



Pantothenic acid



Baseline



Week 12

Dermatol Ther (Heidelb). 2014 Jun;4(1):93-101.



37


Vitamin B5

Intervention	Discussion	Guidance
Vitamin B5	High-dose pantothenic acid has shown some evidence of benefit.	A minimum 12-week course of at least 2.2 g of pantothenic acid could be considered.



38


Acne vulgaris: nutrient management options



39

Oxidative stress: correlation with disease activity

Biomarkers of oxidative and nitrosative stress in serum acne vulgaris (AVS) with mild (n = 20), moderate (n = 23), and severe (n = 7) scores and in normal human sera (NHS, n = 40).



Al-Shobaili HA, et al. Biochemical markers of oxidative and nitrosative stress in acne vulgaris: correlation with disease activity. J Clin Lab Anal. 2013 Jan;27(1):45-52.




40

Antioxidants

An antioxidant complex providing zinc methionine (35 mg), ascorbic acid (180 mg), mixed carotenoids (18 mg), vitamin E as D-alpha tocopheryl acetate (45 IU) and chromium picolinate (36 mcg) daily, in divided doses, resulted in a significant reduction in clinical symptoms over 12-weeks.

Dermatol Ther. 2010 Jul-Aug;23(4):411-8.



41


Antioxidant nutrients

Intervention	Discussion	Guidance
Antioxidant nutrients	Redox imbalance and inflammation are intrinsic to acne pathophysiology, can be modulated by antioxidant nutrients and improve the disease course.	Consider multi-nutrient formulations designed to modulates oxidative stress. Improve dietary antioxidant intake with foods rich in antioxidant vitamins (especially vitamins C and E), carotenoids and polyphenols.



42

Acne vulgaris: nutrient management options



43

Zinc

“Minocycline nevertheless showed a 9% superiority in action at 1 month and one of 17% at 3 months, with respect to the mean change in lesion count. Regarding safety, the majority of the adverse effects of zinc gluconate and of minocycline concerned the gastrointestinal system and were moderate (5 dropouts with zinc gluconate and 4 with minocycline).”

Dermatology. 2001;203(2):135-40.

Pharmacology and Treatment

Dermatology

December 2001;203(12):144

Review Article by 2001
Volume 203, No. 12, 2001

Multicenter Randomized Comparative Double-Blind Controlled Clinical Trial of the Safety and Efficacy of Zinc Gluconate versus Minocycline Hydrochloride in the Treatment of Inflammatory Acne vulgaris

Brigitte Dreno¹, Dominique Meyeux², Moheeb Alirezzi³, Pierre Amblard⁴, Nicole Aufferet⁵, Claire Beyer⁶, Isaac Bodokh⁷, Martine Chivoz⁸, Françoise Daniel⁹, Philippe Humbert¹⁰, Jean Moynadier¹¹, Florence Pott¹² and private practices dermatologists coordinated by the Acne Research and Study Group

¹Department of Dermatology, CHU Nantes, ²Stasbourg, Paris, ³Department of Dermatology, Hôpital Saint-Eloi, Montpellier, ⁴Department of Dermatology, CHU Albert Michallon, Grenoble, ⁵Department of Dermatology, Fondation Rothschild, Paris, ⁶Department of Dermatology, Hôpital de Haut-Lévroux, Bourges, ⁷Dermatology, Caen, ⁸Dermatology, Centre Médical du Grand Bégin, Rouen, ⁹Department of Dermatology, Hôpital Saint-Jacques, Paris, ¹⁰Department of Dermatology, Hôpital Saint-Jacques, Rouen, and ¹¹Department of Dermatology, Hôpital Saint-Maurice, Créteil, France

Key Words: Zinc, Acne, Minocycline, Clinical trial

Abstract: In addition to minocycline, zinc may constitute an alternative treatment in inflammatory lesions of acne. **Objective:** To evaluate the place of zinc gluconate in relation to antibiotics in the treatment of acne vulgaris. **Methods:** Zinc was compared to minocycline in a multicenter, randomized, double-blind trial. 302 patients received either 30 mg elemental zinc or 100 mg minocycline over 3 months. The primary endpoint was defined as the percentage of the clinical success rate on day 90 (i.e., more than 25% decrease in inflammatory lesions, i.e., papules and pustules). **Results:** The clinical success rate was 31.2% for zinc and 43.4% for minocycline. Minocycline nevertheless showed a 9% superiority in action at 1 month and one of 17% at 3 months, with respect to the mean change in lesion count. Regarding safety, the majority of the adverse effects of zinc gluconate and of minocycline concerned the gastrointestinal system and were moderate (5 dropouts with zinc gluconate and 4 with minocycline). **Conclusion:** Minocycline and zinc gluconate are both effective in the treatment of inflammatory acne, but minocycline has a superior effect evaluated 17% in our study.

Introduction: Zinc salts have been used as a topical treatment of acne in 1979. The first available chemical form was zinc sulfate. Zinc gluconate became available in solution in the case of the rightness. The latter salt would have a superior effect...


KEYWORD: © 2001 by Blackwell Science Ltd
Zinc, Acne, Minocycline, Clinical trial
DOI: 10.1046/j.1365-2231.2001.02967.x
www.blackwell-science.com

Editorial Office: Department of Dermatology, Hôpital Saint-Jacques, 104 rue de la Harpe, F-75571 Paris Cedex 12, France
E-mail: derm@blackwell-science.com



44

Zinc



Dermatology. 2001;203(2):135-40.



45


Zinc

Intervention	Discussion	Guidance
Zinc	Zinc deficiency is common in acne, but zinc may also have direct disease-modifying effects.	Supplementation with 30 mg elemental zinc daily would be useful in deficiency but may also be useful as a treatment in inflammatory acne independent of overt deficiency.



46

Acne vulgaris: nutrient management options



47

Fatty acids

A 10-week, randomized controlled trial in adults with mild to moderate acne found that supplementation with EPA and DHA (2000 mg) or gamma-linoleic acid (400mg from borage oil) found that both treatment reduced acne severity and inflammation.

Acta Derm Venereol. 2014 Sep;94(5):S21-5.



48

Acta Derm Venereol 2014; 94: S21-S25

INVESTIGATIVE REPORT

Effect of Dietary Supplementation with Omega-3 Fatty Acid and Gamma-linolenic Acid on Acne Vulgaris: A Randomised, Double-blind, Controlled Trial

Jin Young LAMP^{1,2}, Hyeon Eun KWON^{1,2}, Jung Hye LIM^{1,2}, Ji Young YOON^{1,2}, Mi Sun SHUK^{1,2}, Hee Young LAMP^{1,2} and Dae Hyeo YU^{1,2}

¹Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea; ²Seoul National University Hospital, Seoul, Korea; ³Department of Food Service and Nutrition Care, Seoul National University Hospital, and ⁴Seoul National University College of Medicine, Seoul, Korea

Abstract

This study was undertaken to evaluate the clinical efficacy, safety, and histological changes induced by dietary omega-3 fatty acid and gamma-linolenic acid in acne vulgaris. A 10-week, randomized, controlled parallel dietary intervention study was performed in 40 participants with mild to moderate acne, which were allocated to either an omega-3 fatty acid group (2000 mg of eicosapentaenoic acid and docosahexaenoic acid), a gamma-linolenic acid group (400 mg of gamma-linolenic acid), or a control group. After 10 weeks of omega-3 fatty acid or gamma-linolenic acid supplementation, inflammatory and non-inflammatory acne lesions decreased significantly. Patient subjective assessment of improvement showed a similar result. Histomorphometric analysis of acne lesions demonstrated reduction in inflammation and immunohistochemical staining intensity for interleukin-8. No adverse adverse effect was reported. This study shows for the first time that omega-3 fatty acid and gamma-linolenic acid could be used as adjunct treatment for acne patients. **Key words:** acne; gamma-linolenic acid; omega-3 fatty acid.

Accepted 18. 8. 2014. Epub ahead of print Feb 18, 2014.

Acta Derm Venereol 2014; 94: S21-S25.

Dr Hee Young LAMP, PhD, Department of Dermatology, Seoul National University Hospital, 28 Yongon-dong, Chungjeong-gu, Seoul 151-747, Korea. E-mail: lamhy@snu.ac.kr

Acne vulgaris is one of the most common skin diseases, but the pathogenic mechanism involved is not fully understood. Recently, the effect of diet related to acne vulgaris has been widely discussed. For example, hyperglycemic, food-caloric hyperpalatability is proposed to lead to insulin resistance that aggravates acne (1, 2), and a high glycemic load has been shown to affect acne in epidemiologic studies (3, 4) and in a randomized, controlled trial (5). Dairy foods could also aggravate acne vulgaris (6, 7), and acne is often associated with acne vulgaris because they contain androgens. Secondary steroids (e.g. dihydrotestosterone) and other non-steroidal growth factors that affect the proliferation of keratinocytes.

Many studies have investigated the influence of omega-3 fatty acid and gamma-linolenic acid (GLA) on various diseases (8-13). Omega-3 fatty acid has anti-inflammatory and anticancer properties (10-12). In few, well-controlled studies have been conducted on the influence of these fatty acids on acne. Typically, dietary food contains a higher ratio of omega-6 to omega-3 fatty acids than most Westerners' food (1, 2). Omega-3 fatty acids affect the synthesis of the acute pro-inflammatory mediators (12, 23, 25, 32, 34). GLA is one of the essential omega-6 fatty acids, but its dietary supplementation in patients with acne, dermatitis has produced inconsistent results. Nevertheless, it has anti-inflammatory effect on human skin disorders, and it might play a physical structural role in skin barrier integrity (17, 24, 26, 34, 36). Therefore, we conducted that the anti-inflammatory effects of omega-3 fatty acid and GLA might moderate acne vulgaris.

The aim of this study was to evaluate the clinical efficacy and safety of omega-3 fatty acid and GLA for the treatment of mild to moderate acne vulgaris. To our knowledge, this is the first randomized, double-blind controlled study to be conducted on this topic.


MATERIAL AND METHODS

Study design and subjects

This study was designed as a 10-week, randomized, prospective, double-blind, controlled trial, and was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board approval No. 10-085-003-000. Informed consent was obtained from all study subjects. Patients were not allowed to use any systemic, topical, or other acne treatments during the course of the study. The randomization method was computer-generated random numbers and concealed in opaque envelopes. The randomization sequence was generated by computer software. The study subjects were allocated to randomized groups of omega-3 fatty acid or gamma-linolenic acid group, the GLA group, or the control group. A parallel, double-blind, randomized controlled study was conducted on this topic.

© 2014 Acta Derm Venereol. 94: S21-S25. All rights reserved. Acta Derm Venereol 2014; 94: S21-S25.

Fatty acids



Acta Derm Venereol. 2014 Sep;94(5):521-5.



49


Fatty acids

Intervention	Discussion	Guidance
Fatty acids	Clinical interventions have found a good clinical response to EPA and DHA and/ or GLA.	A minimum 12-week course of fish oil providing around 1000 mg EPA and DHA/ or 320 mg of GLA could be considered in patients with acne.



50

Acne vulgaris: nutrient management options



L rhamnosus GG

A 12-week clinical trial of a *L rhamnosus* GG (3 billion CFU daily) in adults reduced clinical symptoms of acne and improved expression of genes involved in insulin signaling in their skin.

Rating	Probiotic group (n=10)	Placebo group (n=10)
Worsened	0 (0%)	0 (0%)
Unchanged	2 (20%)	9 (90%)
Improved	6 (60%)	1 (10%)
Markedly improved	2 (20%)	0 (0%)
Resolved	0 (0%)	0 (0%)

Benef Microbes. 2016 Nov 30;7(5):625-630.



Benefit Microbes, 2016 online

ARTICLE IN PRESS

Supplementation with *Lactobacillus rhamnosus* SP1 normalises skin expression of genes implicated in insulin signalling and improves adult acne

G. Falhoutsos¹, M. Betsios¹, G. Pissas¹, H. Pette Galanos¹, G. Moustacostas¹ and E. Epanoudaki²

¹Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy; ²SK Science, Via Mezzogiugno, 41, 27019 Abbadesse (PS), Italy; ³Pharmaceutical Education and Consulting, Avenida das Flores, Amadora, 1649-002 Lisbon, Portugal; ⁴International European and Research Institute (I.I. Ite), s/n, Villavieja de Cabeza, 28670 Madrid, Spain, info@benefmicrobes.com

Received 30 Mar 2016 / Accepted 4 June 2016
© 2016 Wageningen Academic Publishers

RESEARCH ARTICLE

Abstract

Synthetic supplementation with probiotics is increasingly being explored as a potential treatment strategy for skin disorders. Because both the gut skin axis and dysregulation of insulin signalling, have been implicated in the pathogenesis of adult acne, we designed the current study to evaluate the effect of supplementation with the probiotic strain *Lactobacillus rhamnosus* SP1 (LSP1) on skin expression of genes involved in insulin signalling and acne improvement in adult subjects. A pilot, randomised, double-blind, placebo-controlled study was conducted with 20 adult subjects (14 females and 6 males) mean age: 25.7 (±3.5) years) with acne. Over a 12-week period, the probiotic group (n=10) received a liquid supplement containing LSP1 at a dose of 3 × 10⁹ CFU/dose (75 mg/dose), whereas the placebo group (n=10) received a liquid placebo. Facial skin biopsies – were obtained before treatment initiation and one obtained at the end of the 12-week treatment period – were analysed for results like growth factor 1 (IGF1) and Insulin like growth protein 1 (IGF1R) gene expression. The clinical criterion of efficacy was the investigator's global improvement rating on a five-point scale. Compared with baseline, the probiotic group showed a 25% (P<0.001) reduction, as well as a 60% increase (P<0.001) in IGF1 and IGF1R gene expression in the skin, respectively. No such differences were observed in the placebo group. Patients in the probiotic group had an adjusted odds ratio of 18.4 (95% confidence interval = 7.2–41.1, P<0.05) to be rated by physicians as improvement/fully improved versus worsened or unchanged (compared with) the placebo group. We conclude that supplementation with the probiotic strain LSP1 normalises skin expression of genes involved in insulin signalling and improves the appearance of adult acne.

Keywords: acne, probiotic, *Lactobacillus rhamnosus* SP1, supplementation, insulin signalling, skin gene expression

1. Introduction

Acne is a common chronic inflammatory disorder characterised by a number of different skin lesions, including comedones as well as papules and inflamed pustules and nodules (Dun and Reynolds, 2014; Tian and Han, 2015). The pathogenesis of inflammatory acne is complex and involves increased sebum production and hyperplasia of the sebaceous glands under androgenic influence. Acne deterioration from increased keratinocyte desquamation and proliferation, Propionibacterium acne colonisation, and inflammatory cell infiltration (Chen and Liaw, 2015; Zhou, 2016).

According to Zhou (2016) suggests that alterations in insulin signalling may play a significant role in the pathogenesis of adult acne (Bhat et al., 2013; Corcos et al., 2002; Dal Pino et al., 2012; Kishimoto and Thang, 2013; Nagai et al., 2014; Taniuchi and Imai, 2014). Insulin-like growth factor (IGF) 1-like growth factor (IGF1) and insulin-like growth factor (IGF1R) have been shown to play a role in acne (Mullali and Sathyan, 2009) and raised serum IGF-1 levels have been associated with increased risk of post-adolescent acne in women (Agnaf and Nilsson, 1995). In fact, increased delivery of IGF1 (KISHIMOTO) has been linked to lower prevalence rates of acne (Mishra et al., 2011). IGF1 potentially stimulates both sebaceous hyperplasia and androgen

ISSN 2042-9246 DOI: 10.1080/20429246.2016.1150000


Probiotics

Intervention	Discussion	Guidance
Probiotics	Probiotics can modulate microbiome composition and/ or function and are emerging as a therapeutic option for improving the function of the gut-brain-skin axis.	Evidence suggests probiotics, regardless of the type of product or strains used, may improve acne symptoms. It appears prudent to trial a course of probiotics in patients with acne.



53

Acne vulgaris: nutrient management options



54

Green tea extract

A 4-week clinical trial in adult women with acne found that green tea extract resulted in a statistically significant improvement in total and inflammatory acne lesions.

Complement Ther Med. 2016 Apr;25:159-63.



Green tea

Intervention	Discussion	Guidance
Green tea extract	Green tea extract is a safe and useful intervention for reducing acne severity.	A 4-week course of green tea extract providing 856mg of epigallocatechin-3-gallate daily may be useful, but care should be taken with long-term use due to hepatic side-effects.



Atopic dermatitis




57

Atopic dermatitis

“Atopic dermatitis (AD) is a common eczematous skin disorder affecting 2-20% of the general population with age and ethnic differences. AD is characterized by chronic cutaneous inflammation and dry skin with epidermal barrier dysfunction. Intense pruritus is the major and burdensome symptom of AD.”

Allergol Int. 2017 Jan 2. pii: S1323-8930(16)30171-X.



Allergology International

Journal homepage: <http://www.aicaster.com/boothby01/>

Review Article

Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies

Masataka Furue^{1,2,3,4,*}, Takahito Chiba², Gaku Tsuji^{3,4}, Dugamma Uthir⁵, Makiko Kido-Nakahara², Takashi Nakahara^{6,7}, Takafumi Kadono⁸

¹Department of Dermatology, Hyogo University, Hyogo, Japan
²Department of Dermatology, Osaka University, Suita, Japan
³Department of Dermatology, Department of Dermatology, Osaka University, Suita, Japan
⁴Department of Dermatology, Osaka University, Suita, Japan
⁵Department of Dermatology, Osaka University, Suita, Japan
⁶Department of Dermatology, Osaka University, Suita, Japan
⁷Department of Dermatology, Osaka University, Suita, Japan
⁸Department of Dermatology, Osaka University, Suita, Japan

ABSTRACT

Atopic dermatitis (AD) is a chronic or chronically relapsing, inflammatory, pruritic skin disorder mostly associated with IgE allergy and skin barrier dysfunction due to the overexpression of ceramides, filaggrin, TLR2 and TLR4, and TLR2-dependent cytokine production. Skin barrier dysfunction due to epidermal barrier dysfunction, such as filaggrin loss, is thought to be a major pathogenic factor in the development of AD. These activities of the immune system, which are not yet fully understood, are thought to be related to the dysregulation of the immune system. TLR2 and TLR4, which induce the Th1 and Th2 immune responses, Th1-dependent cytokines (IFN- γ and TNF- α) induce an Th1 response. TLR2-dependent cytokines (IL-17, IL-22) induce a Th17 response. TLR2-dependent cytokines may also be an adaptive immune to restore the disrupted barrier function (epidermal barrier).

Introduction

Atopic dermatitis (AD) is a common eczematous skin disorder affecting 2–20% of the general population with age and ethnic differences.^{1,2} AD is characterized by chronic cutaneous inflammation and dry skin with epidermal barrier dysfunction.^{3,4} Intense pruritus is the major and burdensome symptom of AD.⁵ Autoimmune-mediated pruritus appears to occur at the site of inflammation by activating cellular damage in the affected skin.⁶

Approximately 80% of AD patients exhibit elevated levels of serum IgE.^{7,8} In contrast to non-IgE and non-allergic atopic AD patients, atopic AD patients with hyper-IgE levels are associated with increased disease severity,^{9,10} eruptions in the IEG phase,¹¹ and impaired skin barrier function.^{12,13} Recent genome-wide association studies and transcriptome analyses indicate at least 30 susceptibility loci for AD, which emphasize the potential involvement of T helper 2 (Th2) cytokines (IL13, IL4, IL5), T helper 17 (Th17) cytokines (IL17A, IL17F), and skin barrier proteins (FLG).^{14–17}

While regarded as immune abnormalities, AD is currently considered as a Th2-type T cell-mediated disease. A Th2 signal predominates in the acute phase, whereas a Th1 or Th17 signal predominates in the chronic phase.^{18,19} However, recent studies have proposed a significant role for Th17 cytokines (IL17A, IL17F) in AD.^{20,21}


*Corresponding author. Department of Dermatology, Osaka University, Suita 565-0871, Japan. E-mail: furue@dermatology.osaka-u.ac.jp
 E-mail address: furue@dermatology.osaka-u.ac.jp (M.F.).
 For reprints and permissions, please contact the publisher.

© 2017 All rights reserved. This is an open access article under the [CC BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/).

Please cite this article in press as: Furue M, et al., Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergology International (2016), <http://dx.doi.org/10.1016/j.allint.2016.12.001>

58

Cellular and molecular immunologic mechanisms




J Allergy Clin Immunol. 2016 Aug;138(2):336-49.




59

Atopic dermatitis: dietary management options




60

Atopic dermatitis: nutrient management options



61

Atopic dermatitis: dietary management options



62

Food triggers

In a double-blind placebo-controlled food challenge, 46% of children with atopic dermatitis experienced a food reaction to cow's milk, hen's egg, wheat or soy, with immediate-onset reactions tending to produce erythema or urticaria, and delayed-onset reactions typically producing a flare up of preexisting lesions.

Clin Exp Allergy. 2004 May;34(5):817-24.



Clin Exp Allergy 2004; 34:817-24 doi:10.1111/j.1365-2222.2004.01033.x

Late eczematous reactions to food in children with atopic dermatitis

K. Breuer*, A. Heratizadeh*, A. Wall*, U. Baumamt, A. Consten*, D. Teusa*, A. Kapp* and T. Werfel*

*Department of Dermatology and Allergy, Hannover Medical University, Germany and †Department of Pediatric Pathology and Nematology, Hannover Medical University, Germany

Summary
Background: Food allergy is a common problem in patients with atopic dermatitis (AD), particularly in children. While immediate reactions to food are well characterized, the importance of food as a provocation factor for late eczematous reactions has been a subject of debate for several decades.
Objective: To investigate the importance of food for the induction of late eczematous reactions in children with AD and to correlate the clinical outcome to the results of specific IgE determinations and atopy patch tests (APT).
Methods: One hundred and six double-blind placebo-controlled food challenges (DBPCFC) to cow's milk, hen's egg, wheat and soy in 64 children with AD (median age 2 years) were analysed retrospectively. Food and food-specific IgE were determined by CAP RAST FEIA and APT with native foodstuffs were performed. The diagnostic values of specific IgE and APT results were calculated.
Results: Forty-nine (60%) of the challenges were related to a clinical reaction. An exacerbation of AD (late eczematous reaction) commonly occurred 24h after the ingestion of food. Isolated late eczematous reactions were seen in 12% of all positive challenges. Forty-three percent of the positive challenges were associated with late eczematous responses, which followed immediate-type reactions. The sensitivity of food-specific IgE and the APT was 76% and 70%, respectively. Specific IgE and APT were often false positive, which resulted in low positive predictive values (64% and 45%, respectively).
Conclusion: Late eczematous reactions may often be observed upon food challenge in children with AD. Due to the poor reliability of food-specific IgE and APT results DBPCFCs have still to be regarded as the gold standard for the appropriate diagnosis of food responsive eczema in children with AD.
Keywords: atopic dermatitis, atopy patch test, food allergy, food challenge, food responsive eczema, food-specific IgE

Submitted 1 August 2003; revised 10 December 2003; accepted 2 February 2004

Introduction
 According to Wittreich, three patterns of cutaneous reactions to food may occur in patients with AD upon oral challenge [10]:
 (i) Immediate-type reactions such as urticaria, angioedema and erythema, commonly occurring a few minutes after ingestion of food without an exacerbation of AD.
 Additionally, gastrointestinal, respiratory and cardiovascular symptoms may evolve.
 (ii) Pruritus occurring soon after the ingestion of food with subsequent scratching leading to an exacerbation of AD.
 (iii) Exacerbations of AD occurring after 6–48 h without late reactions. Late reactions may occur also after an immediate-type response.
 The prevalence of food allergy in infants with AD was reported in a range between 20% and 80% in various studies, and may be estimated at 30% [11–13]. Hen's egg, cow's milk, soy and wheat account for about 80% of allergenic foods in children with AD [1, 14]. Dependent on the kind of food,

Correspondence: Kristin Brauer, Department of Dermatology and Allergy, Hannover Medical University, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany. E-mail: kristinbrauer@mh-hannover.de

© 2004 Blackwell Publishing Ltd 817

63


Trigger foods

Intervention	Discussion	Guidance
Trigger foods	Foods that trigger symptoms are relatively common but often overlooked, and avoidance may help control symptoms.	Trigger foods can be identified based on patient history; however, people may not have previously associated foods with a flare up in their symptoms. Routine elimination and re-challenge with cow's milk, egg, wheat or soy may be useful. Re-challenge in a medical setting may be advise if there is risk of anaphylaxis.



64

Atopic dermatitis: dietary management options



65

Elimination diets

- ✓ Elimination diets are an important consideration in atopic dermatitis and can result in good clinical improvement.
- ✓ The failure of some studies to produce benefits, however, may be due to lack of personalization i.e. non-discriminate elimination of foods without assessment of sensitivity.
- ✓ Dietary removal of industrial food additives and monosodium glutamate have been shown to reduce atopic dermatitis.
- ✓ Prolonged elimination diets in young children could result in increased risk of immediate-onset and severe allergic reactions, including anaphylaxis.



66

Elimination + functional foods

In children, a personalized elimination diet combined with consumption of antioxidant and omega-3 fatty acids rich-foods found that this approach significantly improved nutritional intakes, reduced disease severity, and improved the growth status, as measured by height and weight scores in children.

Asia Pac J Clin Nutr. 2016 Dec;25(4):716-728



716 Asia Pac J Clin Nutr 2016;25(4):716-728

Original Article

Children with atopic dermatitis in Daejeon, Korea: individualized nutrition intervention for disease severity and nutritional status

Seong Hee Kim MS,¹ Jae Ho Lee MD, PhD,² Sun Yung Ly PhD¹

¹Department of Food and Nutrition, Chungnam National University, Republic of Korea
²Department of Pediatrics, College of Medicine, Chungnam National University, Republic of Korea

Background and Objectives: Atopic dermatitis is one of the most common pediatric chronic inflammatory skin diseases, and certain food allergens and nutrients are closely related to the development and severity of atopic dermatitis. While avoidance of the causative foods is considered the mainstay of treatment, unverified excessive restriction might induce unnecessary limitations in the food intake, consequently leading to nutritional deficiencies and poor growth. This study aimed to identify the characteristics and nutrient intake status in children with atopic dermatitis and to investigate the effects of individualized nutrition intervention. **Methods and Study Design:** We retrospectively reviewed electronic medical records of 77 pediatric patients with atopic dermatitis who received 4 months of individualized nutrition intervention combined with an elimination diet. The patient characteristics, nutrient intake status, and clinical status were examined before and after the intervention. **Results:** Before the intervention, 5 children had a weight-for-height z score below -2.0, and 44.1% had experienced food restriction. After the intervention, these children showed a significantly higher SCORing of Atopic Dermatitis index than those without experience, with the number of restricted foods before the intervention positively correlating with the disease severity. The intakes of ω-6 and ω-3 fatty acids, calcium, fiber, and vitamin D were lower than the recommended nutrient intakes for Koreans. After the intervention, the weight-for-height z score of 33 children was significantly increased and their SCORing of Atopic Dermatitis index was significantly reduced ($p < 0.05$). **Conclusions:** Individualized nutrition intervention appears useful for alleviating the severity of atopic dermatitis and improving the growth status by improving the nutrient intake.

Key Words: atopic dermatitis, individualized nutrition intervention, SCORAD index, growth, nutritional status

INTRODUCTION
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, and frequently begins already in early infancy. Although it varies between different regions, the prevalence of childhood eczema or AD is continuously increasing worldwide. The 2003 National Survey of Children's Health in the US showed that the lifetime prevalence of AD was 10.7% in children under 18 years,¹ while the International Study of Allergies and Allergies in Childhood reported one-year prevalence rates of up to 20% in Australia, England, and Scandinavia.² Further, the Korea National Health and Nutrition Examination Survey data showed an AD rate of 13.0% in children aged 1 to 18 years.³
Numerous trigger factors of AD have been verified in recent decades, including genetic factors,⁴ inhaled allergens, food allergens and certain nutrients,⁵ irritating substances, and infectious microorganisms.⁶ Of these factors, the major food allergens, including egg white, cow's milk, soybeans, wheat, and peanuts, have been reported to be more strongly related to AD in childhood than in adults.⁷ The clinical spectrum of food allergy (FA) ranges from mild skin irritation to severe life-threatening anaphylaxis,⁸ and AD secondary to FA includes skin disorders such as

as incessant pruritus, xerosis, eczematous lesions, and lichenification.
These various skin symptoms of AD secondary to FA are caused by adverse cellular responses activated through specific antibodies against the food allergens,⁹ mediated by both immunoglobulin E (IgE) and non-IgE mechanisms. It has been demonstrated that IgE-mediated FA appears as acute reactions such as localized urticaria and angioedema, whereas non-IgE-mediated FA usually results in delayed respiratory, gastrointestinal, and cutaneous symptoms.¹⁰ Moreover, while it has been well established that IgE-mediated FA plays a central role in the immunopathogenesis of AD,¹¹ non-IgE-mediated responses have also been recently reported as a major characteristic of AD. Direct exacerbation of AD with devel-


Corresponding Author: Dr Sun Yung Ly, Department of Food and Nutrition, Chungnam National University, 99 Daehak-ro, Yongsong-gu, Daejeon 305-700, Republic of Korea.
Tel: +82-42-821-6838; Fax: +82-42-821-8968
Email: sunyung@knu.ac.kr
Manuscript received 05 April 2015; Initial review completed 24 June 2015; Revision accepted 14 July 2015.
doi:10.6133/apjn.092015.31

Personalised elimination diet

Intervention	Discussion	Guidance
Personalized elimination diet	Elimination diets can help reduce symptoms by limiting exposure to allergenic foods that are exacerbating atopy.	An elimination diet can be based on food sensitivity testing, including IgG. Without testing, an elimination and re-challenge with major and/ or suspected food allergens may still be useful. Reducing exposure to food additives and MSG may be useful.
Functional foods	Advice to increase intake of foods with anti-allergic, anti-inflammatory effects such as antioxidant and omega-3 fatty acids rich-foods has been shown to complement an elimination diet.	Advise patient to increase intake of polyphenol-rich fruits and vegetable foods and beverages, additionally increase intake of omega-3 rich foods such as nuts, seeds, and fish.



Atopic dermatitis: dietary management options



69

Gluten free diet

A case report described marked symptomatic improvement in a mother and her two daughters, all diagnosed with atopic dermatitis, after gluten removal. Importantly, while the mother was diagnosed with celiac disease her daughters both tested negative for celiac disease.

International Journal of Celiac Disease, 7(1), 31-32.



70

International Journal of Celiac Disease 2019, Vol. 7, No. 1, 31-32
 Available online at <http://www.ijcd.com>
 Published by Science and Research Publishing
 DOI:10.23918/ijcd.v7i1.4

The Link between the Clinical Features of Atopic Dermatitis and Gluten-related Disorders

Mary Sara¹, Andrea Akber², Loredana Dancu³, Emanuela Dancu⁴, Françoise Dancu⁵, Ciprian Stăniș⁶, Lucia Șer⁷, Corina Albuș⁸

¹Medical Specialist, Turda, Romania
²Neurology Hospital, Cluj-Napoca, Romania
³Neurology Hospital, Cluj-Napoca, Romania
⁴Department of Paediatrics, Babeș-Bolyai University of Medicine and Pharmacy, Cluj-Napoca, Romania
⁵Department of Paediatrics, Babeș-Bolyai University of Medicine and Pharmacy, Cluj-Napoca, Romania
⁶Department of Paediatrics, Babeș-Bolyai University of Medicine and Pharmacy, Cluj-Napoca, Romania
⁷Corresponding author: stanișc@ujcluj.ro

Received January 09, 2019; Revised February 14, 2019; Accepted March 27, 2019

Abstract: Patients affected by non-celiac gluten sensitivity usually report both intestinal and extra-intestinal symptoms strongly likely when the ingestion of gluten-containing food. Atopic dermatitis is a chronic inflammatory skin disease that affects both children and adults. We present the case of a gluten-free diet of a mother (32 years old) and her two daughters (9 and 9 years old) who were diagnosed with atopic dermatitis and gluten-related disorders.

Keywords: atopic dermatitis, gluten-related disorders, gluten-free diet

Cite This Article: Mary Sara, Andrea Akber, Loredana Dancu, Emanuela Dancu, Françoise Dancu, Lucia Șer, and Corina Albuș. "The Link between the Clinical Features of Atopic Dermatitis and Gluten-related Disorders." *International Journal of Celiac Disease*, vol. 7, no. 1 (2019): 31-32. DOI:10.23918/ijcd.v7i1.4

1. Introduction

Atopic dermatitis (AD) is a highly prevalent, inflammatory skin disease that affects between 15% and 30% of children and 2% and 15% of adults worldwide [1]. The pathophysiology of AD involves both immune dysregulation and skin barrier abnormalities [2]. Its course is also triggered by allergen exposure, stress, and microbial imbalance [3].

Gluten-related disorders (celiac disease, wheat allergy, and non-celiac gluten sensitivity) have gradually emerged as an immunologically phenomenon with an autoimmune global prevalence around 1% and share similar clinical manifestations, yet their own peculiar pathogenesis, pathways involved in their development [4-6]. In celiac disease (CD), there is a T-cell mediated autoimmune process which is triggered by gluten derived peptides [7]. This process is localized in the small intestine, where it leads to enteropathy and malabsorption syndrome [8]. When allergy (WA) is another type of adverse immunologic response to proteins contained in wheat and related grains. The inflammatory response to these allergenic proteins is mediated by the immunoglobulin E (IgE) antibodies [9]. The majority of WA children suffer from moderate-to-severe atopic dermatitis and wheat ingestion may lead to typical IgE-mediated reactions including angioedema, urticaria, hives, chest obstruction, abdominal pain or its severe cases.

2. Case Presentation

We present the case of a family composed of a mother (32 years old) and her two daughters (9 and 9 years old) who were diagnosed with atopic dermatitis.

The medical history of the mother revealed that she was first diagnosed with AD at the age of 4 months old. The most important clinical manifestations were erythematous squamous plaques affecting the cheeks and the flexural surfaces (like the wrists/ankles and antecubital popliteal fossae). She suggests that worsened her symptoms were environmental factors, seasonal allergies and the usage of some topical medications. Her treatment included emollients to control itching, she was also recommended to avoid some food triggers that occurred to worsen her rashes. At the age of 12 years old the patient was also diagnosed with CD and she was managed with gluten-free diet, vitamins and minerals. Removing gluten from her diet improved her clinical manifestations and the


Gluten free diet

Intervention	Discussion	Guidance
Gluten free diet	Celiac disease and NCGS may be associated with atopic dermatitis, and a gluten-free diet may be supportive.	Screen for celiac disease due to higher prevalence in atopic dermatitis. Consider NCGS and a gluten-free diet.



71

Atopic dermatitis: dietary management options



72

Modified fasting

Adults received a low-energy (1085kcal/ day) density diet supplemented with high-nutrient foods such as vegetables juice, kelp, and non-refined salt to ensure high micronutrient intake. After the 6-week dietary treatment there was a significant reduction in atopic dermatitis symptoms, as well as a significant reduction in oxidative DNA damage.

J Physiol Anthropol Appl Human Sci. 2000 Sep;19(5):225-8.



JAPANESE
PHYSIOLOGICAL
ANTHROPOLOGY
and Applied Human Science

**Low-Energy Diet in Atopic Dermatitis Patients:
Clinical Findings and DNA Damage**

Katsuyasu Kouda¹⁾, Toshio Tanaka²⁾, Mitsuo Kouda³⁾, Hirochika Takouchi⁴⁾,
Akira Tabuchi⁵⁾, Haruhiko Nakamura⁶⁾ and Masahiro Takiguchi⁶⁾

1) Department of Public Health, Aichi University School of Medicine
2) Third Department of Internal Medicine, School of Medicine, Osaka University
3) Research Institute for Rheumatoid Diseases, Osaka University
4) Research and Development Center, Sumitomo Inc.
5) Department of Dermatology, Hirosaki University School of Medicine

Abstract Undernutrition without malnutrition (low-energy diet) increases maximum longevity, reduces the incidence of several cancers and delays their onset, in animal models. It has also been demonstrated by experimental study that caloric restriction provides a beneficial effect on various inflammatory diseases. In this study, we offered a low-energy diet to patients with atopic dermatitis (AD). Nineteen adult patients (5 males and 14 females aged 18 to 36 years) were enrolled in the study which lasted 6 weeks. The energy intake was 55% of nutritional requirements; protein was 73%, calcium 130%, iron 130%, vitamin A 100%, vitamin C 200% and vitamin E 110% of the daily requirements. No patient experienced adverse reaction, and none dropped out of the study. Body weight, body mass index (BMI), and systolic blood pressure had decreased significantly by the end of study. The SCORAD (scoring atopic dermatitis) index, which measures objective content and intensity of lesions) and subjective (dryness pruritus and sleep loss) symptoms, were reduced significantly. In 11 patients with severe AD, there was a significant reduction in oxidative DNA damage. The change in the inflammatory intensity score and the change in BMI caused by energy restriction showed a significant positive correlation. The change in oxidative DNA damage levels and the change in BMI showed a positive correlation. These results clarify the relationship between weight loss and the improvement of AD. It may be hypothesized that the low-energy diet which included several additional nutrients has a possibility to reduce inflammatory symptoms of patients with AD. *J Physiol Anthropol, 19 (5): 225-228, 2000* <http://www.japen-jp.org/journal/>

Keywords: low-energy diet, oxidative DNA damage, atopic dermatitis

Introduction
Undernutrition without malnutrition (low-energy diet) increases maximum longevity, reduces the incidence of several cancers and delays their onset, in animal studies (Weindrach and Wolford, 1982; Lee et al., 1990). It has also been demonstrated by experimental study that energy restriction provides a beneficial effect on various inflammatory diseases (Fornada et al., 1978; Rhee et al., 1987; Ogata et al., 1988; Hatanaka et al., 1991). Moreover, in a controlled clinical trial, a low-energy diet was reported as a useful supplement to the ordinary medical treatment for patients with rheumatoid arthritis (Kaplan-Grad et al., 1991).
For dietary management in patients with atopic dermatitis (AD), there are many reports concerning alternative diets that exclude foods that are considered to be most likely to be allergenic, such as cow's milk, egg, and soy. On the other hand, Ishii et al. (1983) reported 5 cases of AD that responded by modified fasting (low-calorie vegetarian diet). However, this result did not clearly indicate the clinical effect of low-energy intake for AD. In this study, we offered a low-energy diet to 19 patients with AD, and we report clinical findings including oxidative DNA damage, and demonstrate a relationship between weight loss and clinical improvement of AD.


Methods
Nineteen patients (5 males and 14 females aged 18 to 36 years) with AD were enrolled in the study. The mean age was 26.8 years for males and 25.1 years for females, with an overall average of 25.1 years. AD was diagnosed according to Hanifu and Ebla's criteria (Hanifu and Ebla, 1989). One patient had mild AD with erythematous

Modified fasting

Intervention	Discussion	Guidance
Modified fasting	Modified fasting with a low-energy, high-nutrient density diet may reduce food anti-gen exposure, result in weight loss, and/or have direct anti-allergic effects.	Various approaches could be used to construct a modified fasting regime, including a daily low-energy/ high-nutrient density diet, a supervised 24-hour fast, or a daily 16-hour overnight fast.




Atopic dermatitis: nutrient management options



75

Gut-immune-skin axis




J Allergy Clin Immunol. 2016 Mar;137(3):852-60



76

Probiotics for prevention

Mothers & infants at high-risk for atopy were given *L rhamnosus* GG (10 billion daily) from 2–4 weeks prenatally to 24 weeks postnatally. The cumulative risk for developing eczema during the first 7 years of life was significantly lower in the Lactobacillus GG group than in the placebo group (42.6% vs 66.1%) in the group of children completing the 7-year follow-up.




J Allergy Clin Immunol. 2007 Apr;119(4):1019-21.



77

Probiotics for pediatric treatment

Infants with atopic eczema and suspected allergy to cow's milk received *L rhamnosus* GG (10 billion daily) for around 7.5 weeks. The decrease in the SCORAD scores within the viable LGG group tended to be greater than within the placebo group.



J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):223-7.



78

Probiotics for adult treatment

“Patients receiving probiotics (a combination of *L salivarius* LS01 and *B breve* BR03) showed a significant improvement in clinical parameters from baseline. The probiotics reduced microbial translocation, immune activation, improved T-helper cell (Th)17/regulatory T cell (Treg) and Th1/Th2 (P= 0.028) ratios. None of these changes were observed in the placebo group.”

J Clin Gastroenterol. 2012 Oct;46 Suppl:S33-40.



PRESENTATION

Probiotics Reduce Gut Microbial Translocation and Improve Adult Atopic Dermatitis

Enrico Imai, MD, Darla Fisher, MD,† Susana Parfitt, PhD,* Linda Bergman, MD,* Marco Toscano, MSc,‡ Giuliano Riccardini, MD,* Mario Clerici, MD,†q Elena Ricci, PhD,‡ Alexandra Faust, MD,* Elena De Vecchi, MSc,‡ Stefania Picini, MD,* and Lorenz Smeets, PhD,‡†*

Background: It has been suggested that probiotics modulate atopic dermatitis (AD) progression, but to date no study is available on their mechanism of action and on their ability to act as immunomodulators in the gut.

Objectives: The aim of this randomized, double-blind, active-controlled, versus placebo study was to evaluate clinical efficacy of an oral combination of probiotics (*Lactobacillus salivarius* LS01 and *Bifidobacterium breve* BR03) for the treatment of adult AD patients.

Methods: Forty-eight patients were recruited in the study combination with 24 and treated with a combination (LS01 and BR03) or placebo (microbiota-free) for 12 weeks. Clinical efficacy was assessed from baseline by changes in the SCORAD index and DQoL index. Immunologic parameters and changes in gut mucosal and permeability of patients were performed at baseline, at the end of therapy, and 2 weeks later.

Results: Patients receiving probiotics showed a significant improvement in clinical parameters (SCORAD, *P* = 0.008) and DQoL index (*P* = 0.001) from baseline. The probiotics reduced microbial translocation (*P* = 0.002), immune activation (*P* = 0.002), improved Th17/Th1 regulatory and Th17 (*P* = 0.002) and Th1/Th2 (*P* = 0.028) ratios. None of these changes were observed in the placebo group.

Conclusions: Our results suggest that this specific mixture of probiotics (LS01 and BR03) exerts an active beneficial effect on clinical and immunologic alterations in adult AD. This combination could be considered as adjunct therapy for the treatment of AD in adult patients.

Key Words: atopic dermatitis, probiotics, mucositis, T-helper cells, regulatory T cells

Atopic dermatitis (AD) is an inflammatory and pruritic skin disease affecting skin disorder. There is direct and indirect evidence that the prevalence has increased 5- to 10-fold over the last 30 years.¹ The pathogenesis of AD seems to go through the “hygiene and clinical hereditary” link.² The pathogenesis of AD is multifactorial, involving genetic, immunologic, and environmental factors.³ The pathogenesis of AD is multifactorial, involving genetic, immunologic, and environmental factors.³ The pathogenesis of AD is multifactorial, involving genetic, immunologic, and environmental factors.³

MATERIALS AND METHODS

Patients and Study Design
Sixty adult patients suffering from AD were enrolled in the Allergy Unit of Ospedale Spina in Milan. Forty-eight

J Clin Gastroenterol • Volume 46, Suppl. 1, October 2012 www.jcge.com | S33

79


Probiotics, prebiotics

Intervention	Discussion	Guidance
Probiotics	Some probiotics have anti-allergic effects and may help in the development of oral tolerance early in life.	Probiotics are useful as both a preventative and treatment. Use of a probiotic with clinical evidence demonstrating efficacy in atopic dermatitis is important.
Prebiotics	Prebiotics support the development and restoration of the gut microbiota and, consequently, may help reduce atopy.	Prebiotics have mainly been used in formula-fed infants. If breast feeding is not possible a prebiotic should be considered.



80

Atopic dermatitis: nutrient management options



81

Fatty acids

- ✓ Evening primrose oil supplementation (2,000–6000mg/ day) for 5-months resulted in a 96% response rate and significant reduction in symptoms compared to placebo.
- ✓ Hempseed oil (30ml/ day) for 20-weeks significantly improved skin dryness and itchiness and reduced dermal medication use in adults in one study.
- ✓ Fish oil (providing at least 1.8 g omega-3 per day) for 2-4 months has generally resulted an improvement in symptoms in adults with atopic dermatitis.



82


Fatty acids

Intervention	Discussion	Guidance
Fatty acids	Metabolic impairments in fatty acid metabolism, as well as dietary intakes, could affect immunological function and exacerbate atopy	Assessment of dietary intake as well as laboratory values may help direct choice of fatty acids. A trial with either omega-3 rich oils, or omega-6 rich oils alone is recommended to determine treatment response.



83

Atopic dermatitis: nutrient management options



84

Vitamin D

A meta-analysis of four clinical trials, including both children and adults, showed that vitamin D supplementation reduced atopic dermatitis symptoms and clinical signs significantly when compared with placebo.

Nutrients. 2016 Dec 3;8(12).



nutrients MDPI

Article
Vitamin D Status and Efficacy of Vitamin D Supplementation in Atopic Dermatitis: A Systematic Review and Meta-Analysis

Hye Jung Kim ¹, Sun-Hyang Kim ², Yeong Min Lee ^{3,4,*}, Yeong Beom Cho ^{1,4} and Kyea Joong Ahn ^{1,2}

¹ Department of Dermatology, Konkuk University School of Medicine, Seoul 03053, Korea; ² School of Health Science and Technology, Konkuk University, Seoul 03053, Korea; ³ Department of Dermatology, Konkuk University School of Medicine, Seoul 03053, Korea; ⁴ Research Institute of Medical Science, Konkuk University, Seoul 03053, Korea

* Correspondence: ybcho@konkuk.ac.kr; Tel.: +82-2-3009-1171

Received: 9 August 2016; Accepted: 24 November 2016; Published: 3 December 2016

Abstract: Recent literature has highlighted the possible role of vitamin D in atopic dermatitis (AD), and that vitamin D supplementation might help to treat AD. This study determined the relationship between vitamin D level and AD, and assessed the efficacy of vitamin D supplementation. We searched for MEDLINE, EMBASE, and Cochrane databases up to May 2015. Observational studies and randomized controlled trials were included based on the available data on the serum 25-hydroxyvitamin D (25(OH)D) level and quantified data available for severity assessed using the Scoring Atopic Dermatitis (SCORAD) index, or Eczema Area and Severity Index (EASI) score. Compared with healthy controls, the serum 25(OH)D level was lower in the AD patients of all age-standardized mean difference = -2.83 ng/mL, 95% confidence interval (CI): -2.52 to -4.79, and predominantly in the pediatric AD patients (standardized mean difference = -3.05 ng/mL; 95% CI = -4.76 to -1.29). In addition, the SCORAD index and EASI score decreased after vitamin D supplementation (standardized mean difference = -3.05; 95% CI = -7.86 to -0.05). This meta-analysis showed that serum vitamin D level was lower in the AD patients and vitamin D supplementation could be a new therapeutic option for AD.

Keywords: atopic dermatitis; vitamin D; meta-analysis; systematic review

1. Introduction

Atopic dermatitis (AD) is a common and recurring chronic inflammatory disease characterized by pruritus and eczema. It is commonly associated with hypersensitivity to allergens, more frequently with allergic diseases such as allergic rhinitis and asthma [1]. It especially affects 5%–20% of children and 1%–5% adults worldwide, and its prevalence is increasing in industrialized countries [2]. The pathophysiology of AD is unclear, the result of epidermal barrier dysfunction and immune dysregulation [3]. The traditional therapeutic options for AD are antihistamine and immune modulatory agents, including topical/oral corticosteroids and topical/oral calcineurin inhibitors. These classic treatments are focused on reducing skin inflammation [4], but their potential side effects and poor patient adherence indicate the importance of finding new therapeutic options. Recent studies have suggested that vitamin D supplementation may be a safe and effective alternative treatment for AD. A Cochrane review provided evidence for the efficacy of dietary vitamin D supplements as a treatment for AD in 2012 [5]. However, only two studies were reviewed, and owing to their low quality, the review could not produce conclusive evidence for the efficacy of vitamin D supplements in AD treatment.

Nutrients 2016, 8, 1785; doi:10.3390/nut8121785 www.mdpi.com/journal/nutrients

85


Vitamin D

Intervention	Discussion	Guidance
Vitamin D	Vitamin D deficiency has been associated with increased risk of atopic disease due to its immunological consequences.	Assessment of vitamin D status and subsequent supplementation in the case of deficiency. Alternatively, a routine course of vitamin D would be appropriate if deficiency is suspected.




86

Atopic dermatitis: nutrient management options



87

Oxidative stress



Oxid Med Cell Longev. 2016;2016:2721469.



88

Vitamin E

Vitamin E supplementation (400 IU or 268 mg of natural r,r,r- α -tocopherol in an oil base/ day) for 8-months significantly reduced subjective symptoms, with good responders showing a marked decrease in serum IgE levels.

Nutrients. 2016 Dec 3;8(12).

Report
Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels
 Feriuki Tasari-Nikola, MD, Jura Harcopova, MU, Tereza Lotil, MD, and Gossami Mendhi, MD

Abstract
 Vitamin E (VE) is a potent antioxidant that can improve the immune response, decrease the production and/or release of proinflammatory mediators, and decrease the serum levels of immunoglobulin E (IgE) in atopic subjects. **Aim:** To compare the effects of placebo (P) and VE (400 IU/d) in an oil base (VE) on the clinical course and serum IgE levels in 80 subjects with atopic dermatitis. **Methods and results:** A single-blind clinical analysis was performed on 80 subjects randomly divided into two groups. Fifty subjects were given orally 400 IU (268 mg) of VE at a constant dose, once a day for 8 months, and 40 were in the same period. Complete blood count, serum IgE levels, malondialdehyde (MDA) levels, and total antioxidant capacity (TAC) were measured at the start of the study and every 15 days during the 8 months of the study. To evaluate VE therapy, a questionnaire was sent to each subject for completion at the end of the study. **Results:** The results were as follows: (1) 40 subjects treated with VE showed a 28% reduction in the P group, 35% reduction in the VE group and 40% reduction in the P group; (2) 40% improvement was observed in 10 subjects in the VE group and 40% in the P group; (3) 20 of the 50 subjects treated with VE showed great improvement, compared to only one in the P group; and (4) there was almost complete remission of atopic dermatitis in seven of the 40 subjects in the VE group, but none in the P group. Patients showed less progression of atopic dermatitis than those in both groups, and a higher percentage of almost complete remission (five patients) was observed. The range of serum IgE levels varied from 1000 to 400 IU/ml, in the VE group and from 1200 to 800 IU/ml, in the P group over 8 months. Subjects with great improvement and near remission of atopic dermatitis in the VE group demonstrated a decrease in IgE to serum IgE levels toward normal conditions, while in subjects taking P, the difference was approximately 34.4%. No complications were observed in either group. A correlation improvement in skin symptoms, histopathology, and the presence of apparently normal skin was reported. Experiences herein needed further as a result of decreased protein. **Conclusions:** The correlation between VE intake, IgE levels, and the clinical manifestations of atopy indicates that VE could be an excellent therapeutic tool for atopic dermatitis.

Introduction
 Atopic dermatitis (AD) is a well-known, chronic, pruritic, inflammatory skin disease frequently seen in subjects with genetic and/or family history of atopy, such as asthma and allergic rhinitis. Its etiology and pathogenesis are still unclear, although a genetic-chromosomal regulation, with the development of immunoglobulin E (IgE) and IgE receptors and IgE (ANA), has recently been discovered. Due to the lack of specific laboratory diagnostic tests, the diagnosis depends entirely on the recognition of the major and minor clinical features suggested by Hanifin and Rajka.^{1,2} It is a chronic and a chronic relapsing course in over 80% of cases. In addition, owing to their resistance to conventional therapies, AD subjects present a high burden of occurrence and complications after discharge from hospital and low return clinical and social problems. Many subjects find discomfort after trying different, even so, less appropriate treatments.

International Journal of Dermatology 2016, 55: 148-150 © 2016 The International Society of Dermatology



89


Vitamin E

Intervention	Discussion	Guidance
Vitamin E	Vitamin appears to improve skin appearance and reduce IgE, presumably through anti-oxidant, anti-allergic effects as well as improvement of skin barrier health.	A 2-3-month course of natural vitamin E at a dose of 400 IU daily could be considered.



90

Atopic dermatitis: nutrient management options



91

Zinc

Children and adolescents with atopic dermatitis and low hair zinc levels who received zinc supplementation (12mg/ day) for 8-weeks significantly improved their zinc status and reduced symptom severity. (In contrast, a clinical trial investigating the non-discriminant use of zinc found no benefit).

Acta Derm Venereol. 2014 Sep;94(5):558-62.



92

Acta Derm Venereol 2014; 94: 558-62

CLINICAL REPORT

Hair Zinc Levels and the Efficacy of Oral Zinc Supplementation in Children with Atopic Dermatitis

Hong Eun Kim, Seon-Pyo Yoon, Hyeon-Gil Jeong, Joo-Heon Kim and Young-Jaek Kim
Department of Dermatology, Asan Medical Center, Seoul National University College of Medicine, Seoul, Korea

Abstract

Zinc deficiency in patients with atopic dermatitis (AD) and the use of zinc supplementation is still controversial. We assessed hair zinc levels in 48 children with AD and 43 controls (age range 5–14 years). We also investigated the efficacy of oral zinc supplementation in AD patients with low hair zinc levels by comparing eczema assessment severity index (EASI), transepidermal water loss (TEWL), and visual analogue scales for pruritus and sleep disturbance in patients receiving zinc supplementation (Group A) and without receiving supplementation (Group B). At baseline, the mean hair zinc level was significantly reduced in AD patients (182.3 vs 91.1, 23.9 µg/g; $p=0.01$). After 8 weeks of supplementation, hair zinc level increased significantly in Group A ($p=0.001$), and EASI scores, TEWL, and visual analogue scales for pruritus improved more in Group A than in Group B ($p=0.044$, 0.014 and 0.046 , respectively). Thus, oral zinc supplementation may be effective in AD patients with low hair zinc levels. *Key words:* atopic dermatitis; hair; zinc.

Accepted Sep 18, 2013; Epub ahead of print Jan 28, 2014
Acta Derm Venereol 2014; 94: 558–62.

Young-Jaek Kim, MD, PhD, Professor, Department of Dermatology, Asan Medical Center Hospital, Seoul National University College of Medicine, 17 Hongjeong-dong, Songpa-gu, Seoul, 152-792, Korea. E-mail: yjkim@amc.seoul.ac.kr

Introduction

Zinc is one of the essential trace elements necessary for the normal cell growth, proliferation, and regeneration in humans. Zinc deficiency can lead to specific skin disorders such as acrodermatitis enteropathica (1, 2). Although the relationship between zinc deficiency and atopic dermatitis (AD) is not clear, a zinc deficiency diet induced AD-like eruptions and deterioration of skin barrier function in DS-26 mice (3). In mice model, serum zinc levels were lower in children with AD than in controls (4–6). Moreover, the reduction in serum zinc levels in AD did not correlate with the severity of eczema and might be interpreted as zinc-specific findings accompanying the skin disorder (7). Therefore, the status and role of zinc in AD is unclear. Furthermore, there has been no study of the efficacy of oral zinc supplementation in zinc-deficient atopic patients.

The natural content of blood cells has been measured in many studies; however, the procedure is complex and the results are variable (7). On the other hand, hair is easily available, and it is possible to measure elemental trace elements with appropriate specificity, sensitivity, speed and procedural simplicity (8). The use of hair for trace element analysis rather accurately reflects the overall status of the human body (9, 10). This study was undertaken to evaluate the relationship between hair zinc levels and AD and to assess the efficacy of oral zinc supplementation in AD patients with low hair zinc levels.

MATERIALS AND METHODS

Patients

A total of 91 children (28 boys, 27 girls; mean age 8.2 years, range 2–14 years) with confirmed diagnosis of AD according to the criteria of Hanifin & Rajka (11) and with active moderate disease (SCORAD score and Symptom Index (SI) score >10) were enrolled in this study. A sex- and age-matched control group consisted of 43 children without dermatological disorders (Table 1). Single case (17 patients with AD and 43 control cases) were calculated to have power of 80% and detect a difference of 25% in the primary outcome ($p=0.05$). Exclusion criteria were the use of topical corticosteroids or topical steroids in patients in the previous 2 weeks and any systemic immunosuppressive treatment in the previous 3 months. All these medications were prohibited until the end of the study.

The first stage of the study was a comparison of the hair zinc levels of the atopic patients and the control group. The second step consisted of an evaluation of the clinical efficacy of oral zinc supplementation therapy in the atopic patients with low hair zinc levels and no clinical response.

Table 1. Demographic characteristics and hair zinc levels of patients with atopic dermatitis (AD) and controls

Characteristic	AD (n=91)	Control (n=43)	p-value
Gender			
Male	28	28	0.931
Female	63	15	0.021
Age, years, mean (SD)	8.12 (3.97)	8.74 (3.34)	0.322
Height, cm, mean (SD)	124.8 (12.1)	124.8 (12.1)	0.999
Weight, kg, mean (SD)	23.2 (10.1)	23.2 (10.1)	0.999

© 2014 The Authors. Acta Derm Venereol. 2014; 94: 558–62


Zinc

Intervention	Discussion	Guidance
Zinc	Deficiency in zinc has been associated with atopic dermatitis, however, non-discriminate supplementation was not effective.	Zinc status can be assessed with laboratory values or dietary intake. In suspected or confirmed deficiency supplementation with 10-20 mg of zinc per day is warranted.



93

Atopic dermatitis: nutrient management options



94

Isoleucine

In the trial 19 patients ages 5-17 were supplemented with isoleucine at a dose of 10-30 mg/kg daily for 60-days. All patients showed statistically significant clinical improvement in symptoms after supplementation with the most notable reduction in pruritus scores.

Pediatr Allergy Immunol. 2017 Aug;28(5):495-497.

The thumbnail shows the title page of a scientific article. The title is "Isoleucine and atopic dermatitis". The authors listed are "Liu YH, Liu JH, Liu JH, et al." The article is published in "Allergy" journal, volume 72, issue 5, pages 495-497, in August 2017. The abstract and parts of the introduction are visible, discussing the role of isoleucine in atopic dermatitis and the study's findings.




Isoleucine

Intervention	Discussion	Guidance
Isoleucine	Isoleucine could modify inflammation and reduce symptoms, particularly pruritis, but research is limited to a pilot study.	Consider a trial of 10-30 mg/kg daily for >60-days.



Atopic dermatitis: nutrient management options



97

Oolong tea

Adults with atopic dermatitis who were instructed to drink 1 litre of oolong tea (made from a 10g teabag placed in 1000ml of boiling water and steeped for 5-minutes) between meals daily had a good clinical improvement within 1-2 weeks and maintained for at least 6-months.

Arch Dermatol 2001;137:42–43.

STUDY

A Trial of Oolong Tea in the Management of Recalcitrant Atopic Dermatitis

Hansen, Uthman, MD; Shanks, Ingber, MD; Kwan, Sahawneh, MD

Background: Millions of people worldwide suffer from atopic dermatitis (AD), a chronic, pruritic skin condition. However, standard treatments like emollients and corticosteroids are often ineffective. AD-like lesions, study results in animal models have demonstrated that the administration of tea, green, black, or oolong tea improved AD-like lesions in allergic mice.

Objectives: To evaluate the effectiveness of oolong tea in the treatment of recalcitrant AD.

Patients: Although 121 patients with recalcitrant AD were enrolled in the study, 118 patients completed the open study.

Methods: Patients were asked to maintain their diet, usage of treatment. However, they were also instructed to drink oolong tea made from 10g teabag placed in 1000 ml of boiling water and steeped for 5 minutes. This amount was then divided into a 1-gal average and 1 serving was drunk daily after breakfast. The oolong tea was 1 or 2 g per 100 ml of water or 100 ml of water. The oolong tea was steeped for 5 minutes and the amount of water was adjusted to give a total of 1000 ml of oolong tea. Multiple servings of oolong tea were consumed.

Results: After 1 month of oolong tea (1000 ml), 118 patients showed marked to moderate improvement of their condition. The beneficial effect was first noticed after 1 to 2 weeks of treatment. A good response to treatment was still achieved in 94 patients (79%) at 6 months.

Conclusion: The therapeutic efficacy of oolong tea in recalcitrant AD may well be based on the anti-inflammatory properties of its polyphenols.

Arch Dermatol 2001;137:42-43.

Abstract: A good response was still observed in 94 patients (79%) after treatment for 6 months. **Figure:** The oolong tea study in patients reported clinical only effects on physical examination, on histology, or on laboratory tests.

CONCLUSIONS

From this study, it seems reasonable to conclude that oolong tea affords a substantial benefit in the management of at least some patients with recalcitrant AD. An understanding of the pharmacological basis for the benefit of oolong tea in AD is needed. Animal studies demonstrated that the polyphenol fraction of tea was most responsible for the suppression of passive cutaneous anaphylaxis and that epigallocatechin gallate, a major component of tea polyphenols, suppressed cutaneous hyperreactivity. The therapeutic efficacy of oolong tea in AD may well be the result of the antioxidant properties of its polyphenols.

Downloaded from www.archdermatol.com on September 18, 2009
© 2009 American Medical Association. All rights reserved.



98


Therapeutic teas

Intervention	Discussion	Guidance
Oolong tea	Unique anti-allergic properties of oolong tea make it a useful addition to nutritional therapy.	Consider 1 litre of oolong tea (made from a 10 g teabag placed in 1000ml of boiling water and steeped for 5-minutes) between meals each day.
Fig leaf tea	Fig leaf tea may modify IgE activity and alleviate symptoms.	Consider 500 ml of fig leaf tea daily. Care should be taken to use a specific fig cultivar (Grise de Tarascon) to avoid risk of photodermatitis.



99

Atopic dermatitis: nutrient management options



100

Pancreatic enzymes

In a clinical study of pancreatic enzyme therapy, a group of patients with severe atopic dermatitis and known food allergies who were not responding to conventional therapies or exclusion diets were administered pancreatic enzymes supplements (37,500 units of proteases with each meal and one-half of a capsule with snacks) for 6-weeks. At the end of the study patients who received the enzymes supplements had a significant improvement in atopic disease symptoms severity and a reduction in gut permeability, as measured by lactulose: mannitol ratio.

Paediatr Drugs. 2019 Feb;21(1):41-45.



Paediatr Drugs. 2019 Feb;21(1):41-45.

SHORT COMMUNICATION

Pancreatic Enzyme Supplementation in Patients with Atopic Dermatitis and Food Allergies: An Open-Label Pilot Study

Sarfaraz Shekar¹, Justin Koenekamp², Jonathan Madhug³, Julie Powell⁴, Aron Denicolis⁵, Ernest G. Seidman⁶

© Springer Nature Switzerland AG 2018

Abstract
Background Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects both patients and their families. Current therapies often alleviate symptoms but do not prevent or eradicate the disease.
Objectives Our objective was to determine whether pancreatic enzyme supplementation is an effective and safe treatment in refractory pediatric AD associated with food allergies.
Methods We conducted an open-label pilot study using a case-control design. Patients with severe AD and known food allergies refractory to conventional therapies and exclusion diets were recruited and treated for 6 weeks with oral supplementation of pancreatic enzymes. The primary endpoint was the severity of AD using the Scoring Atopic Dermatitis (SCORAD) index. Secondary outcomes included measures of intestinal permeability (lactulose:mannitol ratio) and food/oral allergy scores.
Results A total of 11 patients met all eligibility criteria and completed the trial. Significant improvement in AD was observed after 6 weeks of pancreatic enzyme supplementation (SCORAD index 52.3±7.5 vs. 34.3±7.4, p=0.009). Beneficial effect was observed in 8 of 11 patients, without adverse events. Fractional urinary lactulose:mannitol ratio decreased significantly in that of age-matched controls (p<0.05). However, urinary lactulose:mannitol ratio remained abnormally high compared with level of controls (p=0.01).
Conclusions Pancreatic enzyme supplementation was associated with improved AD and gastrointestinal permeability. Additional randomized placebo-controlled studies are required before this treatment can be recommended in this clinical setting.

Key Points
 Abnormal intestinal barrier function was observed in children with atopic dermatitis (AD) and food allergies, supporting the hypothesis that gut is a contributing factor to pathogenesis.
 This is the first study suggesting pancreatic enzyme supplementation in patients with AD with food allergies, as pancreatic enzyme supplementation resulted in significant clinical improvement.
 In children with severe AD and food allergies, the observed association between pancreatic enzyme supplementation and improved gastrointestinal permeability is novel.

¹ Ernest G. Seidman, MD, PhD, erseid@montreal.ca
² Division of Dermatology, Department of Pediatrics, Sainte Justine Hospital, University of Montreal, Montreal, Canada
³ Division of Allergy, Department of Pediatrics, Sainte Justine Hospital, University of Montreal, Montreal, Canada
⁴ Department of Medicine, University of Calgary, Calgary, Canada
⁵ Division of Otolaryngology, Department of Medicine and Pediatrics, St. Joseph's Hospital and the McGill University Health Centre, 3838 Centre Avenue, C-10 105, Montreal, QC H3T 1M4, Canada

Published online: 17 December 2018

101


Pancreatic enzymes

Intervention	Discussion	Guidance
Pancreatic enzymes	Proteolytic enzymes may reduce food antigen reactivity via digestion and consequently ameliorate symptoms.	In treatment resistant patients with food reactivity, trial 37,500 units of proteases with each meal and one-half of a capsule with snacks for >6-weeks




102

Atopic dermatitis: nutrient management options



103

Circadian redox cycles



Antioxid Redox Signal. 2013 Jul 10;19(2):192-208.




104

Melatonin

In children with atopic dermatitis and sleep disturbance melatonin (3 mg daily at bedtime for 4-weeks) improved sleep-onset latency and reduced disease severity.

JAMA Pediatr. 2016 Jan;170(1):35-42.




Melatonin

Intervention	Discussion	Guidance
Melatonin	Circadian rhythm disruption may play a role in atopic dermatitis symptom severity.	In patients with sleep disturbance, trial melatonin 3 mg daily at bedtime for >4-weeks.



Immunopathogenesis of psoriasis and resolved psoriasis plaques




Lancet. 2021 Apr 3;397(10281):1301-1315.




109

Psoriasis: dietary management options




110

Psoriasis: nutrient management options



111

Psoriasis: dietary management options



112

Nutritional therapy

A woman with severe, treatment resistant psoriasis who was treated with nutritional therapy including increased vegetable intake, low consumption of meat, avoidance of junk food and sugar, and personalized nutritional supplementation experienced complete resolution of symptoms within 6-months.

Exp Ther Med. 2015 Sep;10(3):1071-1073.



113


Healthy diet

Intervention	Discussion	Guidance
Healthy diet	Unhealthy dietary practices appear to be more frequent in patients with psoriasis and could increase disease risk and severity. Conversely, healthy dietary interventions improve the disease course.	Increasing vegetable intake, low consumption of meat, avoidance of junk food and sugar, and specific foods, such as black coffee, black tea, chocolate, pepper, smoked foods, monosodium glutamate, and alcoholic drinks may be useful. Consider dietary supplements to optimize nutritional intake and support skin health.



114

Psoriasis: dietary management options



115

Weight loss

A low-energy diet providing 800-1000 kcal per for 8-weeks to induce weight loss, followed by 8 weeks of reintroduction of normal food intake, reaching 1200 kcal per day resulted in clinically important improvements in symptom and quality of life in overweight patients with psoriasis.

JAMA Dermatol. 2013 Jul;149(7):795-801.



116

STUDY

Effect of Weight Loss on the Severity of Psoriasis
A Randomized Clinical Study

Fraser Jansen, MD, PhD; Claas Zankhuizen, MD, DMSc; Adria Christensen, MSc, PhD; Niels R. W. Geiler, MSc; René K. Schaak, MD, PhD; Soren Sonder, MD, DMSc; Peter R. Hansen, MD, DMSc; Jens Storgaard, MD, DMSc; Lone Zhou, MD, DMSc

Importance: Psoriasis is associated with adiposity and weight gain increases the severity of psoriasis and the risk of recidiv. Therefore, we aimed to measure the effect of weight reduction on the severity of psoriasis in obese patients with psoriasis.

Objective: To assess the effect of weight reduction on the severity of psoriasis in overweight patients.

Design: Fifty obese patients with psoriasis from our dermatology outpatient clinic were enrolled in a prospective randomized clinical trial in which they were allocated to a control group or an intervention group.

Setting: University hospital outpatient dermatology clinic.

Participants: We included 40 of 50 eligible overweight patients with psoriasis (body mass index [BMI] based on weight in kilograms divided by height in meters squared, ≥ 30 ; age, 35.7; 19/21).

Interventions: The intervention group received a low-energy diet (LED) (800-1000 kcal) for 8 weeks to induce weight loss, followed by 8 weeks of reintroduction of normal food intake, reaching 1200 kcal. The control group was instructed to continue using ordinary healthy foods.

Main Outcome and Measure: Psoriasis Area and Severity Index (PASI) after 10 weeks, with Dermatology Life Quality Index (DLQI) as a secondary end point.

Results: The median PASI for all patients was 5.4 (interquartile range, 3.8-7.8) at baseline. At week 18, the mean body weight loss was 13.9 kg (95% CI, 12.3-15.5 kg; $P < .001$) greater in the intervention group than in the control group. The corresponding mean differences in PASI and DLQI, absolute (not of the LED group, were -2.0 (95% CI, -1.1 to -0.1 ; $P = .06$) and -2.0 (95% CI, -3.8 to -0.2 ; $P = .02$), respectively.

Conclusions and Relevance: Treatment with an LED showed an effect to favor of clinically important PASI improvement and a significant reduction in DLQI in overweight patients with psoriasis.

Trial Registration: clinicaltrials.gov Identifier: NCT01135386

JAMA Dermatol. Published online May 20, 2013. doi:10.1001/jamadermatol.2013.1222

Abstract: Psoriasis is a chronic inflammatory skin disease with a prevalence of about 2% in Northern Europe and North America.¹ Psoriasis is associated with an increased prevalence of cardiovascular conditions (ie, risk factors, such as diabetes, arterial hypertension, and hyperlipidemia), and an increased risk of myocardial infarction.²⁻⁴ In addition, epidemiological studies have established that psoriasis is associated with obesity and that increased adiposity and weight gain are risk factors for recidiv. psoriasis.^{5,6} Like psoriasis, obesity is accompanied by low-grade systemic inflammation, and, theoretically, obesity-induced proinflammatory mediators may exacerbate psoriasis lesions in overweight patients with psoriasis.^{7,8} At present, the role of weight loss as a treatment for psoriasis in obese patients is unclear, but it is reasonable to assume that weight loss in such patients may reduce the obesity-induced inflammation, which may in turn improve the skin disease. Indeed, data from case reports of obese patients with psoriasis undergoing weight reduction surgery indicate that patients may improve with weight loss, although no 1 reported case is actually because worse.^{9,10}

See related articles: reduce the obesity-induced inflammation, which may in turn improve the skin disease. Indeed, data from case reports of obese patients with psoriasis undergoing weight reduction surgery indicate that patients may improve with weight loss, although no 1 reported case is actually because worse.^{9,10}

JAMA Dermatol. Published online May 20, 2013. www.jamadermatol.com


Weight loss diet

Intervention	Discussion	Guidance
Weight-loss diet	Overweight and obesity can contribute to disease severity though increased low-grade inflammation and diet-induced weight loss results in clinical improvement.	Dietary and lifestyle-based weight loss regimes, including low-energy diets and very low carbohydrate ketogenic diets, can be considered a component of nutritional management for overweight or obese patients.



117

Psoriasis: dietary management options




118

Celiac disease

Coeliac screening in people with psoriasis revealed a high prevalence (4.1%) compared to controls, as assessed with anti-tissue transglutaminase antibodies and subsequently confirmed histologically. After a 6-month gluten-free diet there was a marked improvement of skin lesions in 7 out of 8 people.

Dermatology. 2015;230(2):156-60.




Gluten-free diet

Intervention	Discussion	Guidance
Gluten-free diet	There is a higher frequency of celiac disease and gluten sensitivity in psoriasis, and gluten-free diets may reduce disease severity.	Confirmed celiac disease must be managed with a strict gluten-free diet, however, a gluten-free diet should be considered even in the absence of histologically confirmed celiac disease or positive antibodies i.e., non-celiac gluten sensitivity.



Psoriasis: dietary management options



121

Intestinal permeability

An intestinal permeability-targeted nutritional intervention involving dietary changes (high fresh fruits and vegetables, low protein from fish and fowl, fiber supplements, olive oil, and avoidance of red meat, processed foods, and refined carbohydrates) and herbal teas (saffron tea and slippery elm bark) was found to improve psoriasis symptom scores and reduce intestinal permeability.

Altern Med Rev. 2004 Sep;9(3):297-307.



122

Case Report **Psoriasis**

Medical Nutrition Therapy as a Potential Complementary Treatment for Psoriasis – Five Case Reports

Amy C. Brown, PhD, RD, Michelle Hairfield, PhD, Douglas G. Richards, PhD, David L. McMillin, MA, Eric A. Stein, MD, Carl D. Nelson, DC

Abstract
This research evaluated five case studies of patients with psoriasis following a dietary regimen. There is no cure for psoriasis and the multiple treatments currently available only attempt to reduce the severity of symptoms. Treatments range from topical applications, systemic therapies, and phototherapy, while some are effective, many are associated with significant adverse effects. There is a need for effective, affordable therapies with fewer side effects that address the cause of the disease. Evaluation consisted of a study group of five patients diagnosed with chronic plaque psoriasis three years and three weeks, average age 22 years, range 40-60 years attending a 70-day, live-in program during which a physician-monitored psoriasis symptoms and bowel permeability. Subjects were then instructed on continuing the dietary protocol at home for six months. The dietary protocol, based on Edgar Cayce's readings, included a diet of fresh fruits and vegetables, small amounts of protein from fish and fowl, fiber supplements, olive oil, and avoidance of red meat, processed foods, and refined carbohydrates. Saffron tea and slippery elm bark water were consumed daily. The five psoriasis cases, ranging from mild to severe at the study onset, improved on all measured outcomes over a six-month period when measured by the Psoriasis Area and Severity Index (PASI) (average pre- and post-test scores were 18.2 and 8.7, respectively), the Psoriasis Severity Scale (PSS) (average pre- and post-

Introduction
Psoriasis is a chronic, inflammatory skin disease characterized by thickened, silvery-scaled patches.¹ Its cause is not yet known, but immune reactions link it with inflammatory and autoimmune mechanisms most likely associated with a genetic predisposition that can be triggered by stress.²

Abstract Med Rev 2004 Sep;9(3):297-307

Amy C. Brown PhD RD - Director, Professor of Human Nutrition, Department of Human Nutrition, Food and Animal Sciences, University of Hawaii at Manoa, Honolulu, Hawaii, USA; Douglas G. Richards PhD - Department of Human Nutrition, Food & Animal Sciences, University of Hawaii at Manoa, Honolulu, Hawaii, USA; Eric A. Stein MD - Chief, Clinical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Carl D. Nelson DC - Director, Researcher, Meridian Health, Eugene, Oregon, USA

Alternative Medicine Review • Volume 9, Number 3 • 2004 Page 297


Intestinal permeability-targeted diet

Intervention	Discussion	Guidance
Intestinal permeability-targeted diet	Nutritional modification of intestinal permeability could benefit psoriasis, but although research is limited.	Assessment of intestinal permeability and, if indicated, a permeability-targeted nutritional intervention might be considered.



123

Psoriasis: nutrient management options



124

Fatty acids

A review of clinical trials evaluating fish oil for the treatment of psoriasis found moderate evidence of benefit, with 12 of the total 15 trials reviewed showing clinical benefits. Positive clinical trials have used high-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily which needed to be taken for at least 6 weeks to 6 months to see improvement; typically, a range of reduction in symptom score of 40-75%.

J Am Acad Dermatol. 2014 Sep;71(3):561-9.



REVIEWS

Diet and psoriasis, part III: Role of nutritional supplements

Julian W. Hilwig, MD,^{1*} Everett S. Smith, BA,² Nina DeWaneth, BA,^{3*} John Kim, MD,⁴ and Wilson Luo, MD⁵
¹San Francisco and Irvine, California; ²Chicago, Illinois; and ³San Jose, California

Patients with psoriasis are increasingly turning to the use of alternative and complementary medicine to manage their psoriasis. Evidence often suggests that dietary supplements may be beneficial, including the use of oral vitamin D, vitamin B12, selenium, and omega-3 fatty acids in fish oils. In this review we evaluate the extent to which each of these common nutritional interventions has been studied for the treatment of psoriasis. We weighed evidence from both controlled and uncontrolled prospective trials. The evidence of benefit was highest for fish oils. For other supplements, there is need for additional large, randomized clinical trials to establish evidence of efficacy. (J Am Acad Dermatol. 2014;71:561-9.)

Key words: diet; fish oil; omega-3; oral vitamin D; psoriasis; selenium; vitamin B12; 1,25-dihydroxy vitamin D₃; 1,25-dihydroxy vitamin D₃ analogs

Abbreviations used:
 EPA, eicosapentaenoic acid;
 DHA, docosahexaenoic acid;
 DMS, psoriasis severity index;
 PUFA, polyunsaturated fatty acid

INTRODUCTION

The use of alternative and complementary medicine has increased in popularity with patients, not just for management of chronic health, but even in the management of chronic conditions such as psoriasis.¹ There is a growing body of popular and scientific literature for the use of nutritional supplements in the treatment of psoriasis. Many interventions readily available, patients often prefer independent research and their own investigations about what they can add to their diet to reduce their condition's symptoms. Here, we sought to explore some of the most common nutritional supplements and evaluate in what extent the scientific literature has evaluated their respective clinical effectiveness. Numerous studies that have examined oral vitamin D, vitamin B12, selenium, and omega-3 fatty acids.

METHODS

We performed our literature search in June 2013 using the following MEDLINE database via PubMed. Search terms included "psoriasis" combined with

"oral vitamin D," "1,25-(OH)₂D₃," "1,25-dihydroxy vitamin D₃," "1,25-dihydroxy vitamin D₃ analog," "vitamin B12," "vitamin B," and "selenium," respectively. In addition, abstracts containing the key words "dietary therapy" and "nutritional treatment" were reviewed. We limited our search to articles available in English and those published between 1990 and 2013. Manual searches of bibliographies of the articles were also performed to identify additional studies to be included. Exclusion criteria included topical regimens and studies that did not specify supplement dosage. The primary outcome evaluated was a statistically significant reduction in Psoriasis Area and Severity

From the Department of Dermatology, University of California, San Francisco¹; University of Utah, School of Medicine²; Rush Medical College, Rush University Medical Center, Chicago³; and University of California, Irvine, School of Medicine⁴. Dr Hilwig and Dr Smith contributed equally to this work. Dr Luo is supported in part by grants from the National Institutes of Health (NIH) (R01AR057073).

Disclosure: Dr Luo is a speaker for Abbvie and Leo. Dr Kim conducts research for Amgen, Amgen Biotech, Biogen/Idec, Galderma, Pfizer, and Merck. Dr Kim has no stocks, equity, or debt ownership with any pharmaceutical company. None of the grants were directly related to this study. Dr Hilwig, Dr Smith, Dr DeWaneth, and Dr Luo have no conflicts of interest in this study.

Accepted for publication March 7, 2014.
 Reprint requests: Wilson Luo, MD, Department of Dermatology, University of California, San Francisco, 215 Green St, San Francisco, CA 94143. Email: luow@ucsf.edu.
 Published online April 18, 2014.
 DOI: 10.1016/j.jaad.2013.12.015
 © 2014 by the American Academy of Dermatology, Inc.
 0732-1226/14/7103-561-9\$36.00/0

125


Fatty acids

Intervention	Discussion	Guidance
Fatty acids	Both high-dose fish oil and increasing fish consumption can be effective for reducing symptoms.	Consider around 4 g EPA and/ or 2.6 g DHA or advice to consume 170 g of omega-3 rich fish daily for >6-weeks.



126

Psoriasis: nutrient management options



127

Vitamin D

“Four RCTs examined the effect of oral vitamin D supplementation on psoriasis for 173 patients and 160 patients were treated with placebo. No significant differences were found in PASI after 3, 6, and 12 months of supplementation. It is shown that 25(OH)D serum levels are significantly lower in psoriasis, but, although the granularity of RCT methodology may have influenced the pooled analysis, vitamin D supplementation did not seem to improve clinical manifestations.”

Nutrients. 2023 Jul 30;15(15):3387.



128

Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis

Elisa Fortunato 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100

Abstract: Psoriasis is a chronic immune-mediated inflammatory disease and hyperpruritus (H) is considered a risk factor. We conducted an online database search to review and meta-analyze the relationship between vitamin D (vitamin D) and psoriasis parameters, and psoriasis. The efficacy of oral vitamin D supplementation in improving Psoriasis Area and Severity Index (PASI) was also evaluated. Non-peer-reviewed articles, case reports, and animal studies were excluded. Meta-analysis was conducted according to the Cochrane Collaboration's tool and the Newcastle-Ottawa scale to assess methodological bias (MOA) and non-overlapping, respectively. Unpublished results were excluded from data synthesis. Twenty-three studies reported overall 25-hydroxyvitamin D (25(OH)D) levels in 187 psoriasis patients and 152 controls. Psoriasis patients had significantly lower 25(OH)D levels than controls (21.6 ± 8.3 vs. 27.2 ± 9.8, p < 0.0001). Conversely, 42 psoriasis patients had lower levels of parathyroid hormone than 47 controls (34.7 ± 12.8 vs. 43.7 ± 16.5, p = 0.015). Four RCTs assessed the effect of oral vitamin D supplementation on psoriasis in 173 patients and 160 patients were treated with placebo. No significant differences were found in PASI after 3, 6, and 12 months of supplementation. It is shown that 25(OH)D serum levels are significantly lower in psoriasis. First, although the granularity of RCT methodology may have influenced the pooled analysis, vitamin D supplementation did not seem to improve clinical manifestations.

Keywords: hyperpruritus (H); psoriasis; vitamin D; supplementation; bone metabolism

1. Introduction: Psoriasis is a chronic autoimmune inflammatory skin disease, characterized by abnormal proliferation and differentiation of keratinocytes [1–3], which is mediated by cytokines, matrix metalloproteinases, and other factors [4–6]. Even though the exact mechanism behind this condition is not fully understood [7], it is known that psoriasis skin lesions are the result of dysregulation of the immune system, which releases pro-inflammatory mediators. Subsequently, the inflammatory response, largely driven by cytokine release, causes accelerated proliferation of keratinocytes [8]. The etiology of psoriasis is still unknown, but researchers have speculated about a possible complex role of genetic and environmental factors [9], including obesity, alcohol consumption, and smoking habits [9]. The prevalence of data of psoriasis is not completely clear; it may range from 0.1% to 8.9% in adults and from 0.2% to 2.7% in children. The worldwide psoriasis disease prevalence is about 2.3% [10], with a higher amount (6–17%) of the total population in Nordic European countries [11].

Recent studies [12,13] have associated with the pathogenesis of several skin disorders, such as atopic dermatitis, vitiligo, alopecia areata, and also psoriasis [14]. In fact, vitamin D is known to influence multiple skin functions, such as proliferation, differentiation, and apoptosis of keratinocytes [15]. Therefore, an elevated vitamin D metabolism could play a key role in the pathogenesis of psoriasis [16].


Vitamin D

Intervention	Discussion	Guidance
Vitamin D	Vitamin D deficiency may be more severe in psoriasis, and the degree of deficiency has been correlated with disease duration and severity.	Vitamin D supplementation with vitamin D3 could be considered in the presence of vitamin D deficiency.



129

Psoriasis: nutrient management options



130


Folate, vitamin B12

Intervention	Discussion	Guidance
Folate	High-dosed folic acid and 5-methyl tetrahydrofolate (5MTHF) methotrexate as it may reduce methotrexate efficacy, while lower doses may reduce side-effects.	For patients receiving <15mg methotrexate weekly consider a dosage regime of 5 mg of folic acid per day for 2 days after the last dose of methotrexate, with an additional third dose of 5 mg on day 3 for patients receiving > 15 mg.
Vitamin B12	Vitamin B12 deficiency may exacerbate disease activity and improving nutritional status could reduce symptoms, but evidence is mixed.	It would be prudent to screen for vitamin B12 deficiency.



131

Psoriasis: nutrient management options



132

Insulin resistance

“With regard to psoriasis, we observed a significant correlation between the Psoriasis Area and Severity Index (PASI) score and insulin secretion. Moreover, the PASI score was significantly correlated with serum resistin levels—a cytokine known to be increased in insulin resistance.”

Br J Dermatol. 2007 Dec;157(6):1249-51.




Chromium

Intervention	Discussion	Guidance
Chromium	Poor blood glucose metabolism could contribute to psoriasis in a subset of people and may be positively impacted by chromium.	Consider chromium supplementation 600 µg daily for 6-weeks in patients with established insulin resistance.



Psoriasis: nutrient management options



135

Antioxidants

A clinical study of coenzyme Q10 (50 mg daily), vitamin E (natural alpha-tocopherol, 50 mg), and selenium (48 mcg) resulted in improvements several parameters related to oxidative stress, included superoxide production, copper/zinc-superoxide dismutase, and catalase, as well as a significant reduction in disease severity which correlated with normalization of the oxidative stress markers.

Nutrition. 2009 Mar;25(3):295-302.



136




Antioxidant nutrients

Intervention	Discussion	Guidance
Antioxidant nutrients	Systemic oxidative stress is a consistent feature of psoriasis and may contribute to disease development and be an important target for management.	Consider trialing a nutritional antioxidants, especially multi-nutrients formulations, CoQ10, and vitamin C.



137

Psoriasis: nutrient management options



138

Turmeric

A trial utilizing an enhanced bioavailability formulation (Meriva; Indeena, Italy) providing 400 mg curcumin daily reduced symptoms more effectively than topical steroids alone. Moreover, IL-22 serum levels were significantly reduced in patients treated with oral curcumin.

Biomed Res Int. 2015;2015:283634.



Medical Publishing Corporation
10000 Rockville Road
Suite 200, Rockville, MD 20850
http://dx.doi.org/10.1155/2015/283634

Clinical Study
Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris

Eniliana Antiga, Veronika Bondolfi, Walter Volpi, Elena Del Bianco, and Maria Caporali
Section of Dermatology, Department of Surgery and Translational Medicine, University of Brescia, Viale Mataragnoli 61, 37139 Brescia, Italy

Correspondence should be addressed to Eniliana Antiga; eniliana.antiga@unibrescia.it

Received 10 March 2015; Accepted 17 May 2015

Academic Editor: Chuan-Tsai Chen

Copyright © 2015 Eniliana Antiga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Curcumin is a complementary therapy that may be helpful for the treatment of psoriasis due to its anti-inflammatory, immunosuppressive, antioxidant, and angioprotective effects. In the present study we performed a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy versus a therapeutic success in the treatment of psoriasis. Forty-four patients with mild to moderate psoriasis vulgaris (PVL) on their hands received oral or topical steroids and Meriva, a commercially available hydrophobic-based delivery system of curcumin at 2g per day (one 100 mg tablet) or placebo (one 100 mg tablet) for 8 weeks. In the beginning, 70% and 60% of the therapy (PVL) clinical assessment had moderate to severe analysis of the serum levels of IL-22 and IL-22 was performed. At T2, both groups showed a significant reduction of PVL disease. The serum level of IL-22 was significantly reduced in patients treated with oral curcumin. These patients treated only with topical steroids. Moreover, IL-22 serum levels were significantly reduced in patients treated with oral curcumin. In conclusion, curcumin was demonstrated to be effective as an adjuvant therapy for the treatment of psoriasis vulgaris and to significantly reduce serum levels of IL-22.

1. Introduction

Psoriasis is a common chronic inflammatory disease of the skin, nails, and joints, which affects about 2% of the general population [1], with a significant impact on the quality of life [2]. The psoriatic lesions mainly associated with chronic and recurrent drug, their immunosuppressive effects with the increased risk of infections and malignancies, and the high costs of some of these lead to a need assessment of therapeutic options and available to patients with psoriasis [3, 4].

An estimated 80% of individuals in developed countries depend primarily on natural products to treat their psoriasis. Herbal and natural extracts suggest that some of these Americans also use medicinal natural products daily [5]. Well-tolerated by patients, 50% of the patients use complementary and alternative medicine therapies to treat their skin, despite limited or no scientific data on the safety and efficacy of these treatments [6]. Among them, curcumin (diferuloylmethane), the active component of the Indian spice turmeric, has been used for centuries in traditional medicine of China and India [7] providing the way for the development of novel studies with a natural origin and in natural remedies, which revealed a surprisingly wide range of beneficial properties of the polyphenol compound, including anticancer and anti-inflammatory activity [8–12]. Furthermore, the extremely good safety profile of curcumin represents the most compelling and best rationale for its use, since data so far have demonstrated any relevant toxic effects even at very high doses [13, 14]. Whereas curcumin has several potential targets it may be promising for the treatment of psoriasis interacting with the main pathogenic pathways of the disease, namely, T cell-mediated inflammation via the inhibition of nuclear factor kappa B (NF- κ B) [15–17], keratinocyte proliferation, inhibiting chemokines release (MIP-1 α) [18–20], and angiogenesis [21–23].

139


Turmeric

Intervention	Discussion	Guidance
Turmeric	Turmeric extracts have shown promise as an adjuvant to standard therapy.	Consider an enhanced-bioavailability extract providing 400 mg curcumin daily.



140

Psoriasis: nutrient management options



141

Is psoriasis a bowel disease?

“Bacterial peptidoglycans absorbed from the gut have direct toxic effects on the liver and skin. Their absorption, as well as endotoxin absorption, must be eliminated to treat psoriasis successfully. Endotoxin absorption is markedly increased by ethanol and peppers. Bioflavonoids, such as quercetin and citrus bioflavonoids, prevent this absorption. Bile acids, given orally, break up endotoxin in the intestinal lumen.”

Clin Dermatol. 2018 May-Jun;36(3):376-389.



142

Bile acids

Intervention	Discussion	Guidance
Bile acids	Bile acids may degrade gastrointestinal-derived endotoxin and prevent its systemic migration and direct adverse effects on the skin.	Consider bovine bile concentrate 500 mg 1-3 times daily with meals.



145

Q&A



146

Acne vulgaris

Acne vulgaris

Acne vulgaris is a very common skin disease with the estimated frequency of moderate-to-severe acne about 20% in the adolescent population and persisting into the 20s and 30s in around 64% and 43% of people.¹ Adult acne is more frequent in women, with an estimated prevalence of 10-12%.² Importantly, acne is associated with significant physical and psychological morbidity, including permanent scarring, social isolation, depression and suicidal ideation.³

Acne is a disease of hair follicles in the skin that are associated with an oil gland, which are known as the pilosebaceous unit. Clinically it is characterized by seborrhoea (excess grease), non-inflammatory lesions (open and closed comedones), inflammatory lesions (papules and pustules) and scarring.⁴ Lesions are most prominent where there is a high density of sebaceous glands i.e. the face (99% of cases), back (60%), and chest (15%).⁵

The pathogenesis of acne is complex and thought to involve genetic predisposition interacting with multiple factors including the action of androgens on the pilosebaceous unit, the proliferation of *Propionibacterium acnes*, growth factors leading to abnormal hyperkeratinization, inflammation and the induction of tissue matrix metalloproteinases and alteration of the oxidant/antioxidant ratio of the skin surface lipids.^{6 7}

Acne medications are generally classed as topical agents, systemic antibiotics, systemic retinoids and hormonal agents and are limited by adverse effects, poor compliance, and lack of cure.⁸

Combination therapy with topical and oral medications for moderate to severe acne is typically utilized based on the premise they target more of the underlying pathogenic factors and improve treatment response.⁹ An emerging treatment approach is nutritional therapy, which has a multi-targeted effect by simultaneously influencing multiple disease processes involved in acne pathogenesis.¹⁰ Clinical trials have suggested an important role for nutritional interventions with evidence that dietary changes and nutritional supplementation can alter the disease pathophysiology and significantly reduce dermatological symptoms as well as related concerns including insulin resistance and mental health. Integrative use of nutritional therapy has also been shown to reduce side effects and improve efficacy of systemic retinoids.

Dietary interventions

- **Low glycemic-load diet**

The observation that a traditional diet devoid of industrialised food is associated with complete absence of acne in adolescents provided the foundation for the hypothesis that acne may be the result of diet-induced hyperinsulinemia.¹¹ Since this observation biological mechanisms have been explored and supported by dietary intervention studies showing that dietary therapy can reduce acne severity.

Insulin resistance is thought to play a key role in the development and pathology of acne with a primary mechanism likely to be insulin binding to insulin/ insulin-like growth factor-1 (IGF-1) receptors on keratinocytes and subsequent increased cell proliferation, in addition to the ability of insulins to stimulate the synthesis of androgens.¹² In addition, insulin-like growth factor (IGF)-1, which is typically elevated in insulin resistance and response to a high glycemic load diet, could play a role by increasing inflammation and sebum production in sebocytes.¹³ Supporting an important role for insulin resistance and hyperinsulinemia patients with severe acne have been shown to have significantly higher fasting insulin levels and reduce insulin sensitivity compared to healthy

Acne vulgaris

controls.¹⁴ As proof of principle, a short term 2-week low glycemic-load (GL)/ glycemic index (GI) diet significantly reduced IGF-1 concentrations in patients with moderate to severe acne (n=66).¹⁵

Low glycemic-load dietary therapy and avoidance of foods that induce hyperinsulinemia may help reduce the pathological sequel of acne by restoring insulin sensitivity, and observational evidence as well as clinical trials have suggested important clinical benefits.¹⁶ In an early observational study, 84% of patients who restricted sugar had substantial improvements or complete clearing of acne lesions after 1-month of the low-sugar diet.¹⁷

A clinical trial in men with treatment-resistant acne and features of insulin resistance/ metabolic syndrome found that an hypocaloric, low-glycemic load diet and an insulin sensitizing agent (metformin) for 6-months resulted in a significant improvement in acne severity.¹⁸ A 12-week intervention with a low glycemic-load (GL) diet in males aged 15 to 25 years, with mild moderate acne found that the diet reduced acne lesions, as well as weight, free androgen index, and increased IGF-1 binding protein and the ratio of saturated to monounsaturated fatty acids of skin surface triglycerides.^{19 20 21} A study of a 10-week low glycemic-load diet in men and women aged 20 to 27 years demonstrated a significant clinical improvement in acne lesions in addition to reduced size of sebaceous glands and decreased cutaneous inflammation.²² A trial in which a 12-week low glycemic index and load diet was added to pharmacological treatment (topical 0.1% adapalene and oral doxycycline 100 mg daily) of men aged 18 to 25 with moderate inflammatory acne found a statistically significant reduction of inflammatory lesions (papules and pustules) in the diet group vs. controls.²³

In contrast an 8-week low glycemic-index (GI) dietary intervention (n=43) failed to produce statistically significant differences to a high-GI comparison group, however there was a trend towards better clinical improvement on the low GL diet (acne severity score mean decrease of -26 vs. -16) with a reduction in symptom severity likely to be clinically significant to patients.²⁴ Similarly, a 12-week clinical trial (n=84) of topical benzoyl peroxide with or without a low-GL diet found that the low-GL diet significantly improved insulin resistance but failed to show any benefit of diet on acne symptoms. However, in this study, benzoyl peroxide treatment may have concealed the effect of diet.²⁵ Despite limitations in the evidence it appears that a >12-week low-glycemic load diet can reduce acne symptoms by improving metabolic health and skin physiology.

- **Acne-promoting foods**

Certain foods have been linked to the development of acne, in particular cow's milk, whey protein and cocoa, therefore limiting dietary exposure to these may be important. Several observational and case-control studies have found an association between cow's milk consumption and acne, suggesting a causal relationship.^{26 27 28 29 30 31} Whey protein has also been linked to acne development in case reports.^{32 33 34 35} Mechanisms underlying this connection include elevations of postprandial insulin and basal insulin-like growth factor-I (IGF-I) plasma levels with milk consumption.³⁶ Importantly, milk causes hyperinsulinemia despite having a low glycemic index (GI).³⁷ Almond and rice milks typically have a high GI and therefore may not be suitable alternatives.³⁸ It has also been proposed that the hyperinsulinemia effect of milk is unique to pasteurized cow's milk, and not fermented milk.³⁹

Early studies investigating a link between chocolate and acne had important flaws in their design limiting the validity of conclusions that chocolate does not cause acne.⁴⁰ A more recent pilot study indicated cocoa may exacerbate acne,⁴¹ and subsequent clinical trial found that a single-dose of pure cocoa resulted in a significant dose-response related increase in acne lesions in patients with pre-existing acne within 4-days.⁴² Experimentally chocolate consumption was found to increase cytokine

Acne vulgaris

release in response to *Propionibacterium acne* or *Staphylococcus aureus*, suggesting a possible mechanism.⁴³

Some dietary supplements have been associated with acne, namely vitamin B12 and Kelp. Data, mostly from case reports, suggests high dose supplementation with B12, with or without vitamin B6, in the range of 5,000-10,000 µg weekly, could exacerbate acne in some people and that acne symptoms resolve within 2-3 weeks after cessation of supplementation.^{44 45 46 47} Some data support a pathogenic role of B12 in acne. Lower serum vitamin B12 has been found in healthy controls vs. acne patients, and post- isotretinoin therapy.^{48 49} And B12 supplementation has been shown to increase *Propionibacterium acnes* activity, a bacterium involved in acne pathogenesis.⁵⁰

Kelp dietary supplements have been associated with acne outbreaks in case reports.^{51 52} However, the clinical presentation does not acutely resemble Acne vulgaris. It has been proposed that iodine, of which Kelp is a rich source, could play a role in acne-pathogenesis but this is contested on the basis that there is no clear evidence that iodine itself is the problem.⁵³

Nutrient interventions

- **Vitamin A**

Vitamin A was studied as a treatment for acne for decades until the synthetic vitamin A analogue isotretinoin was patented and approved for use in 1982, after which time vitamin A research for acne stopped despite no studies comparing the safety and efficacy of isotretinoin to vitamin A.⁵⁴ Because of a lack of research including a comparative clinical study it is not yet clear if there is an advantage or disadvantage of vitamin A over its synthetic analogue, but it is clear that vitamin A is significantly cheaper and much more accessible.

A review of clinical trials of vitamin A for the treatment of acne identified eight prospective studies published between 1943 and 1981.⁵⁵ Of these all the studies reported improvement apart from one study that may have been impacted by an insufficient treatment duration. The treatment response was 82%, which is similar to the clearance rate of 85% observed with isotretinoin. Dose ranges were 36,000 IU/daily to 500,000 IU/ daily, with 100,000 IU/ daily the most common. Relapse rates for vitamin A were comparable to isotretinoin (20-40%). Side effects were mostly mucocutaneous such as cheilitis and xerosis (61%), but also included pruritus (23%), transient liver enlargement (14%), epistaxis (9%), headache (7%), and alopecia (3%). Most side effects subsided during treatment or disappeared after treatment cessation. Benign elevations in triglycerides and liver enzymes occurred in some patients and returned to baseline within 2-3 weeks of stopping treatment, like those seen with isotretinoin.

A more recent case report described successful treatment of severe acne in a 14-year-old male after a 4-month course of 200,000 IU/ daily of vitamin A (with a 100,000 IU/ daily run in for the first week to assess tolerance).⁵⁶ Vitamin A treatment resulted in observable improvement within 1 month and completely eradicated cutaneous symptoms at the end of the treatment period with no relapse at 6 months post-treatment follow-up. Side effects were minimal and included dry chapped lips and redness in the face at the upper cheek/nose area, which resolved within the first 2-months of treatment.

Vitamin A toxicity, known as hypervitaminosis A, is characterized by symptoms such as dry itchy skin, desquamation, anorexia, weight loss, and headache and typically associated with intakes greater than 25, 000 IU/ daily for over 6 years and > 100,000 IU/ daily for over 6 months.^{57 58} Some of these symptoms, mostly pruritus and headache, were noted in clinical trials of vitamin A for acne, however

Acne vulgaris

these were rare, mild and resolved during or after treatment. While a consensus on clinical guidelines for the safe use of vitamin A as a treatment for acne are currently lacking, those used for isotretinoin would be applicable including monitoring symptoms of adverse reactions, liver enzymes, blood lipids and pregnancy tests to avoid teratogenicity, where appropriate.

It has been estimated that a 200,000 IU dose of vitamin A would be comparable to a typical daily dose of isotretinoin.⁵⁹ With evidence that low-dose isotretinoin may be similarly effective to higher dose regimes and with fewer side-effects, it would be interesting to explore the efficacy and tolerance of lower dose vitamin A.⁶⁰ In vitamin A clinical trials marked improvement tended to occur from >100,000 IU/ daily doses with increasing effectiveness at higher doses of up to 300,000 IU/ daily and relapse increased on maintenance doses of 25,000 IU/ daily but not 50,000 IU/ daily.⁶¹

Based on the existing evidence vitamin A at doses of >100,000 IU/ daily for 4-months appears to be relatively safe and effective for the management of acne. A treatment duration of 4-months is considerably less than the years of continuous use associated with hypervitaminosis A, however, because the dose at which symptoms of hypervitaminosis A occurs is unclear and individual care should be taken to monitor possible side-effects.^{62 63 64} High dose vitamin A is contraindicated in pregnancy.⁶⁵

- **Biotin**

Severe biotin deficiency is thought to be rare, but suboptimal intakes may be common with risk factors including pregnancy, smoking, alcoholism, obesity, inflammatory bowel disease, liver disease, long-term parenteral nutrition, and use of certain medications (anticonvulsants, antibiotics) and dietary supplements (lipoic acid).^{66 67 68 69 70 71} Of relevance to acne, the medication isotretinoin reduces hepatic biotinidase activity and could increase biotin requirement.⁷²

Symptoms of overt biotin deficiency include dermatological manifestations, particularly a characteristic scaly, erythematous dermatitis.⁷³ The rash closely resembles the acrodermatitis enteropathica of zinc deficiency, which could be in part a result of biotin dependent changes in zinc metabolism.⁷⁴ Cutaneous symptoms of biotin deficiency may also be due to changes in fatty acid metabolism.⁷⁵ Although biotin has been suggested to play a role in acne there is not yet any evidence to support an association.⁷⁶

Biotin has been used as an adjuvant to prevent mucocutaneous side-effects of isotretinoin. In a clinical trial (n=60), biotin supplementation (10 mg/ day) was added to isotretinoin therapy over 4-months. Compared to isotretinoin alone, biotin decreased sign of hair thinning and loss (telogen and increased anagen hair rates) and maintained skin hydration.⁷⁷

The daily intake level that constitutes an optimal amount of biotin is not yet clear, although severe deficiency is uncommon that does not mean that suboptimal intakes are not or that current recommended daily intakes reflect biotin amounts required to support health beyond preventing frank deficiency.⁷⁸ Data suggest that biotin intakes 2-3 times the current recommended intake (30 µg) may be required to optimize biotin status when there is an increased demand such as in pregnancy.⁷⁹ Clinical trials of biotin in dermatology have typically used doses of 2,500 µg to 10,000 µg daily.⁸⁰

Biotin has no known toxicity and no adverse effects haven been reported with supplementation of 5,000 µg/ daily for 2-years or 300,000 µg/ daily for >3 months.^{81 82} Biotin supplementation can interfere with a wide variety of blood tests (immunoassays of thyroid markers, drugs, hormones,

Acne vulgaris

cancer markers, cardiac function, and others) increasing risk for falsely high or falsely low results and should be stopped >48 hours prior to testing.⁸³

- **Vitamin B3**

Vitamin B3 (niacin) as both nicotinamide and nicotinic acid has been used as a management approach for acne, and although both are forms of niacin and can treat vitamin B3 deficiency, they may have independent and unique pharmacological clinical effects beyond improving vitamin B3 status and so cannot be generalized as being interchangeable.⁸⁴

Pellagra (characterized by the “3 D’s” of dermatitis, dementia and diarrhea) is the classic vitamin B3 deficiency disorder, and although considered rare it may be more common than given appreciation, characterized by more diverse and / or subtle symptoms and therefore overlooked clinically.⁸⁵ Acne has been proposed to be a form of pellagra based on a new set of “3 Ds” of dermatitis (acne, seborrheic dermatitis), dyspepsia, and depression and the role of vitamin B3 in acne pathogenesis and treatment.⁸⁶ An early observational study of nicotinic acid (50 mg/ twice daily) reported that it might reduce symptoms in some patients.⁸⁷ A pilot trial of both nicotinamide (200 mg three times daily) or nicotinic acid (500 mg three times daily) with dietary changes (avoid alcohol, dairy, and a high-protein, low-fat and low-glycemic-load diet) found that although both forms of niacin were associated with improvement, nicotinic acid resulted in significantly better clinical improvements (82% vs. 73%).⁸⁸ If prescribing doses of niacin >30 mg daily patients should be made aware of flushing, a benign side effect of niacin.⁸⁹

Nicotinamide, the amide form of nicotinic acid, has been used in dermatology because of direct anti-inflammatory effects as well as its role as a precursor for nicotinamide adenine dinucleotide, a substrate for nuclear enzyme poly-ADP-ribose polymerase (PARP-1), which repairs damage from genotoxic stresses.⁹⁰ Nicotinamide also has demonstrated a good safety profile at long-term doses of 3 g daily.⁹¹

An 8-week clinical trial of nicotinamide (750 mg daily), zinc (25 mg), copper (1.5 mg), and folic acid (500 mcg) reported a significant improvement in acne severity with treatment.⁹² While another 8-week trial examining adjuvant use of a similar formulation (nicotinamide 600 mg, azelaic acid 5 mg, zinc 10 mg, pyridoxine 5 mg, copper 1.5 mg, folic acid 500 mcg daily) also found significant improvements in acne severity.⁹³

- **Vitamin B5**

An early report suggested that high-dose pantothenic acid (10 g followed by maintenance with 1-5 g daily in divided doses) could rapidly resolve acne, with the author proposing a theory that biochemical individuality may determine greater pantothenic acid requirements in some individuals and that a relative deficiency would influence metabolism of fatty acid and steroid hormones involved in acne pathogenesis.⁹⁴ Subsequently simulated pantothenic acid deficiency was found to suppressed keratinocyte proliferation and promote differentiation.⁹⁵ And a more recent 12-week clinical study in adults with facial acne found that pantothenic acid (2.2 g daily) reduced total facial lesion count and inflammatory blemishes.⁹⁶

- **Homocysteine lowering B vitamins**

Isotretinoin therapy for acne is associated with elevated homocysteine (theorized to be due to the inhibition of cystathionine beta-synthase by the drug and/or the drug-induced liver dysfunction) and reduced folate and vitamin B12 plasma levels, which may underlie its cardiovascular and

Acne vulgaris

neuropsychiatric side effects amongst others.^{97 98 99} Administration of folate and vitamin B12 with isotretinoin may prevent vitamin deficiency and correcting isotretinoin induced deficiency could reverse side effects.

A clinical trial (n=66) examining the ability of folic acid and vitamin B12 with isotretinoin to prevent hyperhomocysteinemia found that vitamin supplementation significantly decreased in homocysteine level, increased blood folate and B12 levels, and prevented decline in folate when compared to the control group (isotretinoin alone).¹⁰⁰ A case series of six patients with isotretinoin induced musculoskeletal pain found that treatment with folic acid and vitamin B12 reversed symptoms within 6-weeks of vitamin treatment.¹⁰¹ A case report of isotretinoin induced severe vitamin B12 deficiency and painful oral aphthous-like lesions described complete healing of the ulcers within 2-weeks of discontinuing isotretinoin treatment and commencing folic acid and vitamin B12.¹⁰²

- **Vitamin E**

A number of reports including clinical trials and anecdote from dermatology practice have suggested that vitamin E supplementation, either alone or with other vitamins (vitamin A, vitamin C) or isotretinoin, may improve acne.^{103 104 105 106 107 108}

Some of these reports employed vitamin E and other vitamins to combat the oxidative and inflammatory pathophysiology now well established in acne pathogenesis.¹⁰⁹ Serum vitamin E has been found to be low in patients with acne.¹¹⁰ Because the quality of evidence for vitamin E is limited more research is needed to determine whether vitamin E is useful for the management of acne, however, considering its relative safety and potential for benefit a course of vitamin E supplementation could be trialed.

Vitamin E has been explored for reducing side-effects of isotretinoin, which does lower serum vitamin E and increase oxidative stress.^{111 112} One study suggested benefit of vitamin E (800 IU alpha tocopherol/ daily) for reducing isotretinoin mucocutaneous side-effects, in contrast two studies failed to show any benefit.^{113 114 115}

- **Antioxidant nutrients**

Systemic and cutaneous oxidative stress is a feature of acne and thought to play an important role in disease pathogenesis, furthermore, nutritional antioxidant therapy is an important therapeutic consideration.¹¹⁶ Studies have found important differences in systemic oxidative stress in patients with acne, in particular low blood superoxide dismutase, glutathione peroxidase (GSH-Px) and elevated malondialdehyde.¹¹⁷ And the severity of serum oxidative/nitrosative stress and oxidative stress-mediated modifications of endogenous proteins has been shown to correlate with disease activity.¹¹⁸

Nutritional antioxidant therapies may help improve endogenous antioxidant defense, lower systemic oxidative stress and improve clinical symptoms. Supplementation with 200 mcg of selenium and 10 mg of vitamin E (as tocopheryl succinate) was shown to result in a good therapeutic response in acne patients with low GSH-Px at baseline.¹¹⁹ And an antioxidant complex providing zinc methionine (35 mg), ascorbic acid (180 mg), mixed carotenoids (18 mg), vitamin E as D-alpha tocopheryl acetate (45 IU) and chromium picolinate (36 mcg) daily, in divided doses, resulted in a significant reduction in clinical symptoms over 12-weeks.¹²⁰ In addition to dietary supplements, improving dietary antioxidant intake with foods rich in antioxidant vitamins (especially vitamins C and E), carotenoids and polyphenols would be an important consideration.¹²¹

Acne vulgaris

- **Zinc**

Zinc deficiency has been found to be more frequent in patients with acne and the degree of deficiency has been associated with greater disease severity.^{122 123 124} This may be due to zinc's role in reducing inflammation, maintaining redox balance, regulation of the immune system function and androgen metabolism.¹²⁵ Zinc supplementation has a long history of use in acne, with some early studies suggesting very high-dose zinc resulting in good clinical improvements in some,^{126 127 128} but not all studies.^{129 130}

Most studies have used zinc sulphate providing 30-150 mg of elemental zinc three times daily, and were associated with a high frequency of side-effects limiting the use of this treatment.¹³¹ Low dose zinc gluconate (30 mg elemental zinc daily), however, was both well-tolerated and clinically effective.¹³² A study assessing zinc gluconate (30mg elemental zinc) found a good clinical response with a 50% decrease in inflammatory lesions at 3 months with only a few mild gastrointestinal side-effects.¹³³ Because zinc may have direct disease-modifying effects zinc therapy could be useful in the absence of deficiency. Supplementation with 30 mg elemental zinc daily will minimize the probability of gastrointestinal side-effects.

Zinc may also lower isotretinoin requirements. A clinical trial (n=60) comparing oral zinc sulfate (based on body weight, estimated at 18.5 mg elemental zinc daily for an 80 kg adult) plus low-dose isotretinoin and to a standard isotretinoin dose found comparable efficacy between the two groups, and no difference in relapse rates.¹³⁴ Side-effects in the zinc plus low-dose isotretinoin were significantly lower (20% vs. 76.7%). Because zinc has known synergy with vitamin A, it would be interesting for future research to explore combined use of lower dose vitamin A regimens and zinc.¹³⁵

- **L-carnitine**

Carnitine supplementation may reduce muscular symptoms (myalgia, weakness) and elevations in liver enzymes due to isotretinoin therapy. A clinical trial (n=230) found that L-carnitine (100 mg per kg/daily) administered at the onset of muscular symptoms completely ameliorated symptoms within 5-6 days, restored serum carnitine levels, and normalised elevations in their liver enzymes.¹³⁶ The effect of carnitine on liver enzymes is consistent with a large number of clinical trials showing benefit, particularly at doses of >2,000 mg daily for > 12 weeks.¹³⁷

- **Fatty acids**

The omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) play a role in acne development, with lower serum levels linked to acne-related inflammation and clinical interventions showing good clinical responses to fish oil. The average omega-3-index, the percentage of EPA plus DHA in erythrocytes, has been found to be very low (<4%) in patients with acne and lower than the general population.¹³⁸ Suboptimal EPA/ DHA may contribute to acne pathology with serum analysis of patients with acne revealing decreased serum EPA levels and an increased pro-inflammatory state.¹³⁹ In addition to anti-inflammatory properties, omega-3 fatty acids have also demonstrated antibacterial effects relevant to acne.¹⁴⁰

A series of case reports was amongst the first to demonstrate important clinical improvements on acne severity, mood and depressive symptoms with EPA (1000 mg daily) combined with zinc gluconate (15 mg), selenium (200 mcg), chromium (200 mcg) and epigallocatechin-3-gallate (200 mg) from green tea extract.¹⁴¹ Subsequently, a 12-week pilot study found that fish oil (equivalent to 930 mg of EPA daily) reduced acne severity in individuals with moderate to severe acne.¹⁴² Most

Acne vulgaris

recently a 10-week, randomized controlled trial in adults with mild to moderate acne found that supplementation with EPA (1000 mg daily) and DHA (1000 mg) or gamma-linoleic acid (400mg from borage oil) found that both treatment reduced acne severity and inflammation.¹⁴³ The therapeutic effect of gamma-linoleic acid (320 mg daily) was also demonstrated in a small 12-week study.¹⁴⁴ Supplementation with omega-3 fatty acids (1000 mg daily) or evening primrose oil (320 mg of gamma-linoleic acid daily) also decreases mucocutaneous side effects of isotretinoin.^{145 146 147 148} A minimum 12-week trial course of fish oil providing around 1000 mg EPA and/ or 320 mg of gamma-linoleic acid could be considered in patients with acne.

- **Probiotics**

Alterations in the gastrointestinal microbiome been proposed to be an important factor in the development of acne and associated psychiatric morbidity with evidence to suggest that gastrointestinal disease, especially bloating, is more frequent in adolescents with acne and that alternations in gut microbiota play a role in acne pathogenesis.¹⁴⁹ Probiotics can modulate microbiome composition and/ or function and are emerging as a therapeutic option for improving the function of the gut-brain-skin axis with benefits likely due to their ability to reduce small intestinal bacterial overgrowth, improve dysbiosis, reduce systemic markers of oxidative stress and inflammation, and improve mental health.¹⁵⁰

A clinical trial of daily lactoferrin-enriched fermented milk in adults found that the intervention resulted in significant reductions in acne symptoms and a decrease of triacylglycerols in skin surface lipids within 12-weeks.¹⁵¹ Adjuvant use of probiotics (*L. acidophilus*, *L. delbrueckii* subspecies *bulgaricus* LB-51, *B. bifidum*; 30 billion CFU daily) with antibiotic therapy demonstrated that probiotic treatment enhanced symptom reduction and reduced antibiotic side effects.¹⁵² A clinical trial of a probiotic (*L. rhamnosus* SP1 also known as *L. rhamnosus* GG; 3 billion CFU daily) in adults reduced clinical symptoms of acne and improved expression of genes involved in insulin signaling in their skin.¹⁵³ When compared to medical care alone (oral and topical medications, a vegetarian diet), the addition of a probiotic (*E. coli* Nissle; 5 to 50 billion CFU daily) resulted in significantly better rates of improvement or complete recovery (89% vs. 56%) of acne, papular-pustular rosacea and seborrheic dermatitis.¹⁵⁴ A probiotic (*B. breve* BR03 DSM 16604, *L. casei* LC03 DSM 27537, and *L. salivarius* LS03 DSM 22776; 2 billion CFU daily) with botanical extracts (lupeol from *Solanum melongena* L. and *Echinacea* extract) significantly reduced total facial lesion count after 8-weeks, when compared to placebo or probiotics and botanical extracts alone.¹⁵⁵

A diversity of probiotics has been used to manage acne, from fermented milks to multi strain formulations. Generally, the evidence suggests probiotics, regardless of the type of product or strains used, may improve acne symptoms and complement other therapies by improving treatment outcomes. It appears prudent to trial a course of probiotics in patients with acne.

- **Green tea extract**

Green tea extract has been shown to reduce acne severity, likely because of its ability to reduce hyperseborrhea, inflammation, and anti-bacterial activity.¹⁵⁶ A 30-day clinical trial of an aqueous green tea extract (500 mg three times daily) found that the treatment decreased inflamed and total acne lesions in adolescents and young adults with facial acne.¹⁵⁷ And a 4-week clinical trial in adult women with acne found that green tea extract (providing 856mg of epigallocatechin-3-gallate daily) resulted in a statistically significant improvement in total and inflammatory acne lesions.¹⁵⁸ Green tea extract could be a useful approach for the treatment of adult acne. However, care should be

Acne vulgaris

taken with high-doses (856mg of epigallocatechin-3-gallate) in the long-term use (several months) as this dose can raise liver enzymes and lead to adverse events in around 1% of people.¹⁵⁹

- **Topical therapies**

Herbal and nutritional topical therapies that have been reported to reduce acne severity in clinical studies include 2% Wild basil (*Ocimum gratissimum*) essential oil,¹⁶⁰ 1% Copaiba (*Copaifera langsdorffii* Desf.) essential oil,¹⁶¹ resveratrol-containing gel,¹⁶² and seaweed-derived oligosaccharide (*Laminaria digitata* or kelp) and 0.1% zinc pyrrolidone.¹⁶³ The most frequently studied herbal topical treatment is 5% tea tree (*Melaleuca alternifolia*) essential oil, with a review of 7 clinical studies concluding that tea tree oil products reduce the number of lesions mild-to-moderate acne.¹⁶⁴

Summary and Clinical Considerations

Intervention	Discussion	Guidance
Low glycemic-load diet	High-GL diets and resultant insulin resistance and hyperinsulinemia contribute to acne development, while low-GL diets may reduce acne severity.	Limit intake of high-GL foods including refined grains and sugars as well as total available sugars from carbohydrate-rich foods.
Acne promoting foods	Cow's milk, whey protein, and cocoa have been linked to the development and/or exacerbation of acne. So have dietary supplements vitamin B12 and Kelp.	Consider limiting or eliminating exposure dietary cow's milk, whey protein and cocoa if suspected to be contributing to symptoms. High dose vitamin B12 and Kelp supplements may also contribute to acne-like symptoms.
Vitamin A	Vitamin A may be a suitable alternative to isotretinoin (a vitamin A analogue).	Consider a course of >100,000 IU/ daily for 4-months. Although relatively safe, monitor for hypervitaminosis A and avoid in pregnancy.
Biotin	Biotin deficiency may be associated with acne, but more evidence is needed.	Consider >30 µg daily if risk factors for deficiency are present. Reduces mucocutaneous side-effects isotretinoin of at 10 mg daily.
Vitamin B3	Subclinical vitamin B3 deficiency may be associated with acne. Nicotinamide has pharmacological anti-inflammatory effects.	Nicotinic acid at a dose of 500 mg three times daily could be trialed, however patients should be counseled about flushing. A minimum 8-week course of 600 mg to 750 mg of nicotinamide may help reduce acne severity.
Vitamin B5	High-dose pantothenic acid has shown some evidence of benefit.	A minimum 12-week course of at least 2.2 g of pantothenic acid could be considered.
Homocysteine lowering B vitamins	Isotretinoin therapy for acne is associated with elevated homocysteine and reduced folate and	Administration of folate and vitamin B12 with isotretinoin may prevent vitamin deficiency and correcting isotretinoin

Acne vulgaris

	vitamin B12 plasma levels, which may underlie its cardiovascular and neuropsychiatric side effects.	induced deficiency could reverse side effects.
Vitamin E	Vitamin E may modulate inflammatory and oxidative stress intrinsic to acne, however, quality of evidence is limited.	Consider an empirical trial of 800 IU daily of vitamin E alone or with other antioxidants if evidence of significant inflammatory and oxidative stress.
Antioxidant nutrients	Redox imbalance and inflammation are intrinsic to acne pathophysiology, can be modulated by antioxidant nutrients and improve the disease course.	Consider multi-nutrient formulations designed to modulates oxidative stress. Improve dietary antioxidant intake with foods rich in antioxidant vitamins (especially vitamins C and E), carotenoids and polyphenols.
Zinc	Zinc deficiency is common in acne, but zinc may also have direct disease-modifying effects.	Supplementation with 30 mg elemental zinc daily would be useful in deficiency but may also be useful as a treatment in inflammatory acne independent of overt deficiency.
Carnitine	Serum carnitine is reduced by isotretinoin and carnitine replacement may offset muscular and hepatic related side-effect.	Consider acute supplementation of l-carnitine at the onset of muscular symptoms. Doses of >2,000 mg daily for > 12 weeks could be used to normalize liver enzymes.
Fatty acids	Clinical interventions have found a good clinical response to EPA and DHA and/ or GLA.	A minimum 12-week course of fish oil providing around 1000 mg EPA and DHA/ or 320 mg of GLA could be considered in patients with acne.
Probiotics	Probiotics can modulate microbiome composition and/ or function and are emerging as a therapeutic option for improving the function of the gut-brain-skin axis.	Evidence suggests probiotics, regardless of the type of product or strains used, may improve acne symptoms. It appears prudent to trial a course of probiotics in patients with acne.
Green tea extract	Green tea extract is a safe and useful intervention for reducing acne severity.	A 4-week course of green tea extract providing 856mg of epigallocatechin-3-gallate daily may be useful, but care should be taken with long-term use due to hepatic side-effects.
Topical therapies	Tea tree essential oil topical treatments have demonstrated benefits in several studies.	Topical treatment with gels and creams containing 5% tea tree essential oil can help reduce acne lesions.

¹ Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013 Mar;168(3):474-85.

Acne vulgaris

- ² Holzmann R, Shakery K. Postadolescent acne in females. *Skin Pharmacol Physiol*. 2014;27 Suppl 1:3-8.
- ³ Gieler U, Gieler T, Kupfer JP. Acne and quality of life - impact and management. *J Eur Acad Dermatol Venereol*. 2015 Jun;29 Suppl 4:12-4.
- ⁴ Williams HC, Dellavalle RP, Garner S. Acne vulgaris. *Lancet*. 2012 Jan 28;379(9813):361-72.
- ⁵ Picardo M, Eichenfield LF, Tan J. Acne and Rosacea. *Dermatol Ther (Heidelb)*. 2017 Jan;7(Suppl 1):43-52.
- ⁶ Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. *Exp Dermatol*. 2009 Oct;18(10):821-32.
- ⁷ Zouboulis CC, Jourdan E, Picardo M. Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions. *J Eur Acad Dermatol Venereol*. 2014 May;28(5):527-32.
- ⁸ Oudenhoven MD, Kinney MA, McShane DB, Burkhart CN, Morrell DS. Adverse effects of acne medications: recognition and management. *Am J Clin Dermatol*. 2015 Aug;16(4):231-42.
- ⁹ Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. *J Eur Acad Dermatol Venereol*. 2015 Jun;29 Suppl 5:1-7.
- ¹⁰ Melnik BC. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update. *Clin Cosmet Investig Dermatol*. 2015 Jul 15;8:371-88.
- ¹¹ Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of Western civilization. *Arch Dermatol*. 2002 Dec;138(12):1584-90.
- ¹² Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. *ScientificWorldJournal*. 2015;2015:479354.
- ¹³ Kim H, Moon SY, Sohn MY, et al. Insulin-Like Growth Factor-1 Increases the Expression of Inflammatory Biomarkers and Sebum Production in Cultured Sebocytes. *Ann Dermatol*. 2017 Feb;29(1):20-25.
- ¹⁴ Emiroğlu N, Cengiz FP, Kemeriz F. Insulin resistance in severe acne vulgaris. *Postepy Dermatol Alergol*. 2015 Aug;32(4):281-5.
- ¹⁵ Burris J, Shikany JM, Rietkerk W, Woolf K. A Low Glycemic Index and Glycemic Load Diet Decreases Insulin-like Growth Factor-1 among Adults with Moderate and Severe Acne: A Short-Duration, 2-Week Randomized Controlled Trial. *J Acad Nutr Diet*. 2018 Oct;118(10):1874-1885.
- ¹⁶ Melnik BC, John SM, Plewig G. Acne: risk indicator for increased body mass index and insulin resistance. *Acta Derm Venereol*. 2013 Nov;93(6):644-9.
- ¹⁷ Cornbleet T, Gigli I. Should we limit sugar in acne? *Arch Dermatol* 1961;83:968–969.
- ¹⁸ Fabbrocini G, Izzo R, Faggiano A, et al. Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. *Clin Exp Dermatol*. 2016 Jan;41(1):38-42.
- ¹⁹ Smith RN, Mann NJ, Braue A, et al. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. *Am J Clin Nutr*. 2007 Jul;86(1):107-15.
- ²⁰ Smith RN, Mann NJ, Braue A, et al. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. *J Am Acad Dermatol*. 2007 Aug;57(2):247-56.
- ²¹ Smith RN, Braue A, Varigos GA, et al. The effect of a low glycemic load diet on acne vulgaris and the fatty acid composition of skin surface triglycerides. *J Dermatol Sci*. 2008 Apr;50(1):41-52.
- ²² Kwon HH, Yoon JY, Hong JS, et al. Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial. *Acta Derm Venereol*. 2012 May;92(3):241-6.
- ²³ Morales-Sánchez MA, Camacho-Rosas LH, García-Becerril I, Peralta-Pedrero ML. Effect of adding a low glycemic load and index diet over 12 weeks in the treatment of moderate acne: a randomized controlled trial. *Int J Dermatol*. 2023 Jan;62(1):e39-e42.
- ²⁴ Reynolds RC, Lee S, Choi JY, et al. Effect of the glycemic index of carbohydrates on Acne vulgaris. *Nutrients*. 2010 Oct;2(10):1060-72.
- ²⁵ Pavithra G, Upadya GM, Rukmini MS. A randomized controlled trial of topical benzoyl peroxide 2.5% gel with a low glycemic load diet versus topical benzoyl peroxide 2.5% gel with a normal diet in acne (grades 1-3). *Indian J Dermatol Venereol Leprol*. 2019 Sep-Oct;85(5):486-490.
- ²⁶ Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in teenaged boys. *J Am Acad Dermatol* 2008; 58: 787–793.
- ²⁷ Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in adolescent girls. *Dermatol Online J* 2006; 12: 1.
- ²⁸ Adebamowo CA, Spiegelman D, Danby FW, et al. High school dietary dairy intake and teenage acne. *J Am Acad Dermatol* 2005; 52: 207–214
- ²⁹ Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. *J Am Acad Dermatol* 2012; 67: 1129–1135.
- ³⁰ Grossi E, Cazzaniga S, Crotti S, et al. The constellation of dietary factors in adolescent acne: a semantic connectivity map approach. *J Eur Acad Dermatol Venereol*. 2016 Jan;30(1):96-100.
- ³¹ LaRosa CL, Quach KA, Koons K, et al. Consumption of dairy in teenagers with and without acne. *J Am Acad Dermatol*. 2016 Aug;75(2):318-22.
- ³² Silverberg NB. Whey protein precipitating moderate to severe acne flares in 5 teenaged athletes. *Cutis*. 2012 Aug;90(2):70-2.
- ³³ Simonart T. Acne and whey protein supplementation among bodybuilders. *Dermatology*. 2012;225(3):256-8.

Acne vulgaris

- ³⁴ Pontes T, Fernandes Filho G, Trindade Ade S, Sobral Filho J. Incidence of acne vulgaris in young adult users of protein supplements in the city of João Pessoa–PB. *An Bras Dermatol*. 2013;88(6):907–12
- ³⁵ Cengiz FP, Cevirgen Cemil B, Emiroglu N, Gulsel Bahali A, Onsun N. Acne located on the trunk, whey protein supplementation: Is there any association? *Health Promot Perspect*. 2017 Mar 5;7(2):106-108. doi: 10.15171/hpp.2017.19. PMID: 28326292; PMCID: PMC5350548.
- ³⁶ Melnik BC. Evidence for acne-promoting effects of milk and other insulinotropic dairy products. *Nestle Nutr Workshop Ser Pediatr Program*. 2011;67:131-45.
- ³⁷ Hoyt G, Hickey MS, Cordain L. Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk. *Br J Nutr*. 2005 Feb;93(2):175-7.
- ³⁸ Jeske S, Zannini E, Arendt EK. Evaluation of Physicochemical and Glycaemic Properties of Commercial Plant-Based Milk Substitutes. *Plant Foods Hum Nutr*. 2017 Mar;72(1):26-33.
- ³⁹ Melnik BC, Schmitz G. Pasteurized non-fermented cow's milk but not fermented milk is a promoter of mTORC1-driven aging and increased mortality. *Ageing Res Rev*. 2021 May;67:101270. doi: 10.1016/j.arr.2021.101270. Epub 2021 Feb 8. PMID: 33571703.
- ⁴⁰ Goh W, Kallianpur KJ, Chow D, et al. Chocolate and acne: how valid was the original study? *Clin Dermatol*. 2011 Jul-Aug;29(4):459-60.
- ⁴¹ Block SG, Valins WE, Caperton CV, et al. Exacerbation of facial acne vulgaris after consuming pure chocolate. *J Am Acad Dermatol*. 2011;65(4):e14–e15.
- ⁴² Caperton C, Block S, Viera M, et al. Double-blind, Placebo-controlled Study Assessing the Effect of Chocolate Consumption in Subjects with a History of Acne Vulgaris. *J Clin Aesthet Dermatol*. 2014 May;7(5):19-23.
- ⁴³ Netea SA, Janssen SA, Jaeger M, et al. Chocolate consumption modulates cytokine production in healthy individuals. *Cytokine*. 2013 Apr;62(1):40-3.
- ⁴⁴ Braun-Falco O, Lincke H. [The problem of vitamin B6/B12 acne. A contribution on acne medicamentosa (author's transl)]. *MMW Munch Med Wochenschr*. 1976;118:155–60.
- ⁴⁵ Sherertz EF. Acneiform eruption due to 'megadose' vitamins B6 and B12. *Cutis*. 1991;48:119–20.
- ⁴⁶ Balta I, Ozuguz P. Vitamin B12-induced acneiform eruption. *Cutaneous and Ocular Toxicology*. 2014;33:94–5.
- ⁴⁷ Veraldi S, Benardon S, Diani M, Barbareschi M. Acneiform eruptions caused by vitamin B12: A report of five cases and review of the literature. *J Cosmet Dermatol*. 2018;17:112–5.
- ⁴⁸ Balta I, Ekiz O, Ozuguz P, et al. Nutritional anemia in reproductive age women with postadolescent acne. *Cutaneous and Ocular Toxicology*. 2013;32:200–3.
- ⁴⁹ Karadag AS, Tatal E, Ertugrul DT, Akin KO. Effect of isotretinoin treatment on plasma holotranscobalamin, vitamin B12, folic acid, and homocysteine levels: non-controlled study. *Int J Dermatol*. 2011;50:1564–9
- ⁵⁰ Kang D, Shi B, Erfe MC, Craft N, Li H. Vitamin B12 modulates the transcriptome of the skin microbiota in acne pathogenesis. *Sci Transl Med*. 2015;7:293ra103
- ⁵¹ Harrell BL, Rudolph AH. Letter: Kelp diet: A cause of acneiform eruption. *Arch Dermatol*. 1976;112:560
- ⁵² Papa CM. Acne and Hidden Iodides. *Arch Dermatol*. 1976;112:555–6.
- ⁵³ Danby FW. Acne and iodine: reply. *J Am Acad Dermatol*. 2007 Jan;56(1):164-5.
- ⁵⁴ Cook M, Perche P, Feldman S. Oral Vitamin A for Acne Management: A Possible Substitute for Isotretinoin. *J Drugs Dermatol*. 2022 Jun 1;21(6):683-686. doi: 10.36849/JDD.6781. PMID: 35674761.
- ⁵⁵ Cook M, Perche P, Feldman S. Oral Vitamin A for Acne Management: A Possible Substitute for Isotretinoin. *J Drugs Dermatol*. 2022 Jun 1;21(6):683-686..
- ⁵⁶ Drake PW. High Dose Vitamin A Cures Severe Acne Vulgaris. *International Journal of Science and Research (IJSR)*. 2021;10:68791.
- ⁵⁷ Olson JM, Ameer MA, Goyal A. Vitamin A Toxicity. [Updated 2023 Sep 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK532916/>
- ⁵⁸ Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. *Am J Clin Nutr*. 2006 Feb;83(2):191-201.
- ⁵⁹ Drake PW. High Dose Vitamin A Cures Severe Acne Vulgaris. *International Journal of Science and Research (IJSR)*. 2021;10:68791.
- ⁶⁰ Kotori MG. Low-dose Vitamin "A" Tablets-treatment of Acne Vulgaris. *Med Arch*. 2015 Feb;69(1):28-30. doi: 10.5455/medarch.2015.69.28-30. Epub 2015 Feb 21. PMID: 25870473; PMCID: PMC4384860.
- ⁶¹ Cook M, Perche P, Feldman S. Oral Vitamin A for Acne Management: A Possible Substitute for Isotretinoin. *J Drugs Dermatol*. 2022 Jun 1;21(6):683-686..
- ⁶² Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. *Am J Clin Nutr*. 2006 Feb;83(2):191-201. doi: 10.1093/ajcn/83.2.191. PMID: 16469975.
- ⁶³ Russell RM. The vitamin A spectrum: from deficiency to toxicity. *Am J Clin Nutr*. 2000 Apr;71(4):878-84. doi: 10.1093/ajcn/71.4.878. PMID: 10731492.
- ⁶⁴ Fedotin MS. Hypervitaminosis causing pseudotumor cerebri. *JAMA*. 1970 Apr 27;212(4):628. PMID: 5467368.
- ⁶⁵ Brown B, Wright C. Safety and efficacy of supplements in pregnancy. *Nutr Rev*. 2020 Oct 1;78(10):813-826.
- ⁶⁶ Zempleni J, Kuroishi T. Biotin. *Adv Nutr*. 2012 Mar 1;3(2):213-4.
- ⁶⁷ Said HM. Biotin: biochemical, physiological and clinical aspects. *Subcell Biochem*. 2012;56:1-19.

Acne vulgaris

- ⁶⁸ Pabuçcuoğlu A, Aydoğdu S, Baş M. Serum biotinidase activity in children with chronic liver disease and its clinical significance. *J Pediatr Gastroenterol Nutr.* 2002 Jan;34(1):59-62. doi: 10.1097/00005176-200201000-00014. PMID: 11753166.
- ⁶⁹ Hayashi A, Mikami Y, Miyamoto K, Kamada N, Sato T, Mizuno S, Naganuma M, Teratani T, Aoki R, Fukuda S, Suda W, Hattori M, Amagai M, Ohyama M, Kanai T. Intestinal Dysbiosis and Biotin Deprivation Induce Alopecia through Overgrowth of *Lactobacillus murinus* in Mice. *Cell Rep.* 2017 Aug 15;20(7):1513-1524.
- ⁷⁰ Belda E, Volland L, Tremaroli V, Falony G, Adriouch S, Assmann KE, Prifti E, Aron-Wisniewsky J, Debédat J, Le Roy T, Nielsen T, Amouyal C, André S, Andreelli F, Blüher M, Chakaroun R, Chilloux J, Coelho LP, Dao MC, Das P, Fellahi S, Forslund S, Galleron N, Hansen TH, Holmes B, Ji B, Krogh Pedersen H, Le P, Le Chatelier E, Lewinter C, Mannerås-Holm L, Marquet F, Myridakis A, Pelloux V, Pons N, Quinquis B, Rouault C, Roume H, Salem JE, Sokolovska N, Søndergaard NB, Touch S, Vieira-Silva S; MetaCardis Consortium; Galan P, Holst J, Gøtze JP, Køber L, Vestergaard H, Hansen T, Hercberg S, Oppert JM, Nielsen J, Letunic I, Dumas ME, Stumvoll M, Pedersen OB, Bork P, Ehrlich SD, Zucker JD, Bäckhed F, Raes J, Clément K. Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism. *Gut.* 2022 Dec;71(12):2463-2480.
- ⁷¹ Greenway FL, Ingram DK, Ravussin E, Hausmann M, Smith SR, Cox L, Tomayko K, Treadwell BV. Loss of taste responds to high-dose biotin treatment. *J Am Coll Nutr.* 2011 Jun;30(3):178-81.
- ⁷² Schulpis KH, Georgala S, Papakonstantinou ED, Michas T, Karikas GA. The effect of isotretinoin on biotinidase activity. *Skin Pharmacol Appl Skin Physiol.* 1999 Jan-Apr;12(1-2):28-33. doi: 10.1159/000029843. PMID: 10325581.
- ⁷³ Mock DM. Skin manifestations of biotin deficiency. *Semin Dermatol.* 1991 Dec;10(4):296-302. PMID: 1764357.
- ⁷⁴ Ogawa Y, Kinoshita M, Sato T, Shimada S, Kawamura T. Biotin Is Required for the Zinc Homeostasis in the Skin. *Nutrients.* 2019 Apr 24;11(4):919.
- ⁷⁵ Mock DM. Evidence for a pathogenic role of omega 6 polyunsaturated fatty acid in the cutaneous manifestations of biotin deficiency. *J Pediatr Gastroenterol Nutr.* 1990 Feb;10(2):222-9.
- ⁷⁶ Piraccini BM, Berardesca E, Fabbrocini G, Micali G, Tosti A. Biotin: overview of the treatment of diseases of cutaneous appendages and of hyperseborrhea. *G Ital Dermatol Venereol.* 2019 Oct;154(5):557-566.
- ⁷⁷ Aksac SE, Bilgili SG, Yavuz GO, Yavuz IH, Aksac M, Karadag AS. Evaluation of biophysical skin parameters and hair changes in patients with acne vulgaris treated with isotretinoin, and the effect of biotin use on these parameters. *Int J Dermatol.* 2021 Aug;60(8):980-985.
- ⁷⁸ Mock DM. Adequate intake of biotin in pregnancy: why bother? *J Nutr.* 2014 Dec;144(12):1885-6.
- ⁷⁹ Mock DM. Biotin: From Nutrition to Therapeutics. *J Nutr.* 2017 Aug;147(8):1487-1492.
- ⁸⁰ Patel DP, Swink SM, Castelo-Soccio L. A Review of the Use of Biotin for Hair Loss. *Skin Appendage Disord.* 2017 Aug;3(3):166-169.
- ⁸¹ Koutsikos D, Agroyannis B, Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. *Biomed Pharmacother.* 1990;44(10):511-4. doi: 10.1016/0753-3322(90)90171-5. PMID: 2085665.
- ⁸² Espiritu AI, Remalante-Rayco PPM. High-dose biotin for multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials. *Mult Scler Relat Disord.* 2021 Oct;55:103159.
- ⁸³ Luong JHT, Male KB, Glennon JD. Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: An emerging threat. *Biotechnol Adv.* 2019 Sep-Oct;37(5):634-641.
- ⁸⁴ Prousky J, Millman CG, Kirkland JB. Pharmacologic Use of Niacin. *Journal of Evidence-Based Complementary & Alternative Medicine.* 2011;16(2):91-101.
- ⁸⁵ Prousky J, Millman CG, Kirkland JB. Pharmacologic Use of Niacin. *Journal of Evidence-Based Complementary & Alternative Medicine.* 2011;16(2):91-101.
- ⁸⁶ Jiang Hao, Li Changyi. Acne Vulgaris Is a Special Clinical Type of Pellagra. *American Journal of Clinical and Experimental Medicine.* Vol. 9, No. 6, 2021, pp. 204-208. doi: 10.11648/j.ajcem.20210906.13
- ⁸⁷ Lynch FW: Nicotinic acid in the treatment of acne vulgaris. *Arch Dermatol Syphilol* 1940, 42:481-2.
- ⁸⁸ Hao J, Changyi L. High dose niacin in the treatment of acne vulgaris: a pilot study. *Chin J Aesthet Med.* 2016; 25 (12): 54–9
- ⁸⁹ Guyton JR, Bays HE. Safety considerations with niacin therapy. *Am J Cardiol.* 2007 Mar 19;99(6A):22C-31C.
- ⁹⁰ Walocko FM, Eber AE, Keri JE, et al. The role of nicotinamide in acne treatment. *Dermatol Ther.* 2017 Feb 21. doi: 10.1111/dth.12481. [Epub ahead of print]
- ⁹¹ Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. *Diabetologia.* 2000 Nov;43(11):1337-45.
- ⁹² Niren NM, Torok HM. The Nicomide Improvement in Clinical Outcomes Study (NICOS): results of an 8-week trial. *Cutis.* 2006 Jan;77(1 Suppl):17-28.
- ⁹³ Shalita AR, Falcon R, Olansky A, et al. Inflammatory acne management with a novel prescription dietary supplement. *J Drugs Dermatol.* 2012 Dec;11(12):1428-33.
- ⁹⁴ Leung LH. Pantothenic acid deficiency as the pathogenesis of acne vulgaris. *Med Hypotheses.* 1995 Jun;44(6):490-2.
- ⁹⁵ Kobayashi D, Kusama M, Onda M, et al. The effect of pantothenic acid deficiency on keratinocyte proliferation and the synthesis of keratinocyte growth factor and collagen in fibroblasts. *J Pharmacol Sci.* 2011;115(2):230-4.
- ⁹⁶ Yang M, Moclair B, Hatcher V, et al. A randomized, double-blind, placebo-controlled study of a novel pantothenic Acid-based dietary supplement in subjects with mild to moderate facial acne. *Dermatol Ther (Heidelb).* 2014 Jun;4(1):93-101.
- ⁹⁷ Namazi MR, Feily A. Hyperhomocysteinemia: can't it account for retinoid-induced fracture proneness? *Indian J Dermatol Venereol Leprol.* 2010 Mar-Apr;76(2):186-7.

Acne vulgaris

- ⁹⁸ Kim HJ, Lee SM, Lee JS, Lee SY, Chung EH, Cho MK, Lee SH, Kim JE. Homocysteine, folic acid, and vitamin B12 levels in patients on isotretinoin therapy for acne vulgaris: A meta-analysis. *J Cosmet Dermatol.* 2020 Mar;19(3):736-745.
- ⁹⁹ Rajput I, Anjankar VP. Side Effects of Treating Acne Vulgaris With Isotretinoin: A Systematic Review. *Cureus.* 2024 Mar 11;16(3):e55946.
- ¹⁰⁰ Ghiasi M, Mortazavi H, Jafari M. Efficacy of Folic Acid and Vitamin B₁₂ Replacement Therapies in the Reduction of Adverse Effects of Isotretinoin: A Randomized Controlled Trial. *Skinmed.* 2018 Jul 1;16(4):239-245. PMID: 30207526.
- ¹⁰¹ Feily A. Successful Treatment of Isotretinoin Induced Musculoskeletal Pain by Vitamin B12 and Folic Acid. *Open Access Maced J Med Sci.* 2019 Oct 10;7(21):3726-3727.
- ¹⁰² Vigaros E, Comont T, Piroth M, Cougoul P, Sibaud V. Severe aphthous stomatitis secondary to vitamin B12 deficiency with isotretinoin therapy. *JAAD Case Rep.* 2019 Jun 12;5(6):563-565.
- ¹⁰³ DAINOW I. La vitamine E dans le traitement de l'acné [Vitamin E therapy of the acne]. *Dermatologica.* 1953;106(3-5):197-200.
- ¹⁰⁴ Ayres S Jr, Mihan R. Synergism of vitamins A and E in acne vulgaris. *Int J Dermatol.* 1981 Nov;20(9):616. doi: 10.1111/j.1365-4362.1981.tb00849.x. PMID: 6458572.
- ¹⁰⁵ Ayres S Jr, Mihan R. Acne vulgaris: therapy directed at pathophysiologic defects. *Cutis.* 1981 Jul;28(1):41-2. PMID: 6455256.
- ¹⁰⁶ Ayres S Jr. Acne vulgaris: correcting pathophysiologic defects versus antibacterial therapy. *Int J Dermatol.* 1986 Jun;25(5):335-6.
- ¹⁰⁷ Kunin NA. Lechenie tiazhelykh form ugrevoï bolezni sochetannym primeneniem roakkutana i vitamina E [Treatment of severe forms of acne by combined administration of Roaccutan and vitamin E]. *Vestn Dermatol Venerol.* 1988;(1):48-50..
- ¹⁰⁸ Acharya SR. Vitamin E (tocopherol acetate) in the treatment of adolescent acne. *J Assoc Physicians India.* 1990 Feb;38(2):189-90.
- ¹⁰⁹ Bowe WP, Patel N, Logan AC. Acne vulgaris: the role of oxidative stress and the potential therapeutic value of local and systemic antioxidants. *J Drugs Dermatol.* 2012 Jun;11(6):742-6. PMID: 22648222.
- ¹¹⁰ Liu X, Yang G, Luo M, Lan Q, Shi X, Deng H, Wang N, Xu X, Zhang C. Serum vitamin E levels and chronic inflammatory skin diseases: A systematic review and meta-analysis. *PLoS One.* 2021 Dec 14;16(12):e0261259.
- ¹¹¹ Aktürk AŞ, Güzel S, Bulca S, Demirsoy EO, Bayramgürler D, Bilen N, Kiran R. Effects of isotretinoin on serum vitamin E levels in patients with acne. *Int J Dermatol.* 2013 Mar;52(3):363-6. doi: 10.1111/j.1365-4632.2012.05676.x. PMID: 23414163.
- ¹¹² Erturan İ, Nazıroğlu M, Akkaya VB. Isotretinoin treatment induces oxidative toxicity in blood of patients with acne vulgaris: a clinical pilot study. *Cell Biochem Funct.* 2012 Oct;30(7):552-7. doi: 10.1002/cbf.2830. Epub 2012 Apr 20. PMID: 22517509.
- ¹¹³ Goforoushan F, Azimi H, Goldust M. Efficacy of vitamin E to prevent dermal complications of isotretinoin. *Pak J Biol Sci.* 2013 Jun 1;16(11):548-50.
- ¹¹⁴ Strauss JS, Gottlieb AB, Jones T, Koo JY, Leyden JJ, Lucky A, Pappas AA, McLane J, Leach EE. Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial. *J Am Acad Dermatol.* 2000 Nov;43(5 Pt 1):777-84.
- ¹¹⁵ Kus S, Gün D, Demirçay Z, Sur H. Vitamin E does not reduce the side-effects of isotretinoin in the treatment of acne vulgaris. *Int J Dermatol.* 2005 Mar;44(3):248-51.
- ¹¹⁶ Bowe WP, Patel N, Logan AC. Acne vulgaris: the role of oxidative stress and the potential therapeutic value of local and systemic antioxidants. *J Drugs Dermatol.* 2012 Jun;11(6):742-6.
- ¹¹⁷ Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. *Lipids Health Dis.* 2010 Dec 9;9:141.
- ¹¹⁸ I-Shobaili HA, Alzolibani AA, Al Robaee AA, et al. Biochemical markers of oxidative and nitrosative stress in acne vulgaris: correlation with disease activity. *J Clin Lab Anal.* 2013 Jan;27(1):45-52.
- ¹¹⁹ Michaëlsson G, Edqvist LE. Erythrocyte glutathione peroxidase activity in acne vulgaris and the effect of selenium and vitamin E treatment. *Acta Derm Venereol.* 1984;64(1):9-14.
- ¹²⁰ Sardana K, Garg VK. An observational study of methionine-bound zinc with antioxidants for mild to moderate acne vulgaris. *Dermatol Ther.* 2010 Jul-Aug;23(4):411-8.
- ¹²¹ Działo M, Mierziak J, Korzun U, et al. The Potential of Plant Phenolics in Prevention and Therapy of Skin Disorders. *Int J Mol Sci.* 2016 Feb 18;17(2):160.
- ¹²² Rostami Mogaddam M, Safavi Ardabili N, Maleki N, et al. Correlation between the severity and type of acne lesions with serum zinc levels in patients with acne vulgaris. *Biomed Res Int.* 2014;2014:474108.
- ¹²³ Ozuguz P, Dogruk Kacar S, Ekiz O, et al. Evaluation of serum vitamins A and E and zinc levels according to the severity of acne vulgaris. *Cutan Ocul Toxicol.* 2014 Jun;33(2):99-102.
- ¹²⁴ Kaymak Y, et al. Zinc Levels in Patients with Acne Vulgaris. *J Turk Acad Dermatol* 2007;1 (3): 71302a
- ¹²⁵ Gupta M, Mahajan VK, Mehta KS, et al. Zinc therapy in dermatology: A review. *Dermatol. Res. Pract.* 2014, 2014, 709152.
- ¹²⁶ Hillström L, Pettersson L, Hellbe L, et al. Comparison of oral treatment with zinc sulphate and placebo in acne vulgaris. *Br J Dermatol.* 1977 Dec;97(6):681-4.

Acne vulgaris

- ¹²⁷ Göransson K, Lidén S, Odsell L. Oral zinc in acne vulgaris: a clinical and methodological study. *Acta Derm Venereol.* 1978;58(5):443-8.
- ¹²⁸ Verma KC, Saini AS, Dhamija SK. Oral zinc sulphate therapy in acne vulgaris: a double-blind trial. *Acta Derm Venereol.* 1980;60(4):337-40.
- ¹²⁹ Orris L, Shalita AR, Sibulkin D, et al. Oral zinc therapy of acne. Absorption and clinical effect. *Arch Dermatol.* 1978 Jul;114(7):1018-20.
- ¹³⁰ Lidén S, Göransson K, Odsell L. Clinical evaluation in acne. *Acta Derm Venereol Suppl (Stockh).* 1980;Suppl 89:47-52.
- ¹³¹ Cunliffe WJ. Unacceptable side-effects of oral zinc sulphate in the treatment of acne vulgaris. *Br J Dermatol.* 1979 Sep;101(3):363.
- ¹³² Dreno B, Amblard P, Agache P, et al. Low doses of zinc gluconate for inflammatory acne. *Acta Derm Venereol.* 1989;69(6):541-3.
- ¹³³ Dreno B, Moyse D, Alirezai M, et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. *Dermatology.* 2001;203(2):135-40.
- ¹³⁴ Salah E. Oral Zinc as a Novel Adjuvant and Sparing Therapy for Systemic Isotretinoin in Acne Vulgaris: A Preliminary Comparative Study. *J Clin Aesthet Dermatol.* 2022 Oct;15(10):58-61. PMID: 36312827; PMCID: PMC9586528.
- ¹³⁵ Christian P, West KP Jr. Interactions between zinc and vitamin A: an update. *Am J Clin Nutr.* 1998 Aug;68(2 Suppl):435S-441S. doi: 10.1093/ajcn/68.2.435S. PMID: 9701158.
- ¹³⁶ Georgala S, Schulpis KH, Georgala C, Michas T. L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. *J Eur Acad Dermatol Venereol.* 1999 Nov;13(3):205-9.
- ¹³⁷ Pirmadah F, Ramezani-Jolfaie N, Mohammadi M, Talenezhad N, Clark CCT, Salehi-Abargouei A. Does L-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials. *Eur J Nutr.* 2020 Aug;59(5):1767-1783.
- ¹³⁸ Guertler A, Fiedler T, Lill D, Kuna AC, Volsky A, Wallmichrath J, Kämmerer T, French LE, Reinholz M. Deficit of Omega-3 Fatty Acids in Acne Patients-A Cross-Sectional Pilot Study in a German Cohort. *Life (Basel).* 2024 Apr 17;14(4):519.
- ¹³⁹ Aslan İ, Özcan F, Karaarslan T, et al. Decreased eicosapentaenoic acid levels in acne vulgaris reveals the presence of a proinflammatory state. *Prostaglandins Other Lipid Mediat.* 2016 Dec 23;128-129:1-7.
- ¹⁴⁰ Desbois AP, Lawlor KC. Antibacterial activity of long-chain polyunsaturated fatty acids against *Propionibacterium acnes* and *Staphylococcus aureus*. *Mar Drugs.* 2013 Nov 13;11(11):4544-57.
- ¹⁴¹ Rubin MG, Kim K, Logan AC. Acne vulgaris, mental health and omega-3 fatty acids: a report of cases. *Lipids Health Dis* 2008, 7:36.
- ¹⁴² Khayef G, Young J, Burns-Whitmore B, et al. Effects of fish oil supplementation on inflammatory acne. *Lipids Health Dis.* 2012 Dec 3;11:165..
- ¹⁴³ Jung JY, Kwon HH, Hong JS, et al. Effect of dietary supplementation with omega-3 fatty acid and gamma-linolenic acid on acne vulgaris: a randomised, double-blind, controlled trial. *Acta Derm Venereol.* 2014 Sep;94(5):521-5.
- ¹⁴⁴ Lee HR, Kim SW, Kim MS, et al. The efficacy and safety of gamma-linolenic acid for the treatment of acne vulgaris. *Int J Dermatol.* 2014 Mar;53(3):e199-200.
- ¹⁴⁵ Mirnezami M, Rahimi H. Is Oral Omega-3 Effective in Reducing Mucocutaneous Side Effects of Isotretinoin in Patients with Acne Vulgaris? *Dermatol Res Pract.* 2018 May 29;2018:6974045.
- ¹⁴⁶ Zainab Z, Malik NA, Obaid S, Malik S, Aftab K, Mumtaz M, Pervez A, Syed Z. Effectiveness Of Oral Omega 3 In Reducing Mucocutaneous Side Effects Of Oral Isotretinoin In Patients With Acne Vulgaris. *J Ayub Med Coll Abbottabad.* 2021 Jan-Mar;33(1):60-63. PMID: 33774956.
- ¹⁴⁷ Park KY, Ko EJ, Kim IS, Li K, Kim BJ, Seo SJ, Kim MN, Hong CK. The effect of evening primrose oil for the prevention of xerotic cheilitis in acne patients being treated with isotretinoin: a pilot study. *Ann Dermatol.* 2014 Dec;26(6):706-12. doi: 10.5021/ad.2014.26.6.706. Epub 2014 Nov 26. PMID: 25473222; PMCID: PMC4252667.
- ¹⁴⁸ Kaźmierska A, Bolesławska I, Polańska A, Dańczak-Pazdrowska A, Jagielski P, Drzymała-Czyż S, Adamski Z, Przysławski J. Effect of Evening Primrose Oil Supplementation on Selected Parameters of Skin Condition in a Group of Patients Treated with Isotretinoin-A Randomized Double-Blind Trial. *Nutrients.* 2022 Jul 21;14(14):2980. doi: 10.3390/nu14142980. PMID: 35889936; PMCID: PMC9317771.
- ¹⁴⁹ Bowe WP, Logan AC. Acne vulgaris, probiotics and the gut-brain-skin axis -back to the future? *Gut Pathog.* 2011 Jan 31;3(1):1.
- ¹⁵⁰ Bowe W, Patel NB, Logan AC. Acne vulgaris, probiotics and the gut-brain-skin axis: from anecdote to translational medicine. *Benef Microbes.* 2014 Jun 1;5(2):185-99.
- ¹⁵¹ Kim J, Ko Y, Park YK, et al. Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris. *Nutrition.* 2010 Sep;26(9):902-9.
- ¹⁵² Jung GW, Tse JE, Guiha I, et al. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. *J Cutan Med Surg.* 2013 Mar-Apr;17(2):114-22.
- ¹⁵³ Fabbrocini G, Bertona M, Picazo Ó, et al. Supplementation with *Lactobacillus rhamnosus* SP1 normalises skin expression of genes implicated in insulin signalling and improves adult acne. *Benef Microbes.* 2016 Nov 30;7(5):625-630.
- ¹⁵⁴ Manzhali E, Hornuss D, Stremmel W. Intestinal-borne dermatoses significantly improved by oral application of *Escherichia coli* Nissle 1917. *World J Gastroenterol.* 2016 Jun 21;22(23):5415-21.

Acne vulgaris

- ¹⁵⁵ Rinaldi F, Marotta L, Mascolo A, Amoroso A, Pane M, Giuliani G, Pinto D. Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement. *Dermatol Ther (Heidelb)*. 2022 Feb;12(2):577-589.
- ¹⁵⁶ Saric S, Notay M, Sivamani RK. Green Tea and Other Tea Polyphenols: Effects on Sebum Production and Acne Vulgaris. *Antioxidants (Basel)*. 2016 Dec 29;6(1).
- ¹⁵⁷ Forest JM, Rafikhah N. Oral aqueous green tea extract and Acne vulgaris: A placebo controlled study. *Asian J. Clin. Nutr.* 2014, 6, 41–46
- ¹⁵⁸ Lu PH, Hsu CH. Does supplementation with green tea extract improve acne in post-adolescent women? A randomized, double-blind, and placebo-controlled clinical trial. *Complement Ther Med*. 2016 Apr;25:159-63.
- ¹⁵⁹ Dostal AM, Samavat H, Bedell S, et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial. *Food Chem Toxicol*. 2015 Sep;83:26-35.
- ¹⁶⁰ Orafidiya LO, et al. Preliminary clinical tests on topical preparations of *Ocimum gratissimum* Linn leaf essential oil for the treatment of Acne vulgaris. *Clin. Drug Investig.* 2002, 22, 313–319.
- ¹⁶¹ da Silva AG, Puziol Pde F, Leitao RN, et al. Application of the essential oil from copaiba(*Copaifera langsdori* Desf.) for acne vulgaris: a double-blind, placebo-controlled clinical trial. *Altern Med Rev*. 2012 Mar;17(1):69-75.
- ¹⁶² Fabbrocini G, Staibano S, De Rosa G, et al. Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study. *Am J Clin Dermatol*. 2011 Apr 1;12(2):133-41.
- ¹⁶³ Capitanio B, Sinagra JL, Weller RB, et al. Randomized controlled study of a cosmetic treatment for mild acne. *Clin Exp Dermatol*. 2012 Jun;37(4):346-9.
- ¹⁶⁴ Hammer KA. Treatment of acne with tea tree oil (*melaleuca*) products: a review of efficacy, tolerability and potential modes of action. *Int J Antimicrob Agents*. 2015 Feb;45(2):106-10.

Atopic Dermatitis

Atopic Dermatitis

Atopic dermatitis is a chronic, inflammatory skin disorder with a high prevalence, affecting 1%-20% of people worldwide including 1-3% of adults and 10%-20% of children.¹ Although more common in childhood, atopic dermatitis can persist into adulthood where it is more frequently refractory to standard treatments.²

The condition is characterized by chronic or chronically relapsing, eczematous, severely pruritic skin manifestations and symptoms are typically accompanied by skin barrier dysfunction, Th2 helper cell polarization, IgE elevation and autoreactivity.³ Regulatory T cell function may also be impaired.⁴ Atopic dermatitis is considered a tissue specific manifestation of a systemic 'atopic syndrome' and frequently overlaps with other atopic and inflammatory diseases.⁵ Symptoms are diverse and clinical manifestations may change with age, season, psychological stress and disease severity.⁶

The pathogenesis of atopic dermatitis is known to involve interactions between environmental factors and genetic susceptibility, particularly gene polymorphisms related to immunological and epidermal barrier function. Current treatments, namely topical emollients, systemic immunosuppressants, allergen-specific immunotherapy and phototherapy, are often not adequate and have significant side effects. A better understanding of environmental factors, individual susceptibility and functional alterations may help individualize patient management and improve outcomes.⁷ Clinical management should consider biological, psychological, behavioral, and dietary factors that affect disease control.⁸

Atopic dermatitis is a tissue specific manifestation of a systemic immunological disorder, the so called 'atopic syndrome,' and as such is characterized by peripheral eosinophilia and elevated IgE.⁹ In support of the atopic syndrome is the association between one atopic disease and increased risk of others, in particular atopic dermatitis, asthma, allergic rhinoconjunctivitis or hay fever, and food allergy.¹⁰ The manifestation of atopic syndrome may change over life course, a phenomena referred to as the 'atopic march,' with atopic dermatitis in infancy typically followed by allergic rhinitis and/or asthma later in life.¹¹

There is a polarization of the immune system towards a T-helper 2 cell (Th2) dominant immune response in atopic dermatitis with Th2 polarization down-regulating Th1 cells and increasing production of IgE and eosinophils.¹² Pollen and food antigens are known to contribute to Th2 polarization.^{13 14}

Dysfunction of IL-10 producing T-regulatory cells, which down-regulate Th2 polarization, may also play a role.¹⁵ Several nutritional factors may down-regulate Th2 polarization and/or improve T-regulatory cell function, including vitamin D,¹⁶ probiotics and prebiotics,¹⁷ and omega-3 fatty acids,¹⁸ which may, at least in part, explain therapeutic effects of these nutrients observed in atopic dermatitis.¹⁹

Elevated systemic and dermal elevations in of oxidative stress are a feature of atopic dermatitis, as are increased oxidative stress during disease exacerbations and decreased endogenous antioxidant capacity.²⁰ For example, in patients with atopic dermatitis aged 10 to 60 years systemic lipid peroxidation assessed with malondialdehyde was increased, while antioxidant parameters including superoxide dismutase, catalase, glutathione peroxidase, glutathione, vitamin A, vitamin E and vitamin C were decreased compared to controls.²¹

Several factors may contribute to elevated oxidative stress including air pollution,²² skin microbes including *Staphylococcus aureus*,²³ circadian rhythm disruption,²⁴ micronutrient deficiencies,²⁵ and

Atopic Dermatitis

nutrient-gene interactions with genetic polymorphisms in glutathione S-transferase.²⁶ The antioxidants have been shown to downregulate Th2 polarization in human T cells in culture, providing a mechanism for antioxidant therapy for atopic dermatitis.²⁷

Dysbiosis and increased intestinal permeability may be a contributing factor in atopic dermatitis. Compared to controls, patients with atopic dermatitis have been shown to have a preponderance of bacteria associated with gut epithelial damage, as well as low levels of butyrate and propionate.²⁸

Gastrointestinal allergic and inflammatory disease has been associated with atopic dermatitis, with a high prevalence found in patients with eosinophilic gastrointestinal disorders,²⁹ and inflammatory bowel diseases.³⁰ Chronic gastrointestinal inflammation may also be an antecedent and feature of established atopic dermatitis.^{31 32} This association may be due to impaired barrier function and a subsequent increase in antigen-specific immune responses.³³ Improving gut barrier integrity would be a rational treatment approach in cases of intestinal permeability or inflammation.³⁴

Exposure to air pollutants, including environmental tobacco smoke, volatile organic compounds, formaldehyde, toluene, nitrogen dioxide, and particulate matter, may increase risk for atopic dermatitis and could contribute to disease severity.³⁵ Exposure to cigarette smoke in particular is an important risk factor, with many studies reporting an association with increased atopic dermatitis prevalence.³⁶ And, of clinical relevance, an observational study found that children with atopic dermatitis who moved to a new daycare center with higher indoor air pollution experienced worsening of their symptoms, and that their symptoms subsequently decreased with later improvement in air quality.³⁷

Psychological stress is well known to play a role in atopic dermatitis risk and symptoms flare ups, and, conversely, the disease may contribute to stigmatization, social withdrawal, anxiety and depression.³⁸ As an integral component of the nervous system the skin is particularly sensitive to psychological stress and immunologically responsive to stressful stimuli.³⁹ A blunted hypothalamus-pituitary-adrenal (HPA) axis reactivity to stress, assessed by cortisol and adrenocorticotropic hormone (ACTH) measurements, as well as an overactive sympathetic nervous system and high concentrations of catecholamine's, have been observed in patients with atopic dermatitis and may contribute to allergic inflammation.⁴⁰

Dietary interventions

- **Trigger foods**

Identification and avoidance of trigger foods in people with atopic dermatitis and suspected food sensitivity can help to reduce symptoms. Immediate-onset (within hours) food reactions tend to be IgE mediated, while delayed-onset reactions (typically within two days) are non-IgE mediated, making elimination and re-challenge of the suspected foods the best way to identify trigger foods.⁴¹ In a double blind placebo-controlled food challenge, 46% of children with atopic dermatitis experienced a food reaction to cow's milk, eggs, wheat or soy, with immediate-onset reactions tending to produce erythema or urticaria, and delayed-onset reactions typically producing a flare up of preexisting lesions.⁴²

- **Personalised elimination diet**

Elimination diets are an important consideration in atopic dermatitis and can result in good clinical improvement, although a lack of benefit in some clinical trials has resulted in debate over their use. The failure of some studies to produce benefits, however, may be due to lack of personalization i.e.

Atopic Dermatitis

non-discriminate elimination of foods without assessment of sensitivity. For example, a Cochrane review of 9 dietary exclusion studies found that the only study in which a clinical improvement was observed was also the only study in which food elimination was based on a suspected food allergy.⁴³

Personalized elimination diets can contribute to amelioration of symptoms. In children with atopic eczema and sensitivity to eggs, confirmed by IgE antibodies, a 4-week elimination diet resulted in significant reduction in dermatitis surface area and symptom severity.⁴⁴ There was also a significant improvement in atopic dermatitis symptoms observed in young children after a 6-week elimination diet based on skin prick testing.⁴⁵ While children who received a yearlong dietary elimination program based on assessment of food allergens by skin prick and patch tests experienced an improvement in the clinical course of their atopic dermatitis, reduction in medication use, less severe allergic rash, and less gastrointestinal disorders.⁴⁶ And an elimination diet based on an IgA and IgG-dependent food sensitivity panel resulted in a mostly good or very good subjective response in children with atopic dermatitis, as well as an improved objective symptom score with elimination of particular foods.⁴⁷

There are reports of patients with atopic dermatitis improving after removal of industrial food additives, with one study examining broad dietary elimination of food additives,⁴⁸ and another specifically eliminating monosodium glutamate.⁴⁹

Elimination of aggravating foods can be complemented with an increase in foods that help reduce symptoms to good effect..⁵⁰

As a precautionary note, prolonged elimination diets in young children could result in increased risk of immediate-onset and severe allergic reactions, including anaphylaxis. Evidence suggests that early introduction and continued exposure to foods is required for the development of immunological tolerance, and there are reports of people on elimination diets for cutaneous symptoms who subsequently developed more severe IgE mediated food reactions.⁵¹ People should be made aware of possible negative consequences of long-term food avoidance and the signs and symptoms of anaphylaxis.

- **Gluten-free diet**

Celiac disease appears to be more prevalent in people with atopic dermatitis and is often clinically silent, that is, with little evidence of malabsorption or gastrointestinal symptoms despite autoantibodies and/ or biopsy-confirmed celiac disease.^{52 53} However, a gluten-free diet did not reduce atopic dermatitis severity in adults with celiac disease following a gluten-free diet for 1-year.⁵⁴ Increased IgE reactivity to food, and inhalant allergen, antigens has been reported in children with celiac disease and may be one reason why gluten restriction alone may not be effective.⁵⁵

Non-celiac gluten sensitivity (NCGS) has not yet been well studied in relationship to atopic dermatitis but may be an important clinical consideration. Elimination diets (discussed above) frequently remove wheat, suggesting potential involvement of NCGS. In a cross-sectional study of self-reported response to elimination diets, patients with atopic dermatitis reported the best clinical improvement with wheat and gluten removal.⁵⁶ A case report described marked symptomatic improvement in a mother and her two daughters, all diagnosed with atopic dermatitis, after gluten removal.⁵⁷ Importantly, while the mother was diagnosed with celiac disease her daughters both tested negative for celiac disease. In contrast, a trial of a gluten-containing vs. gluten free diet in adult patients with atopic dermatitis found no benefit, despite improvement in gastrointestinal symptoms.⁵⁸

- **Modified fasting**

Atopic Dermatitis

Modified fasting with a low-energy, high-nutrient density diet may be useful for atopic dermatitis, particularly in adults. In one study, adults received a low-energy (1085kcal/ day) density diet supplemented with high-nutrient foods such as vegetables juice, kelp, and non-refined salt to ensure high micronutrient intake. After the 6-week dietary treatment there was a significant reduction in atopic dermatitis symptoms, as well as a significant reduction in oxidative DNA damage.⁵⁹ Another study, also in adults, and using the same dietary regime, reported a striking improvement in symptoms and serological immune parameters after 2-months of treatment.⁶⁰ Supervised, short-term (24-hour) modified fasting regimes have also been used with some success.^{61 62} And a small trial (n=4) of a diet with intermittent fasting (a mostly plant based minimally processed diet and 16 hour overnight fast) suggested important clinical benefits for pruritis, overall disease severity, and quality of life.⁶³

Nutrient interventions

- **Probiotics**

Some evidence suggests that that probiotics can reduce intestinal permeability, gut microbial translocation, improve immune alteration and reduce clinical symptoms in both children and adults with atopic dermatitis.^{64 65}

Probiotics may be of benefit in the prevention and treatment of atopic dermatitis, but clinical response can vary depending on patient characteristics such as age and intrinsic microbiota as well as the probiotic strain, or combination of strains, used.^{66 67}

For prevention, evidence from several clinical trials generally suggests that when probiotics are administered to pregnant mothers prenatally for 2-4 weeks and followed by treatment of the infants for the first 6-12 months of life, there is a reduction in atopic dermatitis incidence in both those at higher allergic risk and the general population.⁶⁸

A meta-analysis of clinical studies found that the majority of evidence was for the single strain *Lactobacillus rhamnosus* GG, with some support for another strain of *L rhamnosus* and some strain mixtures.⁶⁹ Probiotics with evidence for preventing atopic dermatitis symptoms include:

- *Lactobacillus rhamnosus* GG ⁷⁰
- *Lactobacillus rhamnosus* HN001 ⁷¹
- *Bifidobacterium bifidum* BGN4, *Bifidobacterium lactis* AD011, and *L acidophilus* AD031 ⁷²
- *L rhamnosus* GG, *L acidophilus* La-5, and *B animalis subsp lactis* Bb-12 ⁷³
- *L acidophilus* DDS-1 and *B lactis* UABLA-12 with fructooligosaccharide ⁷⁴

Importantly, some probiotics failed to show any benefit, emphasizing the importance of using an evidence-based probiotic. Clinical or immunological effects of one probiotic cannot be assumed for another probiotic, even for different strains of the same species.⁷⁵

For treatment, probiotics can help to reduce the extent of lesions and intensity of symptoms. A meta-analysis of 25 clinical studies found that probiotics generally resulted in a significant reduction in symptoms in children and adults.⁷⁶ Analysis of specific species across these studies suggested that *Lactobacillus* and mixtures of different bacterial species showed the greatest benefit, while, conversely, treatment with *Bifidobacterium* species produced negative results. Probiotics with evidence for treating atopic dermatitis symptoms include:

- *Lactobacillus rhamnosus* GG ⁷⁷

Atopic Dermatitis

- *Lactobacillus salivarius* LS01 (DSM 22775) ⁷⁸
- *Lactobacillus paracasei* GMNL-133, *Lactobacillus fermentum* GM090 ⁷⁹
- *Lactobacillus sakei* KCTC 10755BP ⁸⁰
- **Prebiotics**

Prebiotics may be useful as both a preventative approach and treatment in formula-fed infants with a parental history of atopy. Human breast milk provides prebiotic oligosaccharides that help establish the infant microbiome, immune system tolerance, and prevent atopic disease, so blends of prebiotics have been developed to mimic the effects of human milk oligosaccharides on the intestinal microbiota in formula-fed infants. In a clinical study, a prebiotic mixture (90% short-chain galactooligosaccharides and 10% long-chain fructooligosaccharides/ 8 grams per liter), when given to infants for the first 6-months of life, was found to result in significant reductions in the incidence of allergic disease, including atopic dermatitis, recurrent wheezing episodes, and allergic urticaria, as well as infectious episodes, for 18-months after the intervention.⁸¹ Additionally, a small clinical study in infants with atopic dermatitis suggested that prebiotic supplementation (kestose, a short-chain fructooligosaccharides 1-2 g/ day) for 12 weeks significantly reduced symptoms.⁸²

- **Fatty acids**

There have been many studies of different fatty acids, with conflicting clinical results, however, a trial of fatty acid supplementation may be useful in some patients. Several factors may help explain differences in response to fatty acids and could aid in the identification of patients that may benefit from therapy. High steroid usage has been shown to negate the effectiveness of evening primrose oil.⁸³ Differences in the activity of delta-6-desaturase, an enzyme responsible for the conversion of linoleic acid to gamma-linolenic acid, are known to play a role in atopic dermatitis.⁸⁴ Individual variations in gamma-linolenic acid absorption and/or metabolism have been shown to predict treatment response to evening primrose oil.⁸⁵ Some fatty acids may have unique functional properties that influence their therapeutic effects, hemp seed oil is rich in phytonutrients for example.⁸⁶ And background dietary intake of fatty acids, as well as individual differences in metabolism, could explain why some people respond to omega-6 rich oils but not omega-3 rich oils, or vice versa.⁸⁷

Evening primrose oil, black currant seed oil, borage oil, sunflower oil, hemp seed oil and fish oil have all been studied in atopic dermatitis. Evening primrose oil and borage oil failed to show any significant benefit in a review of 27 clinical studies.⁸⁸ However, some individual studies have demonstrated important benefits, such as a small clinical trial in children and adults with atopic dermatitis where evening primrose oil supplementation (2,000–6000mg/ day) for 5-months resulted in a 96% response rate and significant reduction in symptoms compared to placebo.⁸⁹ Similarly, a clinical trial of borage oil (500mg/ day) over 24-weeks found a clinical improvement, but only in those whom an increase in erythrocyte dihomo-gamma-linolenic acid levels was found, indicating either non-compliance or poor absorption or metabolism influenced treatment response.⁹⁰

Hemp seed oil (30ml/ day) for 20-weeks significantly improved skin dryness and itchiness and reduced dermal medication use in adults in one study.⁹¹ And blackcurrant seed oil (3g/day) given to mothers with a history of atopy at 8-16 weeks of pregnancy and continued throughout breastfeeding reduced risk of atopic dermatitis in infants.⁹²

Supplementation with relatively high doses of fish oil (6-10g providing from 1.8g eicosapentaenoic acid up to 5.4g docosahexaenoic acid/day) for 2-4 months has generally resulted an improvement in

Atopic Dermatitis

symptoms in adults with atopic dermatitis.^{93 94 95} Although, one report found that fish oil made symptoms worse.⁹⁶

- **Vitamin D**

Vitamin D status is typically low in people with atopic dermatitis, symptoms may worsen during winter months when vitamin D deficiency is more common, and restoring people to sufficiency can help reduce disease activity. A meta-analysis of four clinical trials, including both children and adults, showed that vitamin D supplementation reduced atopic dermatitis symptoms and clinical signs significantly when compared with placebo.⁹⁷

- **Vitamin E**

Vitamin E supplementation has been shown to be a useful means to reduce the extent and severity of atopic dermatitis, including reducing itching. In one study, vitamin E supplementation (400 IU or 268 mg of natural r,r,r- α -tocopherol in an oil base/ day) for 8-months significantly reduced subjective symptoms, with good responders showing a marked decrease in serum IgE levels.⁹⁸ Subsequent studies using 400-600 IU daily for 2-4 months have also reported good treatment outcomes.^{99 100}

- **Zinc**

Zinc may be useful for atopic dermatitis when there is evidence of deficiency, in contrast zinc is unlikely to help those with adequate zinc status. Children and adolescents with atopic dermatitis and low hair zinc levels who received zinc supplementation (12mg/ day) for 8-weeks significantly improved their zinc status and reduced symptom severity.¹⁰¹ In contrast, a clinical trial investigating the non-discriminant i.e., with no personalization based on zinc status use of zinc found no benefit.¹⁰²

- **Isoleucine**

The branch chain amino acid Isoleucine has shown promise for atopic dermatitis in a pilot trial.¹⁰³ Based on the observation that isoleucine modulates inflammation and that isoleucine restriction for maple syrup disease can trigger a severe dermatological condition with skin dryness and eczematous lesions isoleucine was investigated for atopic dermatitis. In the trial 19 patients ages 5-17 were supplemented with isoleucine at a dose of 10-30 mg/kg daily for 60-days. All patients showed statistically significant clinical improvement in symptoms after supplementation with the most notable reduction in pruritus scores.

- **Oolong tea**

Oolong tea has unique anti-allergic properties, not as evident in green tea, and could be a useful addition to atopic dermatitis treatment.¹⁰⁴ Adults with atopic dermatitis who were instructed to drink 1 litre of oolong tea (made from a 10 g teabag placed in 1000 ml of boiling water and steeped for 5-minutes) between meals daily had a good clinical improvement within 1-2 weeks and maintained for at least 6-months.¹⁰⁵

- **Fig leaf tea**

Fig leaf tea has demonstrated anti-allergic effects, specially reducing IgE interaction with its receptor on eosinophils, mast cells, and basophils.¹⁰⁶ An 8-week clinical trial of fig leaf tea (500 ml daily) in

Atopic Dermatitis

patients with atopic dermatitis (n=30) found that it significantly reduced symptoms scores when compared to placebo, with the effect weakening after 4-weeks of discontinuing use.¹⁰⁷ During the study total IgE increased in the placebo group, but decreased in the fig leaf tea group, although differences between groups were not statistically significant. It is important to note that the fig leaf tea was prepared from a fig cultivar (Grise de Tarascon) that does not contain furanocoumarin because ingestion of fig furanocoumarins has the potential to induce photodermatitis.¹⁰⁸

- **Pancreatic enzyme therapy**

Pancreatic enzyme therapy has been shown to reduce disease activity in patients with atopic dermatitis associated with food reactivity. Food allergies may play a role in atopic dermatitis, especially in patients who are resistant to standard treatments, which suggests food antigens are an important environmental factor in a subgroup of patients.¹⁰⁹ A first line of defense against food antigens is their digestion and subsequent inactivation.¹¹⁰ At the interface between food antigens and the immune system is the gut mucosa, which normally degrades antigens but in atopic individuals is altered in a way that increases dietary antigen transfer and thus provocation of immune activation.¹¹¹ Supporting the involvement of impaired barrier function is the observation that some patients with atopic dermatitis have increased intestinal permeability.¹¹² And notably increased intestinal permeability has been correlated with reduced pancreatic enzyme output.¹¹³

In a clinical study of pancreatic enzyme therapy, a group of patients with severe atopic dermatitis and known food allergies who were not responding to conventional therapies or exclusion diets were administered pancreatic enzymes supplements (37,500 units of proteases with each meal and one-half of a capsule with snacks) for 6-weeks.¹¹⁴ At the end of the study patients who received the enzymes supplements had a significant improvement in atopic disease symptoms severity and a reduction in gut permeability, as measured by lactulose: mannitol ratio.

- **Melatonin**

Circadian rhythm disruption may play a role in atopic dermatitis symptom severity and treatment with melatonin treatment showing some promise. Sleep disturbance is common in atopic dermatitis, is strongly correlated with symptom severity, and associated with lower nocturnal melatonin secretion.¹¹⁵ Several factors may help restore circadian rhythm disruption including sleep hygiene, restoring natural light-dark cycles, and reducing inflammation.¹¹⁶ In children with atopic dermatitis and sleep disturbance melatonin (3 mg daily at bedtime for 4-weeks) improved sleep-onset latency and reduced disease severity.¹¹⁷

- **Topical therapies**

Topical virgin coconut oil can help relieve symptoms of atopic dermatitis, an effect that may be in part due to anti-inflammatory and analgesic properties of virgin coconut oil.¹¹⁸ Virgin coconut oil has also been shown to inhibit *S. aureus* from adults with atopic dermatitis in vitro.¹¹⁹ Compared to mineral oil, topical application of virgin coconut oil (5ml to affected areas/ twice daily) for 8-weeks oil was significantly better for reducing clinical symptoms and improving the health of the skin barrier, with benefits observed by the first assessment at 2-weeks and increasing with continued use.¹²⁰

Black cumin (*nigella sativa*) oil may also be useful. In one study 2% black cumin ointment was as effective as betamethasone for hand eczema.¹²¹ Black cumin is known to have potent anti-inflammatory, analgesic and anti-allergic effects, which could help explain its benefit in atopic dermatitis.¹²²

Atopic Dermatitis

Summary and Clinical Reference

Intervention	Discussion	Guidance
Trigger foods	Foods that trigger symptoms are relatively common but often overlooked, and avoidance may help control symptoms.	Trigger foods can be identified based on patient history; however, people may not have previously associated foods with a flare up in their symptoms. Routine elimination and re-challenge with cow's milk, egg, wheat or soy may be useful. Re-challenge in a medical setting may be advise if there is risk of anaphylaxis.
Personalized elimination diet	Elimination diets can help reduce symptoms by limiting exposure to allergenic foods that are exacerbating atopy.	An elimination diet can be based on food sensitivity testing, including IgG. Without testing, an elimination and re-challenge with major and/ or suspected food allergens may still be useful. Reducing exposure to food additives and MSG may be useful.
Functional foods	Advice to increase intake of foods with anti-allergic, anti-inflammatory effects such as antioxidant and omega-3 fatty acids rich-foods has been shown to complement an elimination diet.	Advise patient to increase intake of polyphenol-rich fruits and vegetable foods and beverages, additionally increase intake of omega-3 rich foods such as nuts, seeds, and fish.
Gluten free diet	Celiac disease and NCGS may be associated with atopic dermatitis, and a gluten-free diet may be supportive.	Screen for celiac disease due to higher prevalence in atopic dermatitis. Consider NCGS and a gluten-free diet.
Modified fasting	Modified fasting with a low-energy, high-nutrient density diet may reduce food anti-gen exposure, result in weight loss, and/or have direct anti-allergic effects.	Various approaches could be used to construct a modified fasting regime, including a daily low-energy/ high-nutrient density diet, a supervised 24-hour fast, or a daily 16-hour overnight fast.
Probiotics	Some probiotics have anti-allergic effects and may help in the development of oral tolerance early in life.	Probiotics are useful as both a preventative and treatment. Use of a probiotic with clinical evidence demonstrating efficacy in atopic dermatitis is important.
Prebiotics	Prebiotics support the development and restoration of the gut microbiota and, consequently, may help reduce atopy.	Prebiotics have mainly been used in formula-fed infants. If breast feeding is not possible a prebiotic should be considered.

Atopic Dermatitis

Fatty acids	Metabolic impairments in fatty acid metabolism, as well as dietary intakes, could affect immunological function and exacerbate atopy	Assessment of dietary intake as well as laboratory values may help direct choice of fatty acids. A trial with either omega-3 rich oils, or omega-6 rich oils alone is recommended to determine treatment response.
Vitamin D	Vitamin D deficiency has been associated with increased risk of atopic disease due to its immunological consequences.	Assessment of vitamin D status and subsequent supplementation in the case of deficiency. Alternatively, a routine course of vitamin D would be appropriate if deficiency is suspected.
Vitamin E	Vitamin appears to improve skin appearance and reduce IgE, presumably through anti-oxidant, anti-allergic effects as well as improvement of skin barrier health.	A 2-3-month course of natural vitamin E at a dose of 400 IU daily could be considered.
Zinc	Deficiency in zinc has been associated with atopic dermatitis, however, non-discriminate supplementation was not effective.	Zinc status can be assessed with laboratory values or dietary intake. In suspected or confirmed deficiency supplementation with 10-20 mg of zinc per day is warranted.
Isoleucine	Isoleucine could modify inflammation and reduce symptoms, particularly pruritis, but research is limited to a pilot study.	Consider a trial of 10-30 mg/kg daily for >60-days.
Pancreatic enzymes	Proteolytic enzymes may reduce food antigen reactivity via digestion and consequently ameliorate symptoms.	In treatment resistant patients with food reactivity, trial 37,500 units of proteases with each meal and one-half of a capsule with snacks for >6-weeks
Melatonin	Circadian rhythm disruption may play a role in atopic dermatitis symptom severity.	In patients with sleep disturbance, trial melatonin 3 mg daily at bedtime for >4-weeks.
Oolong tea	Unique anti-allergic properties of oolong tea make it a useful addition to nutritional therapy.	Consider 1 litre of oolong tea (made from a 10 g teabag placed in 1000ml of boiling water and steeped for 5-minutes) between meals each day.
Fig leaf tea	Fig leaf tea may modify IgE activity and alleviate symptoms.	Consider 500 ml of fig leaf tea daily. Care should be taken to use a specific fig cultivar (Grise de Tarascon) to avoid risk of photodermatitis.
Topical therapies	Topical virgin coconut oil has anti-inflammatory,	It is important to use virgin coconut oil, as processing removes bioactive unique to

Atopic Dermatitis

	analgesic and anti-bacterial effects, in addition to improving skin health.	virgin oil. Apply to affected areas twice daily. Black seed oil and/or ointment may also be effective.
--	---	--

- ¹ Lee JH, Son SW, Cho SH. A Comprehensive Review of the Treatment of Atopic Eczema. *Allergy Asthma Immunol Res.* 2016 May;8(3):181-90.
- ² Megna M, Napolitano M, Patruno C, et al. Systemic Treatment of Adult Atopic Dermatitis: A Review. *Dermatol Ther (Heidelb).* 2016 Dec 26. doi: 10.1007/s13555-016-0170-1. [Epub ahead of print]
- ³ Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. *Allergol Int.* 2017 Jan 2. pii: S1323-8930(16)30171-X.
- ⁴ Bieber T. Atopic dermatitis. *Ann Dermatol.* 2010 May;22(2):125-37.
- ⁵ Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. *J Allergy Clin Immunol.* 2016 Aug;138(2):336-49.
- ⁶ Chu H, Shin JU, Park CO, et al. Clinical Diversity of Atopic Dermatitis: A Review of 5,000 Patients at a Single Institute. *Allergy Asthma Immunol Res.* 2017 Mar;9(2):158-168.
- ⁷ Kim JE, Kim JS, Cho DH, Park HJ. Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis. *Int J Mol Sci.* 2016 Jul 30;17(8).
- ⁸ LeBovidge JS, Elverson W, Timmons KG, et al. Multidisciplinary interventions in the management of atopic dermatitis. *J Allergy Clin Immunol.* 2016 Aug;138(2):325-34.
- ⁹ Darlenski R, Kazandjieva J, Hristakieva E, Fluhr JW. Atopic dermatitis as a systemic disease. *Clin Dermatol.* 2014 May-Jun;32(3):409-13.
- ¹⁰ Thomsen SF. Epidemiology and natural history of atopic diseases. *Eur Clin Respir J.* 2015 Mar 24;2.
- ¹¹ Spergel JM. From atopic dermatitis to asthma: the atopic march. *Ann Allergy Asthma Immunol.* 2010;105:99–106.
- ¹² Bieber T. Atopic dermatitis. *N Engl J Med* 2008;358(14):1483–94
- ¹³ Eyerich K, Huss-Marp J, Darsow U, et al. Pollen grains induce a rapid and biphasic eczematous immune response in atopic eczema patients. *Int Arch Allergy Immunol.* 2008;145(3):213-23.
- ¹⁴ Sicherer SH, Sampson HA. Food allergy. *J Allergy Clin Immunol.* 2010 Feb;125(2 Suppl 2):S116-25.
- ¹⁵ Auriemma M, Vianale G, Amerio P, Reale M. Cytokines and T cells in atopic dermatitis. *Eur Cytokine Netw.* 2013 Mar;24(1):37-44.
- ¹⁶ Lucas RM, Gorman S, Geldenhuys S, et al. Vitamin D and immunity. *F1000Prime Rep.* 2014 Dec 1;6:118.
- ¹⁷ van der Meulen TA, Harmsen H, Bootsma H, et al. The microbiome-systemic diseases connection. *Oral Dis.* 2016 Nov;22(8):719-734.
- ¹⁸ Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochim Biophys Acta.* 2015 Apr;1851(4):469-84.
- ¹⁹ Roesner LM, Werfel T, Heratizadeh A. The adaptive immune system in atopic dermatitis and implications on therapy. *Expert Rev Clin Immunol.* 2016 Jul;12(7):787-96.
- ²⁰ Ji H, Li XK. Oxidative Stress in Atopic Dermatitis. *Oxid Med Cell Longev.* 2016;2016:2721469.
- ²¹ Sivaranjani N, Rao SV, Rajeev G. Role of reactive oxygen species and antioxidants in atopic dermatitis. *J Clin Diagn Res.* 2013 Dec;7(12):2683-5.
- ²² Song S, Paek D, Park C, Lee C, Lee JH, Yu SD. Exposure to ambient ultrafine particles and urinary 8-hydroxyl-2-deoxyguanosine in children with and without eczema. *Sci Total Environ.* 2013 Aug 1;458-460:408-13.
- ²³ Okayama Y. Oxidative stress in allergic and inflammatory skin diseases. *Curr Drug Targets Inflamm Allergy.* 2005 Aug;4(4):517-9.
- ²⁴ Chang YS, Chiang BL. Mechanism of Sleep Disturbance in Children with Atopic Dermatitis and the Role of the Circadian Rhythm and Melatonin. *Int J Mol Sci.* 2016 Mar 29;17(4):462.
- ²⁵ Toyran M, Kaymak M, Vezir E, et al. Trace element levels in children with atopic dermatitis. *J Investig Allergol Clin Immunol.* 2012;22(5):341-4.
- ²⁶ Chung J, Kwon SO, Ahn H, et al. Association between Dietary Patterns and Atopic Dermatitis in Relation to GSTM1 and GSTT1 Polymorphisms in Young Children. *Nutrients.* 2015 Nov 13;7(11):9440-52.
- ²⁷ Bengtsson A, Lundberg M, Avila-Cariño J, et al. Thiols decrease cytokine levels and down-regulate the expression of CD30 on human allergen-specific T helper (Th) 0 and Th2 cells. *Clin Exp Immunol.* 2001 Mar;123(3):350-60.
- ²⁸ Song H, Yoo Y, Hwang J, et al. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. *J Allergy Clin Immunol.* 2016 Mar;137(3):852-60
- ²⁹ Jyonouchi S, Brown-Whitehorn TA, Spergel JM. Association of eosinophilic gastrointestinal disorders with other atopic disorders. *Immunol Allergy Clin North Am.* 2009 Feb;29(1):85-97
- ³⁰ Kim M, Choi KH, Hwang SW, Lee YB, Park HJ, Bae JM. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. *J Am Acad Dermatol.* 2017 Jan;76(1):40-48.

Atopic Dermatitis

- ³¹ Orivuori L, Mustonen K, de Goffau MC, et al. High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6. *Clin Exp Allergy*. 2015 May;45(5):928-39.
- ³² Arisawa T, Arisawa S, Yokoi T, Kuroda M, Hirata I, Nakano H. Endoscopic and histological features of the large intestine in patients with atopic dermatitis. *J Clin Biochem Nutr*. 2007 Jan;40(1):24-30.
- ³³ Niwa Y, Sumi H, Akamatsu H. An association between ulcerative colitis and atopic dermatitis, diseases of impaired superficial barriers. *J Invest Dermatol*. 2004;123:999-1000
- ³⁴ Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A, Wells JM. Intestinal permeability--a new target for disease prevention and therapy. *BMC Gastroenterol*. 2014 Nov 18;14:189.
- ³⁵ Ahn K. The role of air pollutants in atopic dermatitis. *J Allergy Clin Immunol*. 2014 Nov;134(5):993-9; discussion 1000.
- ³⁶ Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: A systematic review and meta-analysis. *J Am Acad Dermatol*. 2016 Dec;75(6):1119-1125.
- ³⁷ Kim EH, Kim S, Lee JH, Kim J, Han Y, Kim YM, Kim GB, Jung K, Cheong HK, Ahn K. Indoor air pollution aggravates symptoms of atopic dermatitis in children. *PLoS One*. 2015 Mar 17;10(3):e0119501.
- ³⁸ Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis. *Br J Dermatol*. 2014 Jul;170 Suppl 1:38-43.
- ³⁹ Alexopoulos A, Chrousos GP. Stress-related skin disorders. *Rev Endocr Metab Disord*. 2016 Sep;17(3):295-304.
- ⁴⁰ Buske-Kirschbaum A, Geiben A, Höllig H, et al. Altered responsiveness of the hypothalamus-pituitary-adrenal axis and the sympathetic adrenomedullary system to stress in patients with atopic dermatitis. *J Clin Endocrinol Metab*. 2002 Sep;87(9):4245-51.
- ⁴¹ Katta R, Schlichte M. Diet and dermatitis: food triggers. *J Clin Aesthet Dermatol*. 2014 Mar;7(3):30-6.
- ⁴² Breuer K, Heratizadeh A, Wulf A, Baumann U, Constien A, Tetau D, Kapp A, Werfel T. Late eczematous reactions to food in children with atopic dermatitis. *Clin Exp Allergy*. 2004 May;34(5):817-24.
- ⁴³ Bath-Hextall F, Delamere FM, Williams HC. Dietary exclusions for established atopic eczema. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD005203.
- ⁴⁴ Lever R, MacDonald C, Waugh P, Aitchison T. Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. *Pediatr Allergy Immunol*. 1998 Feb;9(1):13-9.
- ⁴⁵ Norrman G, Tomićić S, Böttcher MF, Oldaeus G, Strömberg L, Fälth-magnusson K. Significant improvement of eczema with skin care and food elimination in small children. *Acta Paediatr*. 2005 Oct;94(10):1384-8.
- ⁴⁶ Rokaite R, Labanauskas L, Balciūnaite S, Vaideliene L. Significance of dietotherapy on the clinical course of atopic dermatitis. *Medicina (Kaunas)*. 2009;45(2):95-103.
- ⁴⁷ Hon KL, Poon TC, Pong NH, Wong YH, Leung SS, Chow CM, Leung TF. Specific IgG and IgA of common foods in Chinese children with eczema: friend or foe. *J Dermatolog Treat*. 2014 Dec;25(6):462-6.
- ⁴⁸ Worm M, Ehlers I, Sterry W, et al. Clinical relevance of food additives in adult patients with atopic dermatitis. *Clin Exp Allergy*. 2000 Mar;30(3):407-14
- ⁴⁹ Lee JM, Jin HJ, Noh G, Lee SS. Effect of processed foods on serum levels of eosinophil cationic protein among children with atopic dermatitis. *Nutr Res Pract*. 2011 Jun;5(3):224-9.
- ⁵⁰ Kim SH, Lee JH, Ly SY. Children with atopic dermatitis in Daejeon, Korea: individualized nutrition intervention for disease severity and nutritional status. *Asia Pac J Clin Nutr*. 2016 Dec;25(4):716-728.
- ⁵¹ Young MC. Elimination Diets in Eczema--A Cautionary Tale. *J Allergy Clin Immunol Pract*. 2016 Mar-Apr;4(2):237-8.
- ⁵² Zauli D, Grassi A, Granito A, et al. Prevalence of silent coeliac disease in atopics. *Dig Liver Dis*. 2000 Dec;32(9):775-9.
- ⁵³ Röss K, Annus T, Putnik U, et al. Celiac disease in children with atopic dermatitis. *Pediatr Dermatol*. 2014 Jul-Aug;31(4):483-8.
- ⁵⁴ Ciacci C, Cavallaro R, Iovino P, et al. Allergy prevalence in adult celiac disease. *J Allergy Clin Immunol*. 2004 Jun;113(6):1199-203.
- ⁵⁵ Knyziak-Mędrzycka I, Cukrowska B, Nazar W, Bierała JB, Janeczek K, Krawiec P, Gromek W, Wysokiński M, Konopka E, Trojanowska I, Smolińska S, Majsia E. Sensitization to Food and Aero-Allergens in Children with Coeliac Disease Assessed with the Use of a Multiplex Molecular Diagnostic Technique. *J Clin Med*. 2024 May 19;13(10):2992. doi: 10.3390/jcm13102992. PMID: 38792533; PMCID: PMC11122608.
- ⁵⁶ Nosrati A, Afifi L, Danesh MJ, Lee K, Yan D, Beroukhim K, Ahn R, Liao W. Dietary modifications in atopic dermatitis: patient-reported outcomes. *J Dermatolog Treat*. 2017 Sep;28(6):523-538. doi: 10.1080/09546634.2016.1278071. Epub 2017 Jan 24. PMID: 28043181; PMCID: PMC5736303.
- ⁵⁷ Sur, M. , Aldea, A. , Dascal, L. , Duca, E. , Silaghi, C. , Sur, L. , & Aldea, C. (2019). The Link between the Clinical Features of Atopic Dermatitis and Gluten-related Disorders. *International Journal of Celiac Disease*, 7(1), 31-32.
- ⁵⁸ San Mauro Martín I, López Oliva S, Garicano Vilar E, Sánchez Niño GM, Penadés BF, Terrén Lora A, Sanz Rojo S, Collado Yurrita L. Effects of Gluten on Gut Microbiota in Patients with Gastrointestinal Disorders, Migraine, and Dermatitis. *Nutrients*. 2024 Apr 20;16(8):1228. doi: 10.3390/nu16081228. PMID: 38674918; PMCID: PMC11053402.
- ⁵⁹ Kouda K, Tanaka T, Kouda M, Takeuchi H, Takeuchi A, Nakamura H, Takigawa M. Low-energy diet in atopic dermatitis patients: clinical findings and DNA damage. *J Physiol Anthropol Appl Human Sci*. 2000 Sep;19(5):225-8.
- ⁶⁰ Tanaka T, Kouda K, Kotani M, Takeuchi A, Tabei T, Masamoto Y, Nakamura H, Takigawa M, Suemura M, Takeuchi H, Kouda M. Vegetarian diet ameliorates symptoms of atopic dermatitis through reduction of the number of peripheral eosinophils and of PGE2 synthesis by monocytes. *J Physiol Anthropol Appl Human Sci*. 2001 Nov;20(6):353-61.

Atopic Dermatitis

- ⁶¹ Nakamura H, Shimoji K, Kouda K, Tokunaga R, Takeuchi H. An adult with atopic dermatitis and repeated short-term fasting. *J Physiol Anthropol Appl Human Sci.* 2003 Sep;22(5):237-40.
- ⁶² Kim KS, Nam HJ. Detoxification combining fasting with fluid therapy for refractory cases of severe atopic dermatitis. *Evid Based Complement Alternat Med.* 2013;2013:561290.
- ⁶³ Rotter G, Teut M, Schleicher R, Dell'Oro M, Ortiz M, Binting S, Tissen-Diabaté T, Roll S, Michalsen A, Staab D, Wolfarth B, Brinkhaus B. Hypnotherapy, Intermittent Fasting, and Exercise Group Programs in Atopic Dermatitis: A Randomized Controlled Explorative Clinical Trial During the COVID-19 Pandemic. *J Integr Complement Med.* 2023 Feb;29(2):99-110.
- ⁶⁴ Rosenfeldt V, Benfeldt E, Valerius NH, Paerregaard A, Michaelsen KF. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. *J Pediatr.* 2004 Nov;145(5):612-6.
- ⁶⁵ Iemoli E, Trabattini D, Parisotto S, et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. *J Clin Gastroenterol.* 2012 Oct;46 Suppl:S33-40.
- ⁶⁶ Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. *Am J Clin Dermatol.* 2008;9(2):93-103.
- ⁶⁷ Avershina E, Cabrera Rubio R, Lundgård K, Perez Martinez G, Collado MC, Storrø O, Øien T, Dotterud CK, Johnsen R, Rudi K. Effect of probiotics in prevention of atopic dermatitis is dependent on the intrinsic microbiota at early infancy. *J Allergy Clin Immunol.* 2016 Dec 5. pii: S0091-6749(16)31443-9.
- ⁶⁸ Panduru M, Panduru NM, Sălăvăstru CM, Tiplica GS. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. *J Eur Acad Dermatol Venereol.* 2015 Feb;29(2):232-42.
- ⁶⁹ Foolad N, Brezinski EA, Chase EP, Armstrong AW. Effect of nutrient supplementation on atopic dermatitis in children: a systematic review of probiotics, prebiotics, formula, and fatty acids. *JAMA Dermatol.* 2013 Mar;149(3):350-5.
- ⁷⁰ Kalliomäki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. *J Allergy Clin Immunol.* 2007 Apr;119(4):1019-21
- ⁷¹ Wickens K, Black P, Stanley TV, Mitchell E, Barthow C, Fitzharris P, Purdie G, Crane J. A protective effect of *Lactobacillus rhamnosus* HN001 against eczema in the first 2 years of life persists to age 4 years. *Clin Exp Allergy.* 2012 Jul;42(7):1071-9.
- ⁷² Kim JY, Kwon JH, Ahn SH, et al. Effect of probiotic mix (*Bifidobacterium bifidum*, *Bifidobacterium lactis*, *Lactobacillus acidophilus*) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. *Pediatr Allergy Immunol.* 2010 Mar;21(2 Pt 2):e386-93.
- ⁷³ Dotterud CK, Storrø O, Johnsen R, Oien T. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. *Br J Dermatol.* 2010 Sep;163(3):616-23.
- ⁷⁴ Gerasimov SV, Vasjuta VV, Myhovich OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. *Am J Clin Dermatol.* 2010;11(5):351-61.
- ⁷⁵ Fuchs-Tarlovsky V, Marquez-Barba MF, Sriram K. Probiotics in dermatologic practice. *Nutrition.* 2016 Mar;32(3):289-95.
- ⁷⁶ Kim SO, Ah YM, Yu YM, Choi KH, Shin WG, Lee JY. Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials. *Ann Allergy Asthma Immunol.* 2014 Aug;113(2):217-26.
- ⁷⁷ Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. *Am J Clin Dermatol.* 2008;9(2):93-103.
- ⁷⁸ Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S. Effects of *Lactobacillus salivarius* LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. *Int J Immunopathol Pharmacol.* 2011 Oct-Dec;24(4):1037-48.
- ⁷⁹ Wang JJ, Wang JY. Children with atopic dermatitis show clinical improvement after *Lactobacillus* exposure. *Clin Exp Allergy.* 2015 Apr;45(4):779-87.
- ⁸⁰ Woo SI, Kim JY, Lee YJ, Kim NS, Hahn YS. Effect of *Lactobacillus sakei* supplementation in children with atopic eczema-dermatitis syndrome. *Ann Allergy Asthma Immunol.* 2010 Apr;104(4):343-8.
- ⁸¹ Arslanoglu S, Moro GE, Schmitt J, et al. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. *J Nutr.* 2008;138(6):1091-1095.
- ⁸² Shibata R, Kimura M, Takahashi H, Mikami K, Aiba Y, Takeda H, Koga Y. Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants. *Clin Exp Allergy.* 2009 Sep;39(9):1397-403.
- ⁸³ Morse NL, Clough PM. A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries? *Curr Pharm Biotechnol.* 2006 Dec;7(6):503-24.
- ⁸⁴ Horrobin DF. Essential fatty acid metabolism and its modification in atopic eczema. *Am J Clin Nutr.* 2000 Jan;71(1 Suppl):367S-72S.
- ⁸⁵ Simon D, Eng PA, Borelli S, Kägi R, Zimmermann C, Zahner C, Drewe J, Hess L, Ferrari G, Lautenschlager S, Wüthrich B, Schmid-Grendelmeier P. Gamma-linolenic acid levels correlate with clinical efficacy of evening primrose oil in patients with atopic dermatitis. *Adv Ther.* 2014 Feb;31(2):180-8.
- ⁸⁶ Montserrat-de la Paz S, Marín-Aguilar F, García-Giménez MD, Fernández-Arche MA. Hemp (*Cannabis sativa* L.) seed oil: analytical and phytochemical characterization of the unsaponifiable fraction. *J Agric Food Chem.* 2014 Feb 5;62(5):1105-10.
- ⁸⁷ Gaby, AR. Eczema. *Nutritional Medicine.* 2011.

Atopic Dermatitis

- ⁸⁸ Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. *Cochrane Database Syst Rev*. 2013 Apr 30;(4):CD004416.
- ⁸⁹ Senapati S, Banerjee S, Gangopadhyay DN. Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial. *Indian J Dermatol Venereol Leprol*. 2008 Sep-Oct;74(5):447-52.
- ⁹⁰ Henz BM, Jablonska S, van de Kerkhof PC, et al. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. *Br J Dermatol*. 1999 Apr;140(4):685-8.
- ⁹¹ Callaway J, Schwab U, Harvima I, Halonen P, Mykkänen O, Hyvönen P, Järvinen T. Efficacy of dietary hempseed oil in patients with atopic dermatitis. *J Dermatolog Treat*. 2005 Apr;16(2):87-94.
- ⁹² Linnamaa P, Savolainen J, Koulu L, et al. Blackcurrant seed oil for prevention of atopic dermatitis in newborns: a randomized, double-blind, placebo-controlled trial. *Clin Exp Allergy*. 2010;40(8):1247-1255.
- ⁹³ Bjørneboe A, Søyland E, Bjørneboe GE, Rajka G, Drevon CA. Effect of dietary supplementation with eicosapentaenoic acid in the treatment of atopic dermatitis. *Br J Dermatol*. 1987 Oct;117(4):463-9.
- ⁹⁴ Søyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L, Helland S, Middelfart K, Odu S, Falk ES, et al. Dietary supplementation with very long-chain n-3 fatty acids in patients with atopic dermatitis. A double-blind, multicenter study. *Br J Dermatol*. 1994 Jun;130(6):757-64.
- ⁹⁵ Koch C, Dölle S, Metzger M, Rasche C, Jungclas H, Rühl R, Renz H, Worm M. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. *Br J Dermatol*. 2008 Apr;158(4):786-92.
- ⁹⁶ Gimenez-Arnau A, Barranco C, Alberola M, et al. Effects of linoleic acid supplements on atopic dermatitis. *Adv Exp Med Biol* 1997;433:285–289.
- ⁹⁷ Kim MJ, Kim SN, Lee YW, Choe YB, Ahn KJ. Vitamin D Status and Efficacy of Vitamin D Supplementation in Atopic Dermatitis: A Systematic Review and Meta-Analysis. *Nutrients*. 2016 Dec 3;8(12).
- ⁹⁸ Tsourelis-Nikita E, Hercogova J, Lotti T, Menchini G. Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels. *Int J Dermatol*. 2002 Mar;41(3):146-50.
- ⁹⁹ Javanbakht MH, Keshavarz SA, Djalali M, Siassi F, Eshraghian MR, Firooz A, Seirafi H, Ehsani AH, Chamari M, Mirshafiey A. Randomized controlled trial using vitamins E and D supplementation in atopic dermatitis. *J Dermatolog Treat*. 2011 Jun;22(3):144-50.
- ¹⁰⁰ Jaffary F, Faghihi G, Mokhtarian A, Hosseini SM. Effects of oral vitamin E on treatment of atopic dermatitis: A randomized controlled trial. *J Res Med Sci*. 2015 Nov;20(11):1053-7.
- ¹⁰¹ Kim JE, Yoo SR, Jeong MG, et al. Hair zinc levels and the efficacy of oral zinc supplementation in patients with atopic dermatitis. *Acta Derm Venereol*. 2014 Sep;94(5):558-62.
- ¹⁰² Ewing CI, Gibbs AC, Ashcroft C, David TJ. Failure of oral zinc supplementation in atopic eczema. *Eur J Clin Nutr*. 1991 Oct;45(10):507-10.
- ¹⁰³ Aranda CS, Pereira KCHM, Velasco HF, Mallozi MC, Andrade RS, Rodrigues WDR, Pesquero JB, Martins AM, Solé D. Isoleucine and atopic dermatitis. *Pediatr Allergy Immunol*. 2017 Aug;28(5):495-497. doi: 10.1111/pai.12731. Epub 2017 Jun 20. PMID: 28474841.
- ¹⁰⁴ Sano M, Suzuki M, Miyase T, Yoshino K, Maeda-Yamamoto M. Novel antiallergic catechin derivatives isolated from oolong tea. *J Agric Food Chem*. 1999 May;47(5):1906-10.
- ¹⁰⁵ Uehara M, Sugiura H, Sakurai K. A trial of oolong tea in the management of recalcitrant atopic dermatitis. *Arch Dermatol* 2001;137:42–43
- ¹⁰⁶ Abe T. Fig (*Ficus carica* L.) leaf tea suppresses allergy by acceleration disassembly of IgE-receptor complexes. *Biosci Biotechnol Biochem*. 2020 May;84(5):1013-1022. doi: 10.1080/09168451.2020.1722608. Epub 2020 Jan 27. PMID: 31987005.
- ¹⁰⁷ Abe T, Koyama Y, Nishimura K, Okiura A, Takahashi T. Efficacy and Safety of Fig (*Ficus carica* L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial. *Nutrients*. 2022; 14(21):4470. <https://doi.org/10.3390/nu14214470>
- ¹⁰⁸ Takahashi T, Okiura A, Kohno M. Phenylpropanoid composition in fig (*Ficus carica* L.) leaves. *J Nat Med*. 2017 Oct;71(4):770-775. doi: 10.1007/s11418-017-1093-6. Epub 2017 Jun 6. PMID: 28589249.
- ¹⁰⁹ Singer S, Koenekoop J, Meddings J, Powell J, Desroches A, Seidman EG. Pancreatic Enzyme Supplementation in Patients with Atopic Dermatitis and Food Allergies: An Open-Label Pilot Study. *Paediatr Drugs*. 2019 Feb;21(1):41-45. doi: 10.1007/s40272-018-0321-1. PMID: 30556101.
- ¹¹⁰ Nguyen TA, Leonard SA, Eichenfield LF. An Update on Pediatric Atopic Dermatitis and Food Allergies. *J Pediatr*. 2015 Sep;167(3):752-6.
- ¹¹¹ Moreno FJ. Gastrointestinal digestion of food allergens: effect on their allergenicity. *Biomed Pharmacother*. 2007 Jan;61(1):50-60.
- ¹¹² Majamaa H, Isolauri E. Evaluation of the gut mucosal barrier: evidence for increased antigen transfer in children with atopic eczema. *J Allergy Clin Immunol*. 1996 Apr;97(4):985-90.
- ¹¹³ Rosenfeldt V, Benfeldt E, Valerius NH, Paerregaard A, Michaelsen KF. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. *J Pediatr*. 2004 Nov;145(5):612-6
- ¹¹⁴ Singer S, Koenekoop J, Meddings J, Powell J, Desroches A, Seidman EG. Pancreatic Enzyme Supplementation in Patients with Atopic Dermatitis and Food Allergies: An Open-Label Pilot Study. *Paediatr Drugs*. 2019 Feb;21(1):41-45. doi: 10.1007/s40272-018-0321-1. PMID: 30556101.

Atopic Dermatitis

- ¹¹⁵ Chang YS, Chou YT, Lee JH, et al. Atopic dermatitis, melatonin, and sleep disturbance. *Pediatrics*. 2014 Aug;134(2):e397-405.
- ¹¹⁶ Chang YS, Chiang BL. Mechanism of Sleep Disturbance in Children with Atopic Dermatitis and the Role of the Circadian Rhythm and Melatonin. *Int J Mol Sci*. 2016 Mar 29;17(4):462.
- ¹¹⁷ Chang YS, Lin MH, Lee JH, et al. Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial. *JAMA Pediatr*. 2016 Jan;170(1):35-42.
- ¹¹⁸ Intahphuak S, Khonsung P, Panthong A. Anti-inflammatory, analgesic, and antipyretic activities of virgin coconut oil. *Pharm Biol*. 2010 Feb;48(2):151-7.
- ¹¹⁹ Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. *Dermatitis*. 2008 Nov-Dec;19(6):308-15.
- ¹²⁰ Evangelista MT, Abad-Casintahan F, Lopez-Villafuerte L. The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind, clinical trial. *Int J Dermatol*. 2014 Jan;53(1):100-8.
- ¹²¹ Yousefi M, Barikbin B, Kamalinejad M, et al. Comparison of therapeutic effect of topical Nigella with Betamethasone and Eucerin in hand eczema. *J Eur Acad Dermatol Venereol*. 2013 Dec;27(12):1498-504.
- ¹²² Amin B, Hosseinzadeh H. Black Cumin (*Nigella sativa*) and Its Active Constituent, Thymoquinone: An Overview on the Analgesic and Anti-inflammatory Effects. *Planta Med*. 2016 Jan;82(1-2):8-16.

Psoriasis

Psoriasis

Psoriasis, a chronic inflammatory multi organ disorder with clinical manifestation in the skin and often the joints, is very common with an estimated prevalence of approximately 2%–5% of the population.¹ It is typically characterized by raised, well-demarcated, erythematous oval plaques with adherent silvery scales and is associated with significant comorbidity including depressive illness, cardiovascular disease, psoriatic arthritis, and decreased quality of life.²

Although classically considered an autoimmune disorder, psoriasis can move across a spectrum of autoinflammation to autoimmunity. In contrast to autoimmunity, autoinflammation is characterized by systemic inflammation in the absence of high-titer autoantibodies or autoreactive T lymphocytes.³ This spectrum may help explain the progression of psoriasis from an IL-1–TNF-mediated, neutrophil-dominated inflammation (innate autoinflammatory response) that initiates a Th17/Th22-dominated early T-cell infiltrate that turns into a Th1-dominated psoriasis plaque (adaptive autoimmune response).⁴

Chronic inflammation can contribute to the development of psoriasis as well as comorbidities and metabolic disease risk and is thus an important therapeutic consideration. Psoriasis shares immunological pathways with other chronic inflammatory disease, including arthritis, obesity and other autoimmune diseases.⁵ However, there are also distinct differences in the immunopathology, suggesting unique management strategies are needed.⁶ Dysregulation of both innate and adaptive immune systems are involved in psoriasis, and is uncertain if psoriasis is primarily an autoimmune disease or an inflammatory disorder that evolves into an autoimmune disease.⁷

Polarization of Th1 and low Th2 cells is thought to be central to psoriasis, however it appears both Th1 and Th2 are involved in psoriasis pathogenesis.⁸ Other important mediators of inflammation in psoriasis are IL-23,⁹ IL-17,¹⁰ and adipokines including adiponectin.¹¹ Inflammatory pathways are important targets for nutritional interventions,¹² which may have dual benefit of addressing inflammatory comorbidities and reducing metabolic disease risk.¹³ As an adjuvant therapy, curcumin, for example, has been shown to reduce inflammation and improve treatment outcome.¹⁴ C-reactive protein (CRP) correlates with disease severity and may be useful for monitoring nutritional intervention response.¹⁵

Dysbiosis of gut bacteria is thought to play a primary role in the development and perpetuation of autoimmune diseases, and it is well established that the gut microbiota can influence the expression specific lymphocyte subsets involved in autoimmunity.¹⁶ Psoriasis shares genetic and clinical relationships with Cohn's disease, which is linked to gastrointestinal dysbiosis and loss of tolerance to intestinal microbes, and it has been proposed that psoriasis is linked to dermal dysbiosis and loss of tolerance to skin microbes.¹⁷

Although intestinal dysbiosis has not been well studied in psoriasis, an experimental study has suggested it could be an initiating factor in systemic Th17 activation and psoriasis-like skin inflammation.¹⁸ Intriguingly, probiotic administration to people with psoriasis has been shown to reduce systemic inflammation.¹⁹ And a case study of an adult man with treatment refractory psoriasis reported dramatic normalization of his psoriasis after *H. pylori* eradication for gastroduodenitis, despite no previous clinical symptoms indicating gastrointestinal involvement.²⁰

Psychological stress and alterations in sympathetic adrenal medullary axis and hypothalamic pituitary adrenal (HPA) axis function share a bi-directional relationship with psoriasis, the so called brain-skin axis.²¹ On one hand psoriasis itself is a cause of significant psychological stress, while on

Psoriasis

the other psychological stress could contribute to the development and exacerbation of psoriasis though neurogenic inflammation, including interactions with leucocytes and mast cells.²²

Stressful life events have been linked to subsequent psoriasis exacerbations,²³ and there is a clinically significant prevalence of depression, anxiety and perceived stress.²⁴ While features of HPA axis dysfunction in psoriasis include significantly higher HPA axis reactivity to acute stress,²⁵ hypocortisolism,²⁶ and evening elevations in cortisol.²⁷ Cortisol expression and HPA axis dysfunction have been shown to correlate with psoriasis severity.^{28 29} Mind body interventions have some evidence to suggest they can improve quality of life and reduce feelings of stress as well as disease severity in people with psoriasis, especially cognitive behavioral therapy.³⁰

Comorbid illnesses are an important consideration in psoriasis, which is associated with several systemic disorders, including Crohn's disease, type-2 diabetes mellitus, cardiovascular disease, metabolic syndrome, depression, and cancers, particularly lymphoma and skin cancer.³¹ Notably, between 6 to 42% of patients with psoriasis have psoriatic arthritis.³² These associations suggest that psoriasis may be the cutaneous manifestation of a systemic inflammatory state.³³

Standard drug, topical and phototherapy treatments for psoriasis frequently have adverse side effects and suffer from inadequate efficacy, thus safer and more effective management options are needed.³⁴ An improved clinical approach to the management of psoriasis could include individualized, patient-centered care in addition to addressing modifiable environmental and nutritional factors as these play an important role in the both the development and perpetuation of the disease.^{35 36}

Dietary interventions

- **Healthy diet**

Several factors associated with unhealthful diets have been found to be common in people suffering from psoriasis, including a higher consumption of simple carbohydrates, total fat lower intake of complex carbohydrates, omega-3 PUFA, and fiber, some of which correlated with disease severity.³⁷ An observational study found that a greater degree of adherence to a traditional Mediterranean-style diet was associated with lower severity of psoriasis symptom scores and inflammation, as assessed by CRP.³⁸

In an intervention study most patients with psoriasis (88.37%) reported reduced scaling and erythema, milder outbreaks during the year, and improved quality of life with advice to increase consumption of beta-carotene containing foods, fruit, white meat and whole grains and decrease specific foods, such as black coffee, black tea, chocolate, pepper, smoked foods, beef, monosodium glutamate, and alcoholic drinks.³⁹ And a woman with severe, treatment resistant psoriasis who was treated with nutritional therapy including increased vegetable intake, low consumption of meat, avoidance of junk food and sugar, and personalized nutritional supplementation experienced complete resolution of symptoms within 6-months.⁴⁰

- **Weight loss diet**

Overweight and obesity, especially central obesity, may play an important contributory role to the development and exacerbation of psoriasis and nutrition-based weight loss plan could be considered as it has been shown to reduce symptoms.⁴¹ Several clinical studies have found that dietary and lifestyle weight loss intervention reduce the severity of psoriasis in overweight or obese people.⁴²

Psoriasis

A low-energy diet providing 800-1000 kcal per for 8-weeks to induce weight loss, followed by 8 weeks of reintroduction of normal food intake, reaching 1200 kcal per day resulted in clinically important improvements in symptom and quality of life in overweight patients with psoriasis.⁴³ Another investigation found that a low-energy diet, providing 855 kcal per day and mostly comprised of fresh and cooked vegetables, resulted in a significant reduction in serum lipids and clinical symptoms of psoriasis after 4-weeks.⁴⁴ A low-energy diet that was also designed to increase omega-3 (average 2.6 grams per day) and reduce omega-6 polyunsaturated fatty acid intake improved metabolic profile, improved response to immuno-modulating therapy, and resulted in a significant clinical improvement over 6-months.⁴⁵ A 2-phase rapid weight loss diet (4-weeks of a ketogenic diet followed by 6-weeks of a balanced, hypocaloric, Mediterranean-like diet) in overweight or obese adults with chronic plaque psoriasis resulted in a mean body weight reduction of 12.0% (-10.6 kg) and significant improvements in psoriasis symptom scores ($\geq 50\%$ and $\geq 75\%$ in 97.3% and 64.9% of patients, respectively), body surface area involved (-17.4%) and an improvement in itch severity and quality of life.⁴⁶ A comparison of a ketogenic diet to a Mediterranean-style diet in patients with obesity and psoriatic arthritis indicated superiority of the ketogenic diet for reduction of inflammatory markers of inflammation and disease activity.⁴⁷

- **Gluten-free diet**

Both celiac disease and non-celiac gluten sensitivity (NCGS) have been associated with psoriasis, and a gluten-free diet has been shown to reduce symptom severity in some cases.⁴⁸ It has been estimated that people with psoriasis have an approximately 3-fold increased risk of celiac disease.⁴⁹ Although most investigations have implemented gluten-free diets in antibody-positive psoriasis patients, antibodies to gliadin may be elevated in the absence of biopsy-confirmed celiac disease,⁵⁰ and improvements in manifestations similar to psoriasis have been observed in people with NCGS after a gluten-free diet.⁵¹ These observations suggest that the possibility of gluten sensitivity should be considered even in the absence of histologically confirmed celiac disease or positive antibodies.

Clinical studies and case reports have demonstrated important benefits of gluten-free diets in psoriasis patients with gluten sensitivity.^{52 53 54} In one such study, coeliac screening in people with psoriasis revealed a high prevalence (4.1%) compared to controls, as assessed with anti-tissue transglutaminase antibodies and subsequently confirmed histologically. After a 6-month gluten-free diet there was a marked improvement of skin lesions in 7 out of 8 people.⁵⁵ Another report comparing the effects of a gluten-free diet in psoriasis patients with and without positive antibodies found that there was a highly significant decrease in psoriasis symptoms scores, but only in those with positive antibodies.⁵⁶

- **Intestinal permeability-targeted diet**

Increased translocation of gut-derived endotoxin into the peripheral circulation has been suggested to play a role in the development of dermatological disorders.⁵⁷ Indeed, metabolic endotoxemia associated with intestinal permeability is a well-established source of chronic low-grade inflammation.⁵⁸ There is evidence of increased intestinal permeability in patients with psoriasis compared to healthy controls.⁵⁹ A case series utilizing an intestinal permeability-targeted nutritional intervention involving dietary changes (high fresh fruits and vegetables, low protein from fish and poultry, fiber supplements, olive oil, and avoidance of red meat, processed foods, and refined carbohydrates) and herbal teas (saffron tea and slippery elm bark) reported improvement in psoriasis symptom scores and reduced intestinal permeability.⁶⁰ The complex nature of a dietary intervention makes it hard to attribute symptomatic benefit specifically to modification of intestinal permeability, more research is needed to support this hypothesis.

Psoriasis

Nutrient interventions

- **Fatty acids**

Fish oil supplementation may improve psoriasis, however higher doses, and likely long treatment periods, may be necessary for the good clinical effects.⁶¹ A review of clinical trials evaluating fish oil for the treatment of psoriasis found moderate evidence of benefit, with 12 of the total 15 trials reviewed showing clinical benefits.⁶² Positive clinical trials have used an average dose of 4 g eicosapentaenoic acid (EPA) and 2.6 g docosahexaenoic acid (DHA) daily which needed to be taken for at least 6 weeks to 6 months to see improvement; typically, a range of reduction in symptom score of 40-75%.⁶³ In addition to fish oil supplements, advice to consume 170 g of omega-3 rich fish daily for 6-weeks was also effective.⁶⁴ Beyond reduction of psoriasis dermatological symptoms benefits have also been observed for related sequel including risk factors for obesity, cardiovascular disease, and metabolic disease as well as reductions in several inflammatory mediators.⁶⁵

- **Vitamin A**

Synthetic retinoids are used for the management of psoriasis, but their use is limited by adverse effects, especially mucocutaneous and hepatic side effects resembling hypervitaminosis A syndrome.⁶⁶ Oral vitamin A has been explored for psoriasis, however, was abandoned early on due to inadequate clinical response and toxicity.⁶⁷ A potential alternative to vitamin A is the pro-vitamin A carotenoid β -carotene as it is non-toxic. A clinical trial tested the effect of β -carotene in adults with mild, chronic, plaque-type psoriasis (n=34) at a dose of 30-40 mg twice daily with meals for 12-weeks. Compared to placebo, β -carotene significantly reduced symptoms scores with no mucocutaneous side effects or adverse effects on liver function or lipid profiles associated with vitamin A or synthetic retinoids.⁶⁸

- **Vitamin D**

Vitamin D deficiency has been associated with psoriasis, and while benefits of repletion on dermatological manifestations of psoriasis are equivocal, assessment and supplementation in cases of deficiency would have wide-ranging health benefits beyond the skin including on immunological function and metabolic health.⁶⁹ Findings have suggested that vitamin D deficiency is typically more severe in patients with psoriasis, and that the degree of deficiency correlated with disease duration and severity.^{70 71 72}

Supplementation with the active form of vitamin D (1,25-dihydroxyvitamin D) was shown to result in an 88% response rate with 26.5% of patients experiencing complete remission.⁷³ Very high dose vitamin D3 (35,000 IU once daily for six months) and a low-calcium diet significantly improved symptom scores in patients with psoriasis.⁷⁴ And a case report described resolution of adalimumab-induced psoriasis in a woman with rheumatoid arthritis after treatment of vitamin D deficiency with vitamin D3.⁷⁵ In contrast, a meta-analysis of four clinical trials found that vitamin D supplementation did not significantly improve symptoms scores suggesting that it is currently uncertain if low 25(OH)D levels represent a contributory cause or consequence of psoriasis.⁷⁶ Collectively these reports suggest a high frequency of vitamin D deficiency in patients with psoriasis, but it is unclear if this would significantly impact disease activity.

- **Folate**

Caution should be used with high-dose folic acid and 5-methyl tetrahydrofolate (5MTHF) in patients with psoriasis receiving methotrexate. Administration of folic acid at a dose of 2.8 to 5 g daily has

Psoriasis

been shown to reduce the effectiveness of methotrexate in psoriasis patients already in remission.⁷⁷ ⁷⁸ And 5MTHF at a dose of 15 mg daily was reported to result in a psoriasis flare in an individual receiving methotrexate.⁷⁹ Lower doses of folic acid and 5-formyl tetrahydrofolate (folinic acid), however, have been shown to reduce methotrexate gastrointestinal side effects and hepatic dysfunction (elevated serum transaminase levels) and improve methotrexate compliance in patients with rheumatoid arthritis.⁸⁰ For psoriasis patients receiving <15mg methotrexate weekly a dosage regime of 5 mg of folic acid per day for 2 days after the last dose of methotrexate has been proposed, with an additional third dose of 5 mg on day 3 for patients receiving > 15 mg.⁸¹

A higher prevalence of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism has been found in patients with psoriasis, suggesting a possible association with disease development and severity.^{82 83} However, few studies have explored folate or other nutrients involved in one-carbon metabolism as a stand-alone therapy for psoriasis. A small study of folic acid at a dose of 5 mg twice daily and B12 injections found no effect on symptoms.⁸⁴

- **Vitamin B12**

It is possible that vitamin B12 deficiency may contribute to psoriasis disease activity and that improving nutritional status reduces symptoms, but evidence from research is mixed. Nonetheless, a higher prevalence vitamin B12 deficiency and elevated homocysteine associated with low B12 status could be associated with disease severity in some patients.^{85 86} Of two clinical studies examining the effects of intramuscular vitamin B12, one reported good improvement in clinical symptoms while another found no benefit.⁸⁷ Taken together it would be prudent to screen patients with psoriasis for vitamin B12 deficiency.

- **Chromium**

Psoriasis has been associated with a higher prevalence of insulin resistance, type 2 diabetes risk and metabolic syndrome.^{88 89} Although insulin resistance is often considered a co-morbidity there is evidence to suggest that poor insulin metabolism could adversely affect skin physiology by contributing to the pro-inflammatory state in psoriasis.⁹⁰ Some evidence supports a causal role, including correlations between insulin resistance and disease severity,⁹¹ and exacerbation of psoriasis with insulin therapy but risk-reduction with oral hypo-glycemic agents.^{92 93} Dietary supplementation with the insulin-sensitizing mineral chromium at a dose of 600 µg daily for 6-weeks improved both insulin resistance and psoriasis severity, but only in patients with established insulin resistance.⁹⁴ Nutritional and lifestyle-based management of insulin-resistance is an important consideration.

- **Antioxidant nutrients**

Systemic oxidative stress (overproduction and/ or inadequate removal of reactive oxygen species) is a consistent feature of psoriasis that plays a role in disease development and is an important target for patient management.⁹⁵ Oxidative stress could contribute to the development of psoriasis through a number of mechanisms, including DNA modification, lipid peroxidation, and production of inflammatory cytokines.⁹⁶ The oxidative stress characteristic of psoriasis is broadly due to exposure to pro-oxidant stimuli and impaired endogenous antioxidant defenses.⁹⁷

Nutritional interventions that target oxidative stress, sequestering oxidants and improving endogenous defenses, can be useful clinically.⁹⁸ A clinical study of coenzyme Q10 (50 mg daily), vitamin E (natural alpha-tocopherol, 50 mg), and selenium (aspartate salt, 48 µg) resulted in

Psoriasis

improvements several parameters related to oxidative stress, included superoxide production, copper/zinc-superoxide dismutase, and catalase, as well as a significant reduction in disease severity which correlated with normalization of the oxidative stress markers.⁹⁹ In contrast, selenium with or without vitamin E has failed to reduce clinical symptoms, despite some improvement in metabolic markers.^{100 101 102}

Vitamin C (ascorbic acid) has been found to complement NB-UVB phototherapy. In 12-week clinical trial patients with psoriasis (n=74) were assigned randomly to NB-UVB only or NB-UVB with vitamin C (500 mg twice daily). Compared to NB-UVB only the addition of vitamin C significantly improved redox balance (increasing serum vitamin C and glutathione while decreasing malondialdehyde) which correlated significantly with symptomatic improvement.¹⁰³

Addition of ubiquinone (CoQ10) to a biological medicine (adalimumab) to adult patients with psoriasis over 3-months resulted in a significant reduction in symptoms scores and improvement in quality of life when compared to adalimumab plus placebo.¹⁰⁴ CoQ10 was chosen as a therapeutic due to its antioxidant action and the role of oxidative stress in psoriasis.

- **Turmeric**

Turmeric (*Curcuma longa*) has a long-history of use for a wide variety of dermatologic disease, which may be in part due to its anti-inflammatory, antimicrobial, and antioxidant properties.¹⁰⁵ Extracts of turmeric have shown promise as an adjuvant to standard therapy. The addition of 600 mg turmeric extract providing 72 mg of curcumin daily resulted in a good therapeutic response to phototherapy with ultraviolet (UV)-A radiation or visible blue light applied locally,¹⁰⁶ and was more effective than conventional treatment with methoxsalen and psoralen plus UV-A therapy.¹⁰⁷

Clinical trials suggest that a specific enhanced -bioavailability turmeric extract may be more effective. An initial clinical trial with turmeric extract providing 4,500 mg per day of curcuminoids for 12-weeks found no benefit.¹⁰⁸ However, a second trial utilizing an enhanced bioavailability formulation (Meriva; Indeena, Italy) providing 400 mg curcumin daily reduced symptoms more effectively than topical steroids alone.¹⁰⁹

- **Bile acids**

Bile acids have been reported to be a successful management approach for psoriasis with the primary mechanism suggested to be due to their ability to degrade gastrointestinal-derived endotoxin and prevent its systemic migration and direct adverse effects on the skin.¹¹⁰ Primary biliary cirrhosis and its associated cholestasis may have a causal role in psoriasis.¹¹¹ Bile acids have also been shown to directly improve psoriasiform dermatitis by inhibiting Th17 differentiation and production of the cytokine IL-17A.¹¹²

In a trial (n=800) of oral bile acids (dehydrocholic acid 250 mg 2-3 times daily for 1–6 and 3–8 weeks in acute and chronic cases, respectively) and conventional therapy (topical treatments, antibiotics and antihistamines) vs. conventional therapy alone it was found that 78.8% of patients became asymptomatic vs. only 24.9% of those receiving conventional therapy. Bile acids were found to be more effective during the acute phase of the disease with 95.1% of patients becoming asymptomatic.¹¹³ At 2-years follow up 57.9% of those who received bile acids remained asymptomatic, compared to 6.0% receiving the conventional treatment with more pronounced benefit in acute phase patients (79.9% asymptomatic vs. 7.2%). A series of case reports describe resolution of psoriasis after treatment of fatty liver disease with bile acids (ursodeoxycholic acid 300 mg to 600 mg daily).¹¹⁴ A number of other investigators have described similar success in managing

Psoriasis

psoriasis with ursodeoxycholic acid.^{115 116} And a dermatologist has reported his own clinical successes with using bile acids for numerous patients with psoriasis.¹¹⁷ Over-the-counter products utilized include Jarrow Formulas; Bile acid factors providing 1000 mg total bile acids per capsule and Allergy Research Group; Ox bile providing 125 mg or 500 mg per capsule. Concomitant use of dietary therapies (low fat, mostly vegetables, avoid alcohol, peppers and emulsifiers) as well as bioflavonoids (quercetin), turmeric extract and silymarin are recommended as components of an integrative approach.¹¹⁸

- **Topical therapies**

Herbal and nutritional topical therapies that have been examined in clinical trials, including Aloe vera, avocado oil, Curcuma longa, capsicum frutescens, Hypericum perforatum, and Mahonia aquifolium, and have generally resulted in good clinical benefits when applied 2-3 times daily for 4-16 weeks with a high degree of safety.¹¹⁹

Aloe vera cream (0.5% in hydrophilic cream) cured 25/30 (83.3%) adults with slight to moderate psoriasis compared to a placebo cure rate of 2/30 (6.6%) in one study.¹²⁰ And in another Aloe vera gel (70% aloe mucilage) was more effective than triamcinolone acetonide for relief of the clinical symptoms of psoriasis.¹²¹

A vitamin B12 cream containing avocado oil was well-tolerated and effective for reducing symptom score in chronic plaque psoriasis.¹²² Similarly, a vitamin B₁₂-containing ointment had significant clinical superiority when compared to a glycerol-petrolatum-based emollient cream for the treatment of mild-to-moderate plaque psoriasis.¹²³

Summary and Clinical Considerations

Intervention	Discussion	Guidance
Healthy diet	Unhealthy dietary practices appear to be more frequent in patients with psoriasis and could increase disease risk and severity. Conversely, healthy dietary interventions improve the disease course.	Increasing vegetable intake, low consumption of meat, avoidance of junk food and sugar, and specific foods, such as black coffee, black tea, chocolate, pepper, smoked foods, monosodium glutamate, and alcoholic drinks may be useful. Consider dietary supplements to optimize nutritional intake and support skin health.
Weight-loss diet	Overweight and obesity can contribute to disease severity though increased low-grade inflammation and diet-induced weight loss results in clinical improvement.	Dietary and lifestyle-based weight loss regimes, including low-energy diets and very low carbohydrate ketogenic diets, can be considered a component of nutritional management for overweight or obese patients.
Gluten-free diet	There is a higher frequency of celiac disease and gluten sensitivity in psoriasis, and gluten-free diets may reduce disease severity.	Confirmed celiac disease must be managed with a strict gluten-free diet, however, a gluten-free diet should be considered even in the absence of histologically confirmed celiac disease or positive antibodies i.e., non-celiac gluten sensitivity.

Psoriasis

Intestinal permeability-targeted diet	Nutritional modification of intestinal permeability could benefit psoriasis, but although research is limited.	Assessment of intestinal permeability and, if indicated, a permeability-targeted nutritional intervention might be considered.
Fatty acids	Both high-dose fish oil and increasing fish consumption can be effective for reducing symptoms.	Consider around 4 g EPA and/ or 2.6 g DHA or advice to consume 170 g of omega-3 rich fish daily for >6-weeks.
Vitamin A	The pro vitamin A carotenoid β -carotene has been shown to reduce psoriasis symptoms without the side-effects of vitamin A or synthetic retinoids.	Consider β -carotene 30-40 mg twice daily with meals for >12-weeks.
Vitamin D	Vitamin D deficiency may be more severe in psoriasis, and the degree of deficiency has been correlated with disease duration and severity.	Vitamin D supplementation with vitamin D3 could be considered in the presence of vitamin D deficiency.
Folate	High-dosed folic acid and 5-methyl tetrahydrofolate (5MTHF) methotrexate as it may reduce methotrexate efficacy, while lower doses may reduce side-effects.	For patients receiving <15mg methotrexate weekly consider a dosage regime of 5 mg of folic acid per day for 2 days after the last dose of methotrexate, with an additional third dose of 5 mg on day 3 for patients receiving > 15 mg.
Vitamin B12	Vitamin B12 deficiency may exacerbate disease activity and improving nutritional status could reduce symptoms, but evidence is mixed.	It would be prudent to screen for vitamin B12 deficiency.
Chromium	Poor blood glucose metabolism could contribute to psoriasis in a subset of people and may be positively impacted by chromium.	Consider chromium supplementation 600 μ g daily for 6-weeks in patients with established insulin resistance.
Antioxidant nutrients	Systemic oxidative stress is a consistent feature of psoriasis and may contribute to disease development and be an important target for management.	Consider trialing a nutritional antioxidants, especially multi-nutrients formulations, CoQ10, and vitamin C.

Psoriasis

Turmeric	Turmeric extracts have shown promise as an adjuvant to standard therapy.	Consider an enhanced-bioavailability extract providing 400 mg curcumin daily.
Bile acids	Bile acids may degrade gastrointestinal-derived endotoxin and prevent its systemic migration and direct adverse effects on the skin.	Consider bovine bile concentrate 500 mg 1-3 times daily with meals. ¹²⁴
Topical therapies	Several herbal and nutritional topical therapies that have been examined in clinical trials with good results.	Aloe vera cream or gel is widely available and has generally resulted in good clinical benefits when applied 2-3 times daily for 4-16 weeks.

¹ Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. *Autoimmun Rev* 2014;13(495):490.

² Nestle FO, Kaplan DH, Barker J. Psoriasis. *N Engl J Med*. 2009 Jul 30;361(5):496-509.

³ Hedrich CM. Shaping the spectrum - From autoinflammation to autoimmunity. *Clin Immunol*. 2016 Apr;165:21-8.

⁴ Christophers E, Metzler G, Röcken M. Bimodal immune activation in psoriasis. *Br J Dermatol*. 2014 Jan;170(1):59-65.

⁵ Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. *Clin Exp Rheumatol* 2015;33(5 Suppl 93): S2-6.

⁶ Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? *Semin Arthritis Rheum*. 2016 Dec;46(3):291-304.

⁷ Sticherling M. Psoriasis and autoimmunity. *Autoimmun Rev*. 2016 Dec;15(12):1167-1170.

⁸ Deng Y, Chang C, Lu Q. The Inflammatory Response in Psoriasis: a Comprehensive Review. *Clin Rev Allergy Immunol*. 2016 Jun;50(3):377-89.

⁹ Puig L. The role of IL 23 in the treatment of psoriasis. *Expert Rev Clin Immunol*. 2017 Feb 6. doi: 10.1080/1744666X.2017.1292137. [Epub ahead of print]

¹⁰ Owczarczyk-Saczonek A, Placek W. Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. *Int J Dermatol*. 2017 Mar;56(3):260-268.

¹¹ Eder L, Jayakar J, Pollock R, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. *Ann Rheum Dis*. 2013 Dec;72(12):1956-61.

¹² Calder PC, Albers R, Antoine JM, et al. Inflammatory disease processes and interactions with nutrition. *Br J Nutr*. 2009 May;101 Suppl 1:S1-45.

¹³ Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Implications for management. *J Am Acad Dermatol*. 2017 Mar;76(3):393-403.

¹⁴ Antiga E, Bonciolini V, Volpi W, Del Bianco E, Caproni M. Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris. *Biomed Res Int*. 2015;2015:283634.

¹⁵ Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. *J Eur Acad Dermatol Venereol*. 2014 Jun;28(6):700-11.

¹⁶ Kim D, Yoo SA, Kim WU. Gut microbiota in autoimmunity: potential for clinical applications. *Arch Pharm Res*. 2016 Nov;39(11):1565-1576.

¹⁷ Fry L, Baker BS, Powles AV, Engstrand L. Psoriasis is not an autoimmune disease? *Exp Dermatol*. 2015 Apr;24(4):241-4.

¹⁸ Zákostelská Z, Málková J, Klimešová K, et al. Intestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response. *PLoS One*. 2016 Jul 19;11(7):e0159539.

¹⁹ Groeger D, O'Mahony L, Murphy EF, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. *Gut Microbes*. 2013 Jul-Aug;4(4):325-39.

²⁰ Pietrzak A, Jastrzebska I, Chodorowska G, et al. Psoriasis vulgaris and digestive system disorders: is there a linkage? *Folia Histochem Cytobiol*. 2009 Jan;47(3):517-24.

²¹ Moon HS, Mizara A, McBride SR. Psoriasis and psycho-dermatology. *Dermatol Ther (Heidelb)*. 2013 Dec;3(2):117-30.

²² Hunter HJ, Griffiths CE, Kleyn CE. Does psychosocial stress play a role in the exacerbation of psoriasis? *Br J Dermatol*. 2013 Nov;169(5):965-74.

Psoriasis

- ²³ Pacan P, Szepietowski JC, Kiejna A. Stressful life events and depression in patients suffering from psoriasis vulgaris. *Dermatol Psychosom* 2003; 4: 142-5
- ²⁴ Lakshmy S, Balasundaram S, Sarkar S, et al. A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis. *Indian J Psychol Med*. 2015 Oct-Dec;37(4):434-40.
- ²⁵ de Brouwer SJ, van Middendorp H, Stormink C, et al. The psychophysiological stress response in psoriasis and rheumatoid arthritis. *Br J Dermatol*. 2014 Apr;170(4):824-31.
- ²⁶ Richards HL, Ray DW, Kirby B, et al. Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. *Br J Dermatol*. 2005 Dec;153(6):1114-20.
- ²⁷ Brunoni AR, Santos IS, Sabbag C, et al. Psoriasis severity and hypothalamic-pituitary-adrenal axis function: results from the CALIPSO study. *Braz J Med Biol Res*. 2014 Dec;47(12):1102-6.
- ²⁸ Evers AW, Verhoeven EW, Kraaijmaat FW, et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis. *Br J Dermatol*. 2010 Nov;163(5):986-91.
- ²⁹ Amatya B, El-Nour H, Holst M, et al. Expression of tachykinins and their receptors in plaque psoriasis with pruritus. *Br J Dermatol*. 2011 May;164(5):1023-9.
- ³⁰ Schwartz J, Evers AW, Bundy C, Kimball AB. Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis. *Front Psychol*. 2016 Feb 2;7:87.
- ³¹ Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007 Jul 21;370(9583):263-71.
- ³² Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. *An Bras Dermatol*. 2015 Jan-Feb;90(1):9-20.
- ³³ Lotti T, Hercogova J, Prignano F. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? *Dermatol Ther*. 2010 Mar-Apr;23(2):119-22.
- ³⁴ Lebwohl M. Psoriasis. *Lancet*. 2003 Apr 5;361(9364):1197-204.
- ³⁵ Griffiths CE, van de Kerkhof P, Czarnecka-Operacz M. Psoriasis and Atopic Dermatitis. *Dermatol Ther (Heidelb)*. 2017 Jan;7(Suppl 1):31-41.
- ³⁶ Barrea L, Nappi F, Di Somma C, et al. Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. *Int J Environ Res Public Health*. 2016 Jul 22;13(5).
- ³⁷ Barrea L, Macchia PE, Tarantino G, et al. Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. *J Transl Med*. 2015 Sep 16;13:303.
- ³⁸ Barrea L, Balato N, Di Somma C, et al. Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet? *J Transl Med*. 2015;13:18–27
- ³⁹ Festugato M. Pilot study on which foods should be avoided by patients with psoriasis. *An Bras Dermatol*. 2011 Nov-Dec;86(6):1103-8.
- ⁴⁰ Wong AP, Kalinovsky T, Niedzwiecki A, Rath M. Efficacy of nutritional treatment in patients with psoriasis: A case report. *Exp Ther Med*. 2015 Sep;10(3):1071-1073.
- ⁴¹ Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. *Actas Dermosifiliogr*. 2014 Jan-Feb;105(1):31-44.
- ⁴² Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. *Int J Obes (Lond)*. 2015 Aug;39(8):1197-202.
- ⁴³ Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. *JAMA Dermatol*. 2013 Jul;149(7):795-801.
- ⁴⁴ Ručević I, Perl A, Barišić-Drusko V, Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. *Coll Antropol*. 2003;27 Suppl 1:41-8.
- ⁴⁵ Guida B, Napoleone A, Trio R, et al. Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. *Clin Nutr*. 2014 Jun;33(3):399-405.
- ⁴⁶ Castaldo G, Rastrelli L, Galdo G, Molettieri P, Rotondi A, Cereda E. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. *Nutrition*. 2020 Jun;74:110757. doi: 10.1016/j.nut.2020.110757. Epub 2020 Feb 5. PMID: 32222582.
- ⁴⁷ Lambadiari V, Katsimbri P, Kountouri A, Korakas E, Papathanasi A, Maratou E, Pavlidis G, Pliouta L, Ikonomidis I, Malisova S, Vlachos D, Papadavid E. The Effect of a Ketogenic Diet versus Mediterranean Diet on Clinical and Biochemical Markers of Inflammation in Patients with Obesity and Psoriatic Arthritis: A Randomized Crossover Trial. *Int J Mol Sci*. 2024 Feb 20;25(5):2475. doi: 10.3390/ijms25052475. PMID: 38473723; PMCID: PMC10931171.
- ⁴⁸ Bhatia BK, Millsop JW, Debbaneh M, et al. Diet and psoriasis, part II: celiac disease and role of a gluten-free diet. *J Am Acad Dermatol*. 2014 Aug;71(2):350-8.
- ⁴⁹ Ungprasert P, Wijarnpreecha K, Kittanamongkolchai W. Psoriasis and Risk of Celiac Disease: A Systematic Review and Meta-analysis. *Indian J Dermatol*. 2017 Jan-Feb;62(1):41-46.
- ⁵⁰ Akbulut S, Gür G, Topal F, et al. Coeliac disease-associated antibodies in psoriasis. *Ann Dermatol*. 2013 Aug;25(3):298-303.
- ⁵¹ Bonciolini V, Bianchi B, Del Bianco E, et al. Cutaneous Manifestations of Non-Celiac Gluten Sensitivity: Clinical Histological and Immunopathological Features. *Nutrients*. 2015 Sep 15;7(9):7798-805.

Psoriasis

- ⁵² Michaëlsson G, Ahs S, Hammarström I, et al. Gluten-free diet in psoriasis patients with antibodies to gliadin results in decreased expression of tissue transglutaminase and fewer Ki67+ cells in the dermis. *Acta Derm Venereol*. 2003;83:425–9.
- ⁵³ Addolorato G, Parente A, de Lorenzi G, et al. Rapid regression of psoriasis in a coeliac patient after gluten-free diet. A case report and review of the literature. *Digestion*. 2003;68:9–12.
- ⁵⁴ Frikha F, Snoussi M, Bahloul Z. Osteomalacia associated with cutaneous psoriasis as the presenting feature of coeliac disease: a case report. *Pan Afr Med J*. 2012;11:58.
- ⁵⁵ De Bastiani R, Gabrielli M, Lora L, et al. Association between coeliac disease and psoriasis: Italian primary care multicentre study. *Dermatology*. 2015;230(2):156-60.
- ⁵⁶ Michaëlsson G, Gerdén B, Hagforsen E, et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. *Br J Dermatol*. 2000 Jan;142(1):44-51.
- ⁵⁷ Bowe W, Patel NB, Logan AC. Acne vulgaris, probiotics and the gut-brain-skin axis: from anecdote to translational medicine. *Benef Microbes*. 2014 Jun 1;5(2):185-99.
- ⁵⁸ Festi D, Schiumerini R, Eusebi LH, et al. Gut microbiota and metabolic syndrome. *World J Gastroenterol*. 2014 Nov 21;20(43):16079-94.
- ⁵⁹ Humbert P, Bidet A, Treffel P, et al. Intestinal permeability in patients with psoriasis. *J Dermatol Sci*. 1991 Jul;2(4):324-6.
- ⁶⁰ Brown AC, Hairfield M, Richards DG, et al. Medical nutrition therapy as a potential complementary treatment for psoriasis—five case reports. *Altern Med Rev*. 2004 Sep;9(3):297-307.
- ⁶¹ McCusker MM, Grant-Kels JM. Healing fats of the skin: the structural and immunologic roles of the omega-6 and omega-3 fatty acids. *Clin Dermatol*. 2010 Jul-Aug;28(4):440-51.
- ⁶² Millsop JW, Bhatia BK, Debbaneh M, et al. Diet and psoriasis, part III: role of nutritional supplements. *J Am Acad Dermatol*. 2014 Sep;71(3):561-9.
- ⁶³ Talbott W, Duffy N. Complementary and alternative medicine for psoriasis: what the dermatologist needs to know. *Am J Clin Dermatol*. 2015 Jun;16(3):147-65.
- ⁶⁴ Collier PM, Ursell A, Zaremba K, et al. Effect of regular consumption of oily fish compared with white fish on chronic plaque psoriasis. *Eur J Clin Nutr*. 1993 Apr;47(4):251-4.
- ⁶⁵ Chen X, Hong S, Sun X, Xu W, Li H, Ma T, Zheng Q, Zhao H, Zhou Y, Qiang Y, Li B, Li X. Efficacy of fish oil and its components in the management of psoriasis: a systematic review of 18 randomized controlled trials. *Nutr Rev*. 2020 Oct 1;78(10):827-840. doi: 10.1093/nutrit/nuz098. PMID: 31995220.
- ⁶⁶ Zito PM, Patel P, Mazzoni T. Acitretin. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519571/>
- ⁶⁷ Riley PA. Vitamin A and the skin. *Br Med J*. 1969 Jul 12;3(5662):117. doi: 10.1136/bmj.3.5662.117. PMID: 5790260; PMCID: PMC1983890.
- ⁶⁸ Greenberger S, Harats D, Salameh F, Lubish T, Harari A, Trau H, Shaish A. 9-cis-rich β -carotene powder of the alga *Dunaliella* reduces the severity of chronic plaque psoriasis: a randomized, double-blind, placebo-controlled clinical trial. *J Am Coll Nutr*. 2012 Oct;31(5):320-6. doi: 10.1080/07315724.2012.10720430. PMID: 23529989.
- ⁶⁹ Barrea L, Savanelli MC, Di Somma C, et al. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. *Rev Endocr Metab Disord*. 2017 Feb 7. doi: 10.1007/s11154-017-9411-6. [Epub ahead of print]
- ⁷⁰ Bergler-Czop B, Brzezińska-Wcisło L. Serum vitamin D level - the effect on the clinical course of psoriasis. *Postepy Dermatol Alergol*. 2016 Dec;33(6):445-449.
- ⁷¹ Ricceri F, Pescitelli L, Tripo L, et al. Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis. *J Am Acad Dermatol*. 2013;68:511–2.
- ⁷² Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, et al. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. *J Am Acad Dermatol*. 2012;67:931–8.
- ⁷³ Perez A, Raab R, Chen TC, et al. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. *Br J Dermatol*. 1996 Jun;134(6):1070-8.
- ⁷⁴ Finamor DC, Sinigaglia-Coimbra R, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. *Dermatoendocrinol*. 2013 Jan 1;5(1):222-34.
- ⁷⁵ Werner de Castro GR, Neves FS, et al. Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment. *Rheumatol Int*. 2012 May;32(5):1313-6.
- ⁷⁶ Formisano E, Proietti E, Borgarelli C, Pisciotta L. Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis. *Nutrients*. 2023 Jul 30;15(15):3387. doi: 10.3390/nu15153387. PMID: 37571324; PMCID: PMC10421389.
- ⁷⁷ Salim A, Tan E, Ilchyshyn A, et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. *Br J Dermatol*. 2006 Jun;154(6):1169-74.
- ⁷⁸ Chládek J, Simková M, Vanecková J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. *Eur J Clin Pharmacol*. 2008 Apr;64(4):347-55.
- ⁷⁹ Nazarian RS, Lamb AJ. Psoriatic flare after the concomitant administration of L-methylfolate and methotrexate. *JAAD Case Rep*. 2016 Dec 24;3(1):13-15.
- ⁸⁰ Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *J Rheumatol*. 2014 Jun;41(6):1049-60.
- ⁸¹ Baran W, Batycka-Baran A, Zychowska M, et al. Folate supplementation reduces the side effects of methotrexate therapy for psoriasis. *Expert Opin Drug Saf*. 2014 Aug;13(8):1015-21.

Psoriasis

- ⁸² Karabacak E, Aydin E, Ozcan O, et al. Methylenetetrahydrofolate reductase (MTHFR) 677C>T gene polymorphism as a possible factor for reducing clinical severity of psoriasis. *Int J Clin Exp Med*. 2014 Mar 15;7(3):697-702.
- ⁸³ **Izmirli M, Sen BB, Rifaioğlu E, et al. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in psoriasis in southern Turkey. *An Bras Dermatol*. 2016 Sep-Oct;91(5):611-613.**
- ⁸⁴ Dawson TA, Scott KW, Merrett JD. Trial of folic acid therapy in psoriasis. *Ulster Med J*. 1978;47(1):100-1.
- ⁸⁵ Cakmak SK, Gül U, Kiliç C, et al. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. *J Eur Acad Dermatol Venereol*. 2009 Mar;23(3):300-3.
- ⁸⁶ Brazzelli V, Grasso V, Fornara L, et al. Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity. *Int J Immunopathol Pharmacol*. 2010 Jul-Sep;23(3):911-6.
- ⁸⁷ Millsop JW, Bhatia BK, Debbaneh M, Koo J, Liao W. Diet and psoriasis, part III: role of nutritional supplements. *J Am Acad Dermatol*. 2014 Sep;71(3):561-9.
- ⁸⁸ Gyldenløve M, Storgaard H, Holst JJ, et al. Patients with psoriasis are insulin resistant. *J Am Acad Dermatol*. 2015 Apr;72(4):599-605.
- ⁸⁹ Praveenkumar U, Ganguly S, Ray L, et al. Prevalence of Metabolic Syndrome in Psoriasis Patients and its Relation to Disease Duration: A Hospital Based Case-Control Study. *J Clin Diagn Res*. 2016 Feb;10(2):WC01-5.
- ⁹⁰ Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. *ScientificWorldJournal*. 2015;2015:479354.
- ⁹¹ Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. *Br J Dermatol*. 2007 Dec;157(6):1249-51.
- ⁹² Moore AF, Soper T, Jones N, et al. Psoriatic exacerbation associated with insulin therapy. *Diabetes Care*. 2008 May;31(5):e31.
- ⁹³ Wu CY, Shieh JJ, Shen JL, et al. Association between antidiabetic drugs and psoriasis risk in diabetic patients: results from a nationwide nested case-control study in Taiwan. *J Am Acad Dermatol*. 2015 Jan;72(1):123-30.
- ⁹⁴ Brewer G, Turkay A, Yuzbasiyan-Gurkan V, et al. Chromium supplementation and insulin sensitivity in psoriasis. *J Am Coll Nutr* 1993;12:588
- ⁹⁵ Peluso I, Cavaliere A, Palmery M. Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis. *J Biomed Sci*. 2016 Jul 4;23(1):52.
- ⁹⁶ Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. *Free Radic Biol Med*. 2009 Oct 1;47(7):891-905.
- ⁹⁷ Trouba KJ, Hamadeh HK, Amin RP, Germolec DR. Oxidative stress and its role in skin disease. *Antioxid Redox Signal*. 2002 Aug;4(4):665-73.
- ⁹⁸ Lin X, Huang T. Oxidative stress in psoriasis and potential therapeutic use of antioxidants. *Free Radic Res*. 2016 Jun;50(6):585-95.
- ⁹⁹ Kharaeva Z, Gostova E, De Luca C, et al. Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. *Nutrition*. 2009 Mar;25(3):295-302.
- ¹⁰⁰ Fairris GM, Lloyd B, Hinks L, Perkins PJ, Clayton BE. The effect of supplementation with selenium and vitamin E in psoriasis. *Ann Clin Biochem*. 1989 Jan;26 (Pt 1):83-8.
- ¹⁰¹ Harvima RJ, Jägerroos H, Kajander EO, et al. Screening of effects of selenomethionine-enriched yeast supplementation on various immunological and chemical parameters of skin and blood in psoriatic patients. *Acta Derm Venereol*. 1993 Apr;73(2):88-91.
- ¹⁰² Serwin AB, Wasowicz W, Chodyncka B. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. *Nutrition*. 2006 Sep;22(9):860-4.
- ¹⁰³ Al-Katib SR, Al-Wakeel HA, Al-Rawaf RF. Role of vitamin C as antioxidant in psoriasis patients treated with NB-UVB phototherapy. *Indian Journal of Public Health Research and Development*. 2018;9(10):375–380.
- ¹⁰⁴ Al-Oudah GA, Sahib AS, Al-Hattab MK, Al-Ameedee AA. Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy. *J Popul Ther Clin Pharmacol*. 2022 Jun 16;29(2):e52-e60. doi: 10.47750/jptcp.2022.931. PMID: 35848197.
- ¹⁰⁵ Vaughn AR, Branum A, Sivamani RK. Effects of Turmeric (*Curcuma longa*) on Skin Health: A Systematic Review of the Clinical Evidence. *Phytother Res*. 2016 Aug;30(8):1243-64.
- ¹⁰⁶ Carrion-Gutierrez M, Ramirez-Bosca A, Navarro-Lopez V, et al. Effects of Curcuma extract and visible light on adults with plaque psoriasis. *Eur J Dermatol*. 2015 May-Jun;25(3):240-6.
- ¹⁰⁷ Ramírez-Boscá A, Navarro-López V, Carrión-Gutiérrez M, et al. Efficiency and safety of a Curcuma extract combined with visible blue light phototherapy on adults with plaque psoriasis: A phase IV, randomized, open pilot clinical trial. *J Dermatol*. 2016 Oct 28. doi: 10.1111/1346-8138.13668. [Epub ahead of print]
- ¹⁰⁸ Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. *J Am Acad Dermatol*. 2008 Apr;58(4):625-31.
- ¹⁰⁹ Antiga E, Bonciolini V, Volpi W, et al. Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris. *Biomed Res Int*. 2015;2015:283634.
- ¹¹⁰ Ely PH. Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is. *Clin Dermatol*. 2018 May-Jun;36(3):376-389. doi: 10.1016/j.clindermatol.2018.03.011. Epub 2018 Mar 28. PMID: 29908580.

Psoriasis

- ¹¹¹ Zhao D, Zhao Q, Xu F, Zhang F, Bai W. Primary biliary cirrhosis and psoriasis: a two-sample Mendelian randomization study. *Front Immunol.* 2024 Jan 4;14:1264554. doi: 10.3389/fimmu.2023.1264554. PMID: 38239358; PMCID: PMC10794341.
- ¹¹² Shi Z, Wu X, Wu CY, Singh SP, Law T, Yamada D, Huynh M, Liakos W, Yang G, Farber JM, Wan YY, Hwang ST. Bile Acids Improve Psoriasisform Dermatitis through Inhibition of IL-17A Expression and CCL20-CCR6-Mediated Trafficking of T Cells. *J Invest Dermatol.* 2022 May;142(5):1381-1390.e11.
- ¹¹³ Gyurcsovics K, Bertók L. Pathophysiology of psoriasis: coping endotoxins with bile acid therapy. *Pathophysiology.* 2003 Dec;10(1):57-61. doi: 10.1016/j.pathophys.2003.07.001. PMID: 14643904.
- ¹¹⁴ Itoh S, Kono M, Akimoto T. Psoriasis treated with ursodeoxycholic acid: three case reports. *Clin Exp Dermatol.* 2007 Jul;32(4):398-400. doi: 10.1111/j.1365-2230.2007.02401.x. Epub 2007 Mar 21. PMID: 17376209.
- ¹¹⁵ Ohira H, Rai T, Takiguchi J, Abe K, Sato Y. Six cases of primary biliary cirrhosis complicated by psoriasis. *Hepatol Res.* 2004 Oct;30(2):111-115. doi: 10.1016/j.hepres.2004.06.003. PMID: 15519276.
- ¹¹⁶ Lajevardi V, Kashiri A, Ghiasi M, Khosravi D, Fazlolahi S, Etesami I. Evaluating the efficacy of ursodeoxycholic acid plus methotrexate vs methotrexate alone in the treatment of moderate to severe plaque-type psoriasis: A randomized clinical trial. *Dermatol Ther.* 2020 Jul;33(4):e13455.
- ¹¹⁷ Ely PH. Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is. *Clin Dermatol.* 2018 May-Jun;36(3):376-389. doi: 10.1016/j.clindermatol.2018.03.011. Epub 2018 Mar 28. PMID: 29908580.
- ¹¹⁸ Ely PH. Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is. *Clin Dermatol.* 2018 May-Jun;36(3):376-389. doi: 10.1016/j.clindermatol.2018.03.011. Epub 2018 Mar 28. PMID: 29908580.
- ¹¹⁹ Herman A, Herman AP. Topically Used Herbal Products for the Treatment of Psoriasis - Mechanism of Action, Drug Delivery, Clinical Studies. *Planta Med.* 2016 Nov;82(17):1447-1455.
- ¹²⁰ Syed TA, Ahmad SA, Holt AH, et al. Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. *Trop Med Int Health.* 1996 Aug;1(4):505-9.
- ¹²¹ Choonhakarn C, Busaracome P, Sripanidkulchai B, et al. A prospective, randomized clinical trial comparing topical aloe vera with 0.1% triamcinolone acetonide in mild to moderate plaque psoriasis. *J Eur Acad Dermatol Venereol.* 2010 Feb;24(2):168-72.
- ¹²² Stücker M, Memmel U, Hoffmann M, et al. Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis. *Dermatology.* 2001;203(2):141-7.
- ¹²³ Del Duca E, Farnetani F, De Carvalho N, Bottoni U, Pellacani G, Nisticò SP. Superiority of a vitamin B₁₂-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis. *Int J Immunopathol Pharmacol.* 2017 Dec;30(4):439-444.
- ¹²⁴ Based on label instructions for Jarrow Formulas Bile acid factors and Allergy Research Group Ox bile 500 mg. Accessed online at <https://jarrow.com/products/bile-acid-factors-120-capsules> and <https://www.allergyresearchgroup.com/ox-bile-500-mg-100-vegicaps/> June, 2024.